The regulation of self-renewal in normal human urothelial cells by Kirkwood, Lisa A
 
 
The Regulation of Self-Renewal in 
Normal Human Urothelial Cells 
 
 
Lisa A. Kirkwood 
 
PhD 
 
University of York 
 
Department of Biology 
April 2012
2 
 
Abstract  
The urinary tract is lined by a mitotically-quiescent, but highly regenerative 
epithelium, the urothelium. The mechanisms regulating urothelial regeneration 
are incompletely understood although autocrine stimulation of the Epidermal 
Growth Factor Receptor (EGFR) signalling pathway has been implicated. The 
hypothesis developed in this thesis is that urothelial homeostasis is regulated 
through resolution of interactive signal transduction networks downstream of 
local environmental cues, such as cell:cell contact. Here, canonical Wnt 
signalling was examined as a candidate key pathway due to the pivotal role of 
β-catenin in both nuclear transcription and intercellular adherens junctions.  
Normal human urothelial (NHU) cells isolated from surgical biopsies were grown 
as finite cell lines in monolayer culture. mRNA analysis from proliferating 
cultures inferred all components for a functional autocrine-activated canonical 
Wnt cascade were present. In proliferating cells, β-catenin was nuclear and 
Axin2 expression provided an objective hallmark of β-catenin/TCF transcription 
factor activity. This endogenous activity was not mediated by Wnt receptor 
activation, as Wnt ligand was produced in inactive (non-palmitylated) form in 
serum-free culture, but instead -catenin activation was driven via EGFR-
mediated phosphorylation of GSK3 and inhibition of the β-catenin destruction 
complex. In quiescent, contact–inhibited cultures, β-catenin was seen to re-
localise to the adherens junctions and GSK3β activity was re-established. 
Knock-down of β-catenin using RNA interference led to significant changes in  
p-ERK and p-AKT activity as well as an increase in E-cadherin protein 
expression. The results presented in this thesis identifies β-catenin as a central 
component of a bi-directional feedback loop between growth factor-mediated 
cell signalling and cell:cell contact and provides preliminary evidence that de-
regulation of the mechanisms that control β-catenin regulation and EGFR 
signalling are important in neoplastic growth. 
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1 Introduction 
1.1 The urinary system 
The urinary system secretes and excretes the nitrogenous waste products of 
metabolism and regulates the amount of water in our bodies.  In mammals, this 
system consists of two kidneys, two ureters, a bladder and a urethra (Figure 
1-1) (1). 
 
 
Figure 1-1 Schematic representation of the human urinary system 
Schematic of the human urinary system depicting kidneys, ureter, bladder and urethra. 
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1.2 The kidneys 
In the functional unit of the kidney, the nephron, blood is filtered under high 
pressure into an ultra-filtrate via the highly permeable glomerular capillaries.  
This process of glomerular filtration removes water, excess solutes, glucose and 
urea, the main nitrogenous waste product of amino acid deamination and the 
ornithine cycle, from the blood.  The filtrate passes along the renal tubules 
where active re-absorption of glucose and sodium ions occurs prior to passive 
reabsorption of water in the loop of Henlé.  Active secretion of unwanted ions is 
undertaken in the distal convoluted tubule, before a final cycle of passive water 
reabsorption in the collecting ducts (renal papillary ducts) and transport to the 
bladder via the ureters (Figure 1-2) (1).  
 
 
Figure 1-2 Schematical representation of a Nephron 
Illustration depicting the functional unit of the kidney, the nephron, where filtration, passive 
and active reabsorption and secretion occur to produce urine. 
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1.2.1 The ureters 
Urine leaves the kidneys via the collecting ducts and enters the renal pelvis and 
ureters.  The ureters transport urine by peristalsis from the kidneys to the 
bladder via the ureterovesical junction.  In adult humans, the ureters are 
approximately 25-30cm in length, 3-5mm in diameter and when analysed cross-
sectionally can be divided into three layers: fibrous connective tissue 
(adventitia), smooth muscle (muscularis) and urothelium. On the luminal 
surface of the urothelium, specialised hinged plaques known as assymetric unit 
membrane can be found (Figure 1-3; reviewed in section 1.3). 
  
 
Figure 1-3 Cross-section through a Normal Human Ureter 
Tissue section through a normal human ureter.  Three morphologically distinct layers can be 
observed: adventitia (fibrous connective tissue), smooth muscle and urothelium.  Tissue section 
has been immunolabelled with anti-asymmetric unit membrane (AUM) antibody (AU1) to 
highlight the specialised plaques found on the lumenal surface of the urothelium and 
counterstained with haematoxylin to illustrate tissue architecture. Micrograph taken by L. A. 
Kirkwood (unpublished data). 
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1.2.2 The bladder 
The main role of the urinary bladder is to store urine at low pressure (and thus 
avoid reflux back to the kidneys), as well as maintain urine composition prior to 
excretion via the urethra.  
The adult human bladder can accommodate up to 500ml of urine and may fill 
and void several times a day.  Successful micturition is dependent on a 
coordinated response between the bladder and the smooth muscle of the 
bladder neck and urethra (2).  As the bladder fills and distends, stretch 
receptors excite sacral parasympathetic nerve fibres and results in detrusor 
muscle fibre contraction, while concurrently inhibiting somatic motor neurones 
supplying the external sphincter of the urethra.  This increase in internal 
bladder pressure and external sphincter relaxation leads to urine release via the 
urethra (3). 
Cross-sectionally, the bladder can be divided into several layers which are 
depicted in Figure 1-4.  The bladder wall (also known as the peritoneum) 
covers the outer surface of bladder, inside this is the muscularis detrusor which 
is composed of smooth muscle bundles, the lamina propria or stroma; a layer of 
connective tissue containing blood and nerves in a collagen matrix, the 
basement membrane, and then, lining the lumen, a transitional epithelium 
known as the urothelium can be found (Figure 1-4) (1). 
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Figure 1-4 Schematical representation of the human bladder and 
urethra 
Illustration depicting multiple layers of muscle and connective tissue within the human bladder. 
Lining the lumen is a transitional epithelium known as the urothelium. 
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1.3 The Human Urothelium 
1.3.1 Tissue Architecture 
Urothelium lines the majority of the lower urinary tract, including the renal 
pelvis, ureters, bladder and proximal urethra.  Cross-sections through this tissue 
reveal it is multilayered and stratified into discrete cell layers which “transition” 
between simple columnar through to stratified squamous epithelia and can be 
divided into three distinct zones: basal, intermediate and superficial (4) (Figure 
1-5).  These morphologically-distinct layers increase in specialisation from basal 
through to the highly specialised superficial cells which line the luminal surface 
(4). The basal cell layer is composed of a single layer of small cuboidal cells 
which are anchored in place via a basement membrane to the lamina propria.  
On top of these, lies a layer 1-4 cells thick, of larger, polygonal shaped 
intermediate cells and then, towards the luminal surface, the terminally 
differentiated, large and often binucleate superficial cells reside which are 
characterised by “scallop-like” rigid plaques known as asymmetric unit 
membrane (AUM) (4, 5). 
1.3.2  Origins of the human urothelium  
The urothelium is unusual in that it develops from both embryological 
mesoderm and endoderm.  Urothelium that lines the renal pelvis, ureters and 
bladder trigone develops in conjunction with the kidneys and is derived from 
mesoderm.  The urothelium of the bladder and proximal urethra develop from 
the urogenital sinus and are derived from endoderm (reviewed by (6)).  
Although the urothelium that lines the bladder and bladder trigone evolve from 
two different lineages, morphologically they appear to be identical (4). 
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Figure 1-5 Schematic representation and actual cross-section through 
Normal Human Urothelium 
Illustration depicting a cross-section through normal human urothelium (A; adapted from (7)) 
and a tissue section of human bladder immunolabelled with anti-AUM antibody and 
counterstained with haematoxylin to illustrate tissue architecture (B). Micrograph taken by L. A. 
Kirkwood (unpublished data). 
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1.3.3  Characteristics of the urothelium in situ 
1.3.3.1  Uroplakin (UPK) expression 
Uroplakins (UPK) are highly conserved glycoproteins which were first isolated 
from the bovine urothelium and identified as important transcriptional targets of 
urothelial differentiation by T.T Sun and colleagues in the 1990s (8-11).  In 
humans, five uroplakin proteins have been cloned (UPK1a, UPK1b, UPK2, 
UPK3a and UPK3b) (12, 13).  UPK1a, UPK2 and UPK3a/b have been shown to 
be expressed only by the specialised superficial cells of the urothelium making 
them ideal markers of terminal differentiation (14).  UPK1b is less 
differentiation-specific and is expressed by the intermediate cells of the 
urothelium, as well as by several other human tissues (12, 14).  Genetically and 
structurally, uroplakins can be split into two groups: UPK1a and UPK1b are 
members of the tetraspanin family of transmembrane proteins, whereas UPK2, 
UPK3a and UPK3b are single transmembrane-domain proteins (Figure 1-6 (10)).  
In the cow, uroplakins have been shown to heterodimerise in the endoplasmic 
reticulum (ER) (UPK1a with UPK2 and UP1b with UPK3a or UPK3b), and then 
combine in the Golgi apparatus to form polygonal AUM plaques which are 
transported to the apical cell surface via the exocytosis pathway (15, 16).  
These plaques are expressed on the apical surface of superficial cells in several 
mammals including cow, human, monkey, sheep, pig, dog, rabbit, rat, and 
mouse (9).  Results from mouse knockout studies imply the uroplakins are 
important in the trans-cellular permeability barrier of the urothelium (17-19). 
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Figure 1-6 Structure of the uroplakin proteins 
UPK1a and UPK1b are members of the tetraspanin family which possess 4 transmembrane 
domains.  UPK2, UPK3a and UPK3b are single transmembrane proteins.  In the endoplasmic 
reticulum, uroplakins heterodimerise as shown (UPKIa with UPK2 and UPKIb with UPK3a or 
UPK3b).  Adapted from (13). 
1.3.3.2  Tight Junctional proteins 
A further specialised differentiation-associated feature of urothelium is the 
highly developed terminal tight junctions between adjoining superficial cells.  
Intracellular tight junctions (TJ) control para-cellular diffusion of water and ions 
(reviewed in (20)) and are a specific form of cell-cell contact found between the 
lateral membranes of adjacent cells.  Tight junctions are composed of several 
types of proteins including cytoplasmic plaque proteins such as the zonula 
occludins (ZO), as well as transmembrane proteins including occludins, 
junctional adherens molecule (JAM) and the claudins (CLDN), which anchor the 
cell-cell junction to the cytoskeleton.  The type of claudins expressed account 
for the tightness of the epithelium.  In human urothelium, CLDN3, CLDN4, 
CLDN5, CLDN7, ZO1 and occludin are expressed, with CLDN3,CLDN5 and ZO1 
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confined to either “kissing points” (CLDN3 and ZO1) or basolaterally (CLDN5) 
between superficial cells of the urothelium (21) 
1.3.3.3  Cytokeratin (CK) expression 
Cytokeratins are the polypeptides that form the cytoskeletal intermediate 
filaments in epithelial cells.  In humans, there are 20 known CK proteins but the 
urothelium only expresses a subset of these (reviewed by (22)).  In normal 
human urothelium, CK7, CK8, CK18 and CK19 can be found throughout all 
layers (23, 24).  CK13 expression is found only in the basal and intermediate 
cells of the urothelium, whereas CK5 and CK17 expression is restricted to the 
basal cells (24).  CK20 is only found in the terminally differentiated superficial 
cells of the urothelium making it an ideal marker of urothelial terminal 
differentiation (25)(reviewed by (22)).  
1.3.4 Function of the urothelium 
1.3.4.1  Storage of urine 
During the initial stages of bladder filling, superficial cells can be seen to 
elongate by up to ten times their normal size (26).  This is achieved via folding 
and unfolding of the luminal surface made possible by “hinge-like” narrow 
bands of normal plasma membrane that lie between the rigid AUM plaques (5).  
Supplemental to this, fusiform vesicles containing AUM enter and exit the apical 
membrane during the bladders expansion/contraction cycle (5, 27, 28).  This 
ability to alter the surface area of the urothelium helps maintain a low 
hydrostatic pressure and thus avoid damage to the upper urinary tract during 
the micturition cycle (reviewed in (5)).  
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1.3.4.2  Barrier function 
The bladder has two primary roles: to accommodate large fluctuations in urine 
volume during the micturition cycle, and to act as a barrier between the 
hypertonic excretory products (urine) and isotonic blood that bathes the 
underlying tissue (5).  AUM found on the apical surface of superficial cells is 
thought to minimise trans-cellular permeability (18), and in partnership with the 
tight junctions, which limit para-cellular transport (4) they  make the urothelium 
the tightest of all known epithelial barriers (29).  Loss of barrier function is 
associated with several painful bladder diseases, such as interstitial cystitis (30, 
31). 
 
1.4 Urothelial tissue homeostasis 
Loss of cells though normal cell turnover or through tissue damage must be 
replaced to maintain tissue function and is termed tissue homeostasis. 
In many epithelial tissues such as the skin and gut, tissue homeostasis is 
achieved via a constitutive program of self-renewal and replacement; this 
however is not seen in the bladder urothelium.  Under normal conditions, 
urothelial cells are long-lived and mitotically quiescent, with only ~1% of cells 
in the cell cycle at any one time (32, 33).  Urothelium does however have a 
high capacity for renewal, which is evident in response to injury (34).  During 
such a response, cells from all layers of the urothelium are seen to re-enter the 
cell-cycle and contribute to the proliferative pool (5).  This results in rapid repair 
of the damaged tissue and thought to be critical in maintaining urinary barrier 
function.  It has been suggested that stem cells and their progenitors may be 
key to this responsive program of self-renewal.  Tissue-specific stem cells were 
first described in the hematopoietic system (35), but since then, many other 
organs have disclosed resident stem cell populations, including brain, lung, and 
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heart, as well as many epithelial tissues, including liver, colon and skin 
(reviewed by (36)).  The fact that many of the morphogenic signalling 
pathways present in embryonic development are also active during tissue repair 
helps support this hypothesis.  Sonic Hedgehog (Shh) and Wnt for example are 
both active during epithelial repair of the gut lining (37, 38).  In 2007, 
Fierabracci and colleagues successfully established self-replicating human 
urothelial spheroids which were shown to express markers of progenitor cells 
(CD34+ and CD45-)(39).  Research into urothelial stem cells is ongoing, but so 
far, no resident stem cell population has been conclusively identified in the 
human urothelium (40).  Research into urothelial stem cells has however been 
more fruitful in the rodent urothelium.  In the rat, a sub-population of highly 
clonogenic, BrdU label-retaining (i.e., long lived) basal cells were identified and 
shown to express markers consistent with stem cells in other tissues (e.g., Bcl, 
p63, CK14 and β1-integrin) (41).  In the mouse bladder, a subset of CK5+ 
basal urothelial cells have been shown to express Sonic hedgehog (Shh), a 
ligand important during embryological development.  Upon bacteria-induced 
injury, Shh was shown to act as a paracrine signal on the underlying stromal 
cells of the lamina propria leading to stromal release of Wnt ligand that induced 
basal urothelial cell proliferation (42). The relevance of this work to human 
urothelium still remains unclear, as human and rodent urothelium in vivo differ 
significantly in their expression of markers of terminal differentiation as well as 
ki67 expression, suggesting there may be fundamental difference in the 
regulation of urothelial regeneration between the two (43).  
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1.5 Cancer: When tissue homeostasis goes wrong 
Cancer is a disease associated with an imbalance in the mechanisms that 
control normal tissue homeostasis (Figure 1-7).  According to the Office for 
National Statistics, 309,527 new cases of cancer (excluding non-melanoma skin 
cancer) were diagnosed in the UK in the year 2008 equating to 504 cases per 
100,000 people (44). 
 
Figure 1-7 Schematic illustrating the link between dysregulated tissue 
homeostasis and cancer progression 
Imbalances in the control of normal tissue homeostasis can result in two very different 
outcomes in the bladder.  If the urothelium is damaged and not repaired, barrier function is lost 
causing conditions such as interstitial cystitis. However, bladder cancer may develop if repair 
mechanisms allow urothelial cells to proliferate too much. 
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1.5.1  Bladdder Cancer 
1.5.1.1  Epidemiology 
According to the latest UK cancer statistics published in December 2011, 
bladder cancer is the 7th most common cancer in the UK, with 10,335 new cases 
diagnosed in 2008 (Figure 1-8 (44)).  In the UK, bladder cancer affects over 
twice as many men (7390 new cases in the UK in 2008) as women (2945 new 
cases in the UK in 2008) and is the 4th most common cancer in males after 
prostate, lung and colorectal cancer.  Like most cancers, bladder cancer is a 
disease of the elderly, with two thirds of all new cases diagnosed in people over 
the age of 70.  In 2009, bladder cancer accounted for 5011 deaths, 3% of the 
total cancer related deaths in the UK (44). 
 
Figure 1-8 The 20 most commonly diagnosed human cancers in the UK 
Pie-chart illustrating the 20 most commonly diagnosed human cancers in the UK in 2008.  
Bladder cancer accounts for 3% (10,335) of all newly diagnosed cancers making it the 7th most 
prevalent cancer in the UK.  Adapted from data published in (44). 
Chapter 1 
35 
 
1.5.1.2  Aetiology 
Symptoms of bladder cancer include but are not limited to, blood in the urine 
(haematuria), a burning sensation on voiding, pelvic pain and the need to pass 
urine more frequently.  
90% of all bladder cancers develop from neoplastic changes in the urothelial 
lining of the bladder and are termed urothelial carcinoma (UC).  The other 10% 
include the much rarer squamous carcinoma (SC), which arises from cells which 
have obtained a squamous phenotype (usually after chronic infection with the 
parasitic worm Schistosoma haematobium (reviewed by (45)) and 
adenocarcinoma (reviewed by (46)).  
Upon diagnosis, all tumours undergo histopathological assessment using clearly 
defined criteria set out by the World Health Organisation (WHO) and the 
International Society for Urological Pathology (ISUP) in 2004 (47).  Tumours 
are biopsied and classified according to their grade and stage.  Grade gives an 
indicator of the differentiation status of the cells involved and uses two 
concurrent grading systems. These are the 1973, WHO classification system 
and the 2004 WHO/ISUP classification system which is currently being validated 
in clinical trials and is reviewed in (48) (Table 1-1,Table 1-2).  Stage determines 
the degree of invasion into the underlying tissue and currently uses the 2002 
Tumour, Node Metastasis (TNM) staging system (Table 1-3) (49).  
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Approximately 75-85% of newly diagnosed UC presents as a superficial tumour 
involving only the mucosa and lamina propria (Ta-Tis).  Of these, most are 
papillary, highly recurrent, but non-invasive in nature, whereas those that are 
classified as Tis, are flat, carcinomas in situ (CIS) which are high grade (i.e., 
poorly differentiated) and have high metastatic potential (50).  The remaining 
15-25% of patients present with invasive tumours which have already invaded 
the muscularis (and beyond) and have a poor clinical outcome (51).  
 
 
Table 1-1 UC grading using the 1973 WHO classification system 
Adapted from (52).  
 
 
Table 1-2 UC grading using the 2004 WHO/ISUP classification system 
Adapted from (52). 
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Table 1-3 Staging of a urothelial primary tumour using the WHO 2002 
TNM staging system 
Adapted from (52).  
1.5.1.3 Molecular pathways involved in the development of UC 
Genetic mutations in chromosome 9, such as loss of 9p or 9q are frequently 
seen in all types of UC and thus believed to be an early initiating event involved 
in neoplastic transformation (53, 54)  reviewed by (55).  UC can clearly be 
segregated into two clinically distinct forms: superficial papillary and CIS.  
Certain genetic mutations have been shown to correlate with one or the other 
of these two forms giving rise to the hypothesis that Ta and CIS tumours arise 
from different molecular mechanisms (56).  Activating mutations in the 
fibroblast growth factor receptor 3 (FGFR3) or HRAS genes are found in 
approximately 70% of all low grade (Ta) superficial tumours compared to only 
20% of high grade invasive tumours (57).  Both of these mutations lead to 
increased proliferation, driven via the MAPK/ERK and PI3K/STAT pathways (58).  
In comparison to this, p53 and Retinoblastoma (Rb) inactivating mutations are 
closely associated with high grade, invasive tumours and are markers of poor 
prognosis (53).  
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1.6 Factors regulating human urothelial tissue homeostasis 
1.6.1 Cell signalling 
Mitogenic polypeptide growth factors are important mediators of tissue 
homeostasis and can exert their effect via several mechanisms: autocrine 
signalling (self stimulation by secreting growth factor and expressing the 
appropriate receptor to respond), juxtacrine signalling (where ligand is an 
integral part of the cell membrane and only adjacent cells that express the 
appropriate receptor can respond) or paracrine signalling (where ligand is 
released in soluble form to act on distant receptor-expressing cells of the same 
or different type) (Figure 1-9).  
 
Figure 1-9 Schematic illustrating autocrine, juxtacrine and paracrine 
signalling 
Growth factors can activate their receptor via an autocrine (A), juxtacrine (B) or paracrine 
mechanism (c) to regulate cell size, cell survival and cell cycle progression.  
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Although there is evidence that urothelial regeneration is responsive to 
paracrine signalling via the stromal compartment (42), there is also evidence 
for autocrine and juxtacrine growth factors in urothelial tissue regeneration.  
Best characterised is autocrine activation of the EGFR-family of receptors 
(reviewed in 1.6.1.1) which has been intensively researched using normal 
human urothelial cells in vitro (33, 59-62).   
1.6.1.1  Expression of EGFR-family receptors in the human urothelium 
THE EGFR-family of receptors consists of four members: EGFR (synonym; 
HER1), ERBB2 (synonym; HER2), ERBB3 (synonym; HER3) and ERBB4 
(synonym; HER4).  ERBB2 lacks a ligand binding domain and ERBB3 has no 
tyrosine kinase activity, therefore both must heterodimerise with either EGFR or 
ERBB4 to elicit a signal transduction pathway.  In vitro, urothelial cells 
predominantly express EGFR which has been shown to drive self-renewal via 
juxtacrine amphiregulin engagement and MAPK/ERK-mediated gene 
transcription (33).  In situ and upon culture confluence, ERBB2 and ERBB3 
expression is also found but the relevance of their expression still remains to be 
fully explored (33, 61).  Varley and colleagues have proposed that modulation 
of ERBB2 and ERBB3 expression and subsequent heterodimerisation with EGFR, 
may be an important mechanism modulating EGFR signalling upon confluence 
and contact-induced quiescence (33). 
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1.6.1.2  Expression of EGF-family ligands in the human urothelium 
The EGF-family of ligands consists of several low molecular weight mitogenic 
polypeptide growth factors that bind with high affinity to the EGFR-family of 
tyrosine kinase receptors.  In normal human urothelial cells, heparin-binding 
EGF (HB-EGF) (33, 60) transforming growth factor α (TGFα) (59, 61) and 
amphiregulin (33, 59, 61)have all been proposed as endogenous autocrine- 
ligands. 
1.6.1.3  EGFR signalling 
Upon ligand activation, EGFR dimerises, causing a conformational change and 
auto-phosphorylation of several C-terminal tyrosine residues (Y992, Y1045, 
Y1068, Y1148 and Y1173) in its extracellular domain.  Auto-phosphorylated 
EGFR dimer can then activate downstream signalling via 3 main signalling 
cascades: mitogen-activated protein kinase (MAPK) pathway, 
phosphatidylinositol 3 kinase (PI3K) pathway and the signal transducers and 
activators of transcription (STAT) pathway (Figure 1-10 and reviewed by (63)). 
1.6.1.4  MAPK pathway 
The auto-phosphorylated EGFR dimer is recognised by the adaptor protein 
Grb2, which contains specific phosphotyrosine binding domains, Src homologue 
2(SH2) and Src homologue 3 (SH3).  In turn, this binding leads to the 
recruitment of guanine nucleotide exchange factors (GEFs) such as, Son of 
Sevenless (SOS), a GTPase-activating protein which triggers downstream Ras 
proteins by facilitating the exchange of guanosine diphosphate (GDP) for 
guanosine triphosphate (GTP).  Once Ras is activated the signal is transduced 
via phosphorylation through the MAPK cascade, starting with the 
phosphorylation of Raf which in turn phosphorylates MEK and finally 
extracellular signal regulated-kinase (ERK).  ERK then translocates to the 
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nucleus and initiates transcription of cell cycle regulatory genes such as cyclin D 
and c-MYC.  
1.6.1.5  PI3K pathway  
The P13K/AKT pathway is an important pathway in controlling cell proliferation, 
cell survival and cell growth (reviewed in (64)) and can be activated via two 
separate mechanisms downstream of the EGFR. 
In the first cascade, auto-phosphorylation of EGFR dimers allows direct 
recruitment of phosphatidylinositol 3 kinases (PI3K) to the plasma membrane 
through interactions of the SH2 domains on the EGFR dimer with the regulatory 
unit (p85) of PI3K (or indirectly via the adaptor proteins IRS1 or IRS2).  This 
results in a conformational change in PI3K, releasing the inhibitory effect of p85 
on the catalytic subunit (p110) of PI3K.  Active PI3K can then convert its 
substrate, membrane bound phosphatidylinositol (4,5) triphosphate (PIP2) into 
phosphatidylinositol (3,4,5) triphosphate (PIP3).  PIP3 recruits AKT to the 
plasma membrane where phosphorylation of residues threonine 308 and serine 
473 occur via the kinases, phosphoinositide dependent kinase-1 (PDK1) and 
integrin-linked kinase (ILK), respectively.  Once phospho-activated, AKT can 
positively regulate cell growth by phosphorylation of mammalian target of 
rapamycin (mTOR), mediate cell survival via direct inhibition of pro-apoptotic 
signals such as Bad and regulate cell proliferation by translocating to the 
nucleus and up-regulating transcriptional targets such as p21 and p27, two 
cyclin dependent kinase inhibitors (CDKs). 
In the second cascade, the catalytic domain of PI3K is activated via binding to 
Ras which results in the same downstream cascade as above (65). 
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1.6.1.6  STAT pathway 
Auto-phosphorylated EGFR dimer activates the phosphorylation of signal 
transducers and activators of transcription (STAT) STAT1, STAT3 and STAT5 via 
the tyrosine kinase JAK (66, 67).  Activated STATs can then translocate to the 
nucleus and exert their effect on gene transcription. 
 
 
Figure 1-10 EGFR signalling pathways 
Illustration depicting the three main signalling cascades downstream of EGFR. Each pathway is 
highlighted in a separate colour: The MAPK pathway in orange, the PI3K pathway in blue and 
the STAT pathway in green.  Component shared by more than one pathway are shaded 
accordingly.  Pharmacological inhibitors are shown in red.  
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1.6.2  Cell environment 
In vitro, the cellular microenvironment can dramatically affect a cells response 
to growth promoting signals.  At confluence, normal human urothelial (NHU) 
cells are seen to down regulate EGFR expression and up-regulate ERBB2 and 
ERBB3 (33), but how this is coordinated still remains unclear.  Upon confluence, 
cell spread is curtailed and several types of cell:cell junctions form.  These 
interactions abrogate any response to proliferation-promoting signals and force 
the cell into growth arrest, a process known as contact inhibition or contact-
induced quiescence (68).  Wounding a confluent urothelial monolayer allows 
cells at the wound edge to spread, break cell:cell contact and respond to 
growth promoting signals (33).  
One such cell:cell junction which may be involved in modulating a cell’s 
response to growth promoting signals is the adherens junction (AJ).  Adherens 
junctions are cell:cell anchoring junctions which form via calcium-dependent 
homophilic interactions between epithelial-cadherin (CDH1) and are anchored 
internally to the actin cytoskeleton via α- and β-catenins (69).  These junctions 
not only mediate cell adhesion but also transmit signals from the plasma 
membrane to the nucleus where they regulate gene expression (68, 70).  
The dynamics between growth factor signalling and cell:cell contact are clearly 
involved in urothelial self-regeneration, but how they fully interconnect and 
regulate each other to allow close coordination of gene expression with cell 
contact still remains uncertain.  Research has focused on proteins that localise 
to both sites of cell:cell contact and to the nucleus in the hope of finding the 
key mediators of this process.  One such protein that may be important is  
β-catenin, as it is a pivotal component of the canonical Wnt signalling cascade 
(reviewed in section 1.7), as well as an intrinsic component of the adherens 
junction (reviewed by (71) and in section 5.3).  As yet, little research has been 
undertaken to explore the role of β-catenin in normal human urothelial 
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homeostasis although several studies have looked at the potential role of  
β-catenin in human bladder tumours (reviewed in section 1.8).  
1.7 The canonical Wnt pathway 
In the absence of Wnt ligand (Figure 1-11), β-catenin exists in two forms: one 
form is membrane-bound to α-catenin and E-cadherin where it is involved in 
maintaining cell-cell adhesion, the other is also cytoplasmic, but bound to a 
clustered group of proteins including the scaffold protein axin, glycogen 
synthase kinase 3β (GSK3β), the tumour suppressor protein APC and casein 
kinase Iα (CKIα), collectively known as the “destruction complex”. When bound 
to this structure, β -catenin is phosphorylated by CKIα at the amino acid serine 
45 allowing GSK3β to phosphorylate serine/theonine residues 41, 37, 33.  
Phosphorylation of amino acids 37 and 33 triggers ubiquitination of β -catenin 
by the phospho-recognising protein β-transducin repeat-containing protein  
(β-TrCP) and ultimately results in β –catenin proteosome degradation (104).  
Canonical Wnt signalling begins with the binding of Wnt ligand to its G-protein 
coupled receptor, Frizzled (Fzd) and co-receptor, low density lipoprotein 
receptor (LRP).  Ligand activation results in several phosphorylation events but 
the exact mechanism(s) involved have yet to be fully elucidates.  Fzd receptor 
is thought to trigger the phosphorylation of Dsh by activating the 
serine/theonine kinases, CKIε, CK2 and PAR1 (105-107).  Once primed, Dsh 
recruits Frat1 and together they bind as a complex to Axin and GSK3 resulting 
in the release of β-catenin (108).  Free, cytoplasmic, non-phosphorylated  
β-catenin can then translocate to the nucleus where it acts as a co-activator of 
TCF/LEF driven transcription by recruiting members of the chomatin remodeling 
complex and ultimately drives cell cycle progression (Figure 1-11).  
Canonical Wnt signalling is tightly regulated with agonists and antagonists 
acting on almost all parts of the signalling cascade.  Several antagonists have 
been shown to inhibit Wnt signalling outside the cell by sequestering Wnt ligand 
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and include: secreted frizzled related protein (sFrp), Cerberus and Wnt 
inhibitory factor-1 (Wif1).  Even if bound to Fzd, Dickkopf (DKK) can block 
ligand access to its co-receptor LRP5/6 by inducing endocytosis of LRP5/6 via 
Kremen (109-112).  Within the nucleus, β-catenin signalling can be blocked via 
Nemo-like kinase (NLK) phosphorylation of TCF or binding of  
β –catenin to ICAT (113, 114).   
 
Figure 1-11 Schematic illustrating the canonical Wnt pathway 
A) Inactive pathway: Without Wnt stimulation, β-catenin is held within a complex of proteins 
called the “destruction complex” and is targeted for proteosome degradation.  (B) Active 
pathway: Wnt ligand binds to Fzd and LRP5/6 and leads to activation of Dsh and phospho-
inhibition of GSK3β, destroying the “destruction complex.”  Non-phosphorylated β-catenin 
accumulates and translocates to the nucleus where it activates Tcf/Lef-1 transcription factors 
leading to target gene expression and cell cycle progression.  Inhibitors (blocking antibodies) 
are shown in red.   
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1.8 Wnt/β-catenin signalling in the bladder 
Early work in 2003 by Thievessen and colleagues concluded there was no 
Wnt/β-catenin signalling in normal human urothelium or in seven human 
urothelial cancer cell lines using a luciferase TCF reporter assay (72).  Many 
research groups have however found an increase in nuclear β-catenin protein 
expression in UC biopsies compared to normal urothelium using 
immunohistochemistry (73-76).  More recently, APC missense mutations and/or 
nuclear β-catenin accumulation has been shown to be associated with shorter 
disease free intervals and poor clinical outcome in a cohort of patients with 
invasive UC, suggestive of a role for deregulated Wnt/β-catenin signalling in 
cancer progression (77).  In support of this, epigenetic studies have shown a 
number of Wnt antagonists to be silenced in UC, for example, secretory 
frizzleds (sFrp) were shown to be promoter hypermethylated in a cohort of 
patients with invasive disease (78), while research undertaken by Urakami and 
colleagues has shown CpG hypermethylation of Wnt inhibitory factor 1 (Wif1), 
sFrp2 and Dickkopf-3 (DKK-3) correlating with higher levels of nuclear  
β-catenin in UC (79, 80).  In support of a role for Wif-1 in UC, Tang and 
colleagues saw growth inhibition via G1 cell cycle arrest when human bladder 
cancer cell lines T24 and TSU-PR1 were incubated in the presence of Wif-1 
(81). 
The role of Wnt/β-catenin signalling has been more widely studied in rodent 
urothelium than in human and has been found to play an important role in 
tissue homeostasis.  In the mouse, proliferation in response to bacterial or 
chemical induced injury is regulated by signal feedback between the basal 
urothelial cells and the underlying stromal cells (42).   After injury, basal 
urothelial cells were seen to secrete Sonic Hedgehog (shh) evoking expression 
of Wnt2 and Wnt4 (via Gli1) from the underlying stroma.  Both stromal and 
urothelial cells proliferated in response to Wnt ligand, restoring urothelial 
integrity (42).   
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Genetically engineered mouse models harbouring mutations found in human 
bladder cancer have helped advanced our understanding of the disease and 
have implicated deregulated Wnt/β-catenin signalling in the process.  In vivo 
experiments investigating deregulated Wnt/β-catenin signalling by expression of 
a GSK3 resistant mutant form of β-catenin (missing exon 3) driven by a UPK2 
promoter led to localised urothelial hyperplasia but did not develop into cancer 
(82).  These lesions contained elevated levels of phosphatase and tensin 
homologue (PTEN), known to inhibit the PI3K pathway by dephosphorylating 
phosphatidylinositol-3,4,5-trisphosphate (82).  In contrast, in vivo experiments 
where PTEN was deleted alongside constitutively active β-catenin went on to 
form papillary carcinoma and displayed high levels of P-AKT (S473), suggesting 
the tumour suppressor PTEN blocked cancer progression  and implied β-catenin 
activity and PTEN loss were both required before bladder cancer would develop 
(82).  Alongside this work, Ahmad and colleagues also investigated the 
potential interaction between H-Ras activating mutations and deregulated Wnt/ 
β-catenin signalling.  Addition of constitutively active HRas (using the HRasQ61L 
mutant) alongside activated β-catenin also resulted in low grade UC but these 
lesions were dependent on the MAPK/ERK pathway and showed little activation 
of the AKT pathway, indicating both mutations in the AKT and MAPK pathways 
could synergise with deregulated Wnt/β-catenin signalling to drive 
tumorigenesis in the mouse bladder (83). As yet, it is unclear what actual role 
Wnt signalling plays in the development of bladder cancer. Published data 
would however imply that the Wnt pathway could be deregulated on both the 
genetic and epigenetic level and thus does not follow the trend seen in bowel 
cancer where a specific mutation in APC is reponsible for cellular 
transformation.  
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1.9 Urothelial cells in vitro 
1.9.1  Isolation and propagation 
The capacity of the human urothelium to regenerate can be exploited to 
propagate normal human urothelial (NHU) cells in vitro and provide a valuable 
research tool to investigate the mechanisms involved in urothelial homeostasis.  
Using well-defined methodologies developed by Southgate and colleagues, 
viable NHU cells can be isolated and propagated from small surgical specimens 
(84, 85).  Using this technique, urothelium is dissociated, intact, from the 
basement membrane (using a calcium-chelating EDTA solution to limit stromal 
contamination) and then disaggregated using collagenase to form a single-cell 
suspension.  Cultures are maintained in low calcium keratinocyte serum-free 
medium (KSFM) to discourage the growth of non-epithelial cells which is 
supplemented with recombinant human epidermal growth factor (rhEGF), 
bovine pituitary extract (BPE) and cholera toxin (CT; to aid plating efficiency 
(84)).  PrimariaTM tissue culture flasks are used as the plastic is coated with a 
mixture of negative, positive, and nitrogen containing functional groups which 
aid cellular attachment (86).   
1.9.2  NHU cell phenotype  
In serum-free, low calcium (0.09mM) culture medium, NHU cells adopt a highly 
proliferative “wound healing” phenotype, form non-stratified monolayers with a 
typical epitheliod “cobblestone” morphology and undergo contact inhibited G1 
growth arrest upon attaining confluence (Figure 1-12 (33, 84, 85)).  Under 
normal growth conditions, NHU cells express a non-differentiated, 
basal/intermediate cytokeratin profile with expression of CK7, CK8, CK17, CK18, 
CK19 and low levels of CK13 (84).  CK20 and uroplakin protein expression 
(except for UPK1b) is absent under normal culture conditions (12, 84).  
Increasing the extracellular calcium concentration from 0.09mM to 2mM 
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induces stratification, desmosome formation and E-cadherin adherens junction 
formation, but does not permit urothelial cytodifferentiation  (12, 84).  
 
 
Figure 1-12 Phase-contrast micrograph of NHU cells in culture 
NHU cells exhibiting a typical epitheliod “cobble-stone” morphology when cultured in KSFMc. 
Scale bar 100µm.  
1.9.3  NHU growth and proliferation 
In KSFMc, NHU cells display a high rate of proliferation with a mean population 
doubling time of 14.7 ± 1.8 hours (84).  NHU cells can be sub-cultured for ~12 
passsages before they undergo replicative senescence (87, 88).  Over-
expression of telomerase (hTERT) can immortalise urothelial cells but results in 
compromised differentiation and functional capacity (89-91).  Proliferation is an 
autonomous process driven primarily by autocrine epidermal growth factor 
(EGF) activation of EFGR and leads to transcription of genes that promote G1-S 
phase transition (33).  
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1.9.4  NHU cell differentiation 
Cultured NHU cells retain their ability to undergo differentiation.  Initial 
evidence of this was first reported when NHU cells were combined in organ-
culture with de-epithelialised stroma and formed a stratified transitional 
urothelium identical to that seen in situ (92).  Since these early experiments, 
two methods for induction of differentiation have been developed.  In the first 
method, NHU cells are treated with a peroxisome proliferator activated 
receptor-γ (PPAR-γ) agonist, troglitazone, which induces differentiation but only 
when the EGFR pathway is concurrently blocked with EGFR tyrosine kinase 
antagonist, PD153035 (protocol hereafter termed TZ/PD)(21, 93).  TZ/PD 
treatment induces epithelial differentiation by heterodimerisation of activated 
PPARγ with retinoid X receptor  (RXRα) to form a transcription factor complex 
and transcription of genes with peroxisome proliferator response elements 
(PPRE) within their promoters.  This method induces transcription of urothelial 
cytodifferentiation-associated genes, but does not result in organisation of a 
functional barrier. 
In the second method, NHU cells are grown in KSFMc, pre-treated with serum 
and then sub-cultured in the presence of physiological calcium concentrations 
(hereafter referred to as ABS/Ca)(94).  These cultures form a biomimetic 
urothelial tissue facsimile which displays many functional properties of the 
native urothelium including stratification, polarisation and barrier function (94).   
Irrespective of method, induction of differentiation results in transcriptional up-
regulation of terminal differentiation-associated genes, such as the uroplakins, 
CK13 and CK20 (93-95).   
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1.10 Thesis Aims 
The overall aim of this project was to build on the current understanding of how 
urothelial regeneration is regulated to maintain tissue homeostasis. The 
dynamics between growth factor signalling and cell:cell contact clearly play an 
important role in regulating self-renewal mechanisms, but to date, it remains 
unclear how this is coordinated.  Research has focused on proteins that localise 
to both sites of cell contact and to the nucleus in the hope of finding the key 
mediators of this process.  In this thesis, the canonical Wnt signalling cascade 
was examined as a potential key pathway due to the pivotal role of β-catenin in 
both gene transcription and cell:cell contact.  
The role of Wnt/β-catenin signalling in urothelial homeostasis was investigated 
by meeting the following objectives:  
 To utilise previously generated MicroarrayTM data to assess whether key 
components and regulators of the canonical Wnt signalling pathway 
were present at the mRNA level in NHU cells.  
 
  To use pharmacological inhibitors of the destruction complex to 
ascertain whether there was a functional Wnt signalling cascade present 
in urothelial cells. 
 
 To assess if NHU cells could respond canonically to Wnt ligand and 
determine whether this might be an alternate paracrine or autocrine 
signalling mechanism utilised by NHU cells to drive transcription of cell 
cycle associated genes and thus the regenerative phenotype seen during 
tissue repair. 
 
 To utilise EGFR signalling antagonist, shRNA knock down and exogenous 
calcium modulation to address whether urothelial proliferation is 
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regulated through the resolution of multiple interacting signal 
transduction pathways downstream of cell:cell contact.  
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2 Materials and Methods 
2.1 General 
All practical work was carried out in the Jack Birch Unit for Molecular 
Carcinogenesis, or within the central Technology Facility, at the Department of 
Biology, University of York. 
2.2 Suppliers 
Commercial suppliers and manufacturer are indicated at the first mention of the 
reagent or equipment in the text.  A full list of all suppliers can be found in 
Appendix I. 
2.3 Dissection equipment, glassware and disposable 
plasticware 
Metal dissection instruments, glassware, Pasteur glass pipettes (SLS), as well as 
disposable centrifuge tubes and pipette tips (Starlab) were sterilised by 
autoclaving in a Harvard/LTE Series 100 autoclave at 121°C (1 bar) for 15 
minutes and then air dried at 80°C in a drying oven.  Single use sterile 
plasticware was purchased from Sterilin (SLS), except for RNase/DNase-free 
pipette tips which were from (Axygen; Fisher Scientific), RNase-free tubes 
(Applied Biosystems), and serological pipettes (Starstedt). 
2.4 Stock solutions 
All chemical reagents were either of analytical or tissue culture grade, as 
appropriate for the experiment and were supplied by Sigma Aldrich unless 
otherwise stated.  General laboratory stock solutions were prepared with 
deionised water (dH2O).  Solutions for use in tissue culture were prepared with 
ultra-pure water from a Purelab Ultra Genetic (Elga) ultra violet purification 
unit.  Heat stable solutions were sterilised by autoclaving at 121°C (1 bar) for 
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15 minutes or filter-sterilised using an Acrodisc low-protein binding Tuffryn® HT 
syringe filter with a pore size of 0.2µm (VWR).  Recipes for all stock solutions 
can be found in Appendix II. 
2.5 Reagents 
2.5.1  Antibodies 
Primary antibodies used in this study are listed in Table 2-1.  Antibodies were 
titrated on known positive controls to establish optimal concentrations prior to 
use.  Primary antibodies were aliquoted and stored as recommended by the 
manufacturer.  Working stocks were diluted in Tris buffered saline (TBS; 
appendix II) with 0.1% (v/v) bovine serum albumin (BSA; Sigma), 0.1% (w/v) 
sodium azide (Sigma), and stored at 4°C. 
Fluorochrome-conjugated secondary antibodies were titrated prior to use and 
stored in the dark at 4°C (Table 2-2). 
2.5.2  Agonists/Antagonists 
Agonists/antagonists were reconstituted in either tissue culture grade dimethyl 
sulphoxide (DMSO; Sigma) or sterile H2O according to the manufacturer’s 
instructions and stored in single use aliquots at -20°C.  Prior to use, compounds 
were titrated to determine the effective dosage and solvent-balanced dilutions 
were made from the stock solutions into growth medium (Table 2-3). 
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Antigen Clone/catalogue 
number 
Host Supplier Use Molecular 
weight of 
antigen 
Active  
β-catenin 
8E7(dephosphorylated on 
Ser 37 and Thr 41) 
Mouse Kind gift from 
Prof. H.Clevers 
WB, 
IIF 
92 (KDa) 
AKT 7 Mouse BD Bioscience WB, 
IIF 
59 
β-actin AC-15 Mouse Sigma WB 42 
β-catenin C2206 (raised against 
amino acids 768-781) 
Rabbit Sigma Aldrich WB, 
IIF, 
IHC 
92 
E-cadherin HECD-1 Mouse Abcam WB, 
IIF, 
IHC 
110 
ERK 16 Mouse Transduction 
Laboratories 
WB, 
IIF 
42/44/54/ 
90 
MKI67 MM1 Mouse Novacastra 
Laboratories 
IIF, 
IHC 
N/A 
Phospho-  
473 AKT 
D9E Rabbit Cell Signalling WB, 
IIF 
60 
Phospho-9 
GSK3β 
AB30619 Rabbit Abcam WB 47 
Phospho 
42/44 MAPK 
D13.14.4E Rabbit Cell Signalling WB, 
IIF 
42/44 
Wnt 3a 3A6 Mouse Santa Cruz WB 39 
Wnt 5a C-16 Goat Santa Cruz WB 41 
Table 2-1 Primary antibodies 
Table listing primary antbodies used throughout this study and their use (WB: western blotting, 
IIF: indirect immunofluorescence, IHC: immunohistochemistry, N/A not applicable). Antibodies 
used for western blotting also include molecular weight of protein.    
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Antigen Conjugate Host Supplier Application 
Mouse IgG Alexa 488 Goat Molecular Probes IF 
Rabbit IgG Alexa 594 Goat Molecular Probes IF 
Mouse IgG Alexa 680 Goat Invitrogen WB 
Rabbit IgG Alexa 800 Goat Invitrogen WB 
Goat IgG Alexa 680 Donkey Invitrogen WB 
Table 2-2 Secondary antibodies 
 
Compound Target Published 
IC50/EC50 
Supplier Stock conc. Effective 
concentration 
in NHU cells 
PD153035 EGFR 
Inhibitor 
25pM* Calbiochem 1mM (DMSO) 1µM 
U0126 MEK1 and 
MEK2 
inhibitor 
72/58nM* Calbiochem 5mM(DMSO) 5µM 
LY294002 PI3K 
inhibitor 
1.4µM Calbiochem 5mM(DMSO) 5µM 
 
SB415286 GSK3 
inhibitor 
2.9µM Sigma 
Aldrich 
10mM(DMSO) 10µM 
Lithium 
Chloride 
GSK3 
inhibitor 
15mM 
 
Sigma 
Aldrich 
10M(H2O) 25mM 
 
Troglitozone PPARγ 
agonist 
- Parke Davis 1µM (DMSO) 1µM 
Table 2-3 Agonists/Antagonists 
*published IC/EC50 in cell-free system.  
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2.6 Tissue Culture 
2.6.1 General 
All tissue culture work was undertaken using aseptic technique within a class II 
laminar flow safety cabinet with HEPA filtration.  For routine tissue culture, a 
recycling class II safety cabinet (Medical Air Technology), or an externally 
ducted (Envair) cabinet was used.  Before and after use, cabinets were cleaned 
with 70% (v/v) ethanol (Fisher) and once weekly with Mikrozid® AF disinfectant 
(SLS).  Culture media was replenished every 2-3 days, unless otherwise stated.  
Waste cells and medium were aspirated into a Buchner flask containing 10% 
(w/v) Virkon® and left for a minimum of 30 minutes prior to disposal.  All cell 
culture reagents were of tissue culture grade and were from Sigma, unless 
otherwise stated. 
All centrifuge steps were carried out in a bench top centrifuge (Sigma) at 400g 
for 5 minutes, unless otherwise stated.  Cells were counted in single cell 
suspension using an “improved Neubauer” haemocytometer (VWR) prior to  
re-seeding.  Cells were then incubated in a Heracell 240 incubator (Thermo 
Scientific) at 37°C in a humidified atmosphere of either 5% CO2 in air for cells 
cultured in Karatinocyte Serum-Free Medium (KSFM; Invitrogen) or 10% CO2 in 
air for other media. 
2.6.2  Primary Urothelial Cell Culture 
2.6.2.1  Tissue specimens 
Specimens of human bladder, ureter and renal pelvis were provided by 
surgeons from York District Hospital, St James’ University Hospital, Leeds and 
Guy's and St Thomas' NHS Foundation Trust, London.  Tissue biopsies were 
taken for research purposes with fully informed consent from patients with no 
history of urothelial neoplasia and with the permission of the relevant Local 
Research Ethics Committee.  Biopsies were collected in sterile 25ml polystyrene 
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Universal tubes containing 15mls of sterile transport medium (Appendix II) and 
where possible were stored at 4°C until processing.  Prior to isolation, each 
sample was given an arbitrary laboratory record number (Y-number) and the 
patient’s age, sex and operation were recorded.  Each Y-number used in the 
study, along with the patients age, sex and operation details can be found in 
Appendix III). 
2.6.2.2  Isolation of primary human urothelial cells 
Primary urothelial cultures were established as previously describes (84, 85).  
Specimens were dissected in sterile Petri dishes (Nunc) using scissors and 
forceps to remove unwanted fat and connective tissue.  Ureters were split 
longitudinally to allow access to the urothelium.  Where possible, a small cross-
section was removed and fixed overnight in 10% (v/v) formalin in PBSc 
(appendix II) for routine histological analysis.  The remaining tissue was 
incubated in 5mls of stripper medium (Appendix II) for 4 hours at 37°C to 
dissociate the urothelium from the basement membrane.  Urothelial sheets 
were detached from the underlying stroma using forceps and pelletted via 
centrifugation.  A single cell suspension was achieved via incubation in 2mls 
(400U) of Collagenase IV (Appendix II) for 20 minutes at 37°C.  Cells were then 
collected via centrifugation and counted prior to seeding into Primaria® flasks or 
Petri dishes (Falcon; BD Biosciences).  NHU primary cell cultures were 
established in KSFM, supplemented with 50µg/ml bovine pituitary extract (BPE; 
Invitrogen), 5ng/ml epidermal growth factor (rhEGF; Invitrogen) and 30ng/ml 
cholera toxin (Sigma) termed complete KSFM (KSFMc).   
2.6.2.3  Subculture of human urothelial cell lines 
NHU cells were sub-cultured when approximately 90% confluent.  Cell 
monolayers were incubated in 0.1% (w/v) in Ethylenediaminetetra-acetic acid 
disodium salt (EDTA) in PBS for 5 minutes at 37°C to chelate calcium and 
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promote dissociation.  Cells were then incubated in 0.5ml of Hank’s balanced 
salt solution (HBSS; Invitrogen) containing 0.25% (w/v) trypsin and 0.02% 
(w/v) EDTA for <1 minute at 37°C.  Cells were resuspended in 10ml of KSFMc 
containing 2mg of Soya bean trypsin inhibitor (Sigma) and collected by 
centrifugation prior to reseeding at a ratio of 1:3.  Cells were used for 
experiments between passage 0-7 (P0-P7). 
2.6.3  Differentiation of human urothelial cell lines 
2.6.3.1  Induction of differentiation with Troglitazone and PD153035 
(21, 95) 
NHU cells were seeded into T25 flasks at a concentration of 4x105/flask and 
incubated in 5ml of KSFMc until approximately 70% confluent.  The PPARγ 
agonist troglitazone was added at a final concentration of 1µM (Day -1).  After 
24 hours, medium was replaced with fresh KSFMc containing 1µM PD153035 
and cultures incubated at 37°C (day 0).  RNA was harvested at day 3 post 
PD153035 addition, whilst protein and immunofluorescence analysis were 
carried out at day 6.  Medium was replaced with fresh PD153035 at day 3 if 
cells were to be cultured for longer than three days.  Control cells were treated 
as above except no Troglitozone or PD153035 was added but instead were 
solvent-balanced with DMSO and harvested as above. 
2.6.3.2  Induction of differentiation by ABS and 2mM CaCl2 (94) 
NHU cells were seeded at a concentration of 4x105 /T25 flask and incubated in 
KSFMc until approximately 80% confluent.  KSFMc medium was supplemented 
with batch tested Adult Bovine Serum (Harlan Sera-lab) at a final concentration 
of 5% (v/v) and incubated until confluent.  Cultures were trypsinised and 
passaged 1:2 into fresh flasks with KSFMc + 5% (v/v) ABS.  After 24 hours, 
CaCl2 was adjusted to 2mM to induce stratification.  Cell sheets were incubated 
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for a further 7 days, with the medium being replaced every 3 days.  Control 
samples were untreated in KSFMc and harvested at the same time point. 
2.6.4  Culture of established carcinoma cell lines 
2.6.4.1  Human urothelial carcinoma cell lines 
Three established urothelial cell carcinoma (UC) cell lines; RT4, RT112 and EJ 
(T24) were obtained from the Health Protection Agency Culture Collection 
(HPACC; Porton Down).  Prior to use, all UCC cell lines were genotyped to verify 
pedigree.  Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 5% (v/v) fetal bovine serum (FBS; Harlan Sera-Lab) and 
1% (v/v) L-glutamine in Iwaki tissue culture flasks (SLS) at 37°C in 10% CO2 in 
air.  UCC cell lines were passaged as for NHU cells, except the addition of 
trypsin inhibitor was omitted due to the presence of serum in the medium.  
Cells were passaged using a split ratio of between 1:10 and 1:60.  Genotyping 
data for all carcinoma cell lines used in this study can be found in Appendix IV. 
2.6.4.2  Osteoblast SaOS2 cell line 
The osteosarcoma cell line SaOS2 was obtained from American Type Culture 
Collection (ATCC; Manassas).  SaOS2 cells were cultured in McCoy’s 5A medium 
(ATCC) supplemented with 15% (v/v) FBS at 37°C in 5% CO2 in air.  Cells were 
passaged as for UC cell lines and were split at a ratio of 1:3, for a maximum of 
10 passages. 
2.6.4.3  Wnt3a and Wnt5a secreting L-cell lines 
Parental L cells, L Wnt-3a and L Wnt-5a lines were kindly provided by  
Dr. P. Genever, University of York.  All three lines are derived from the mouse 
fibroblast cell line LM(TK-) and were stably transfected with a Wnt3a or Wnt5a 
phosphoglycerate kinase (PGK) driven expression vector (96, 97).  These lines 
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are used for the production of conditioned medium containing either mouse 
Wnt3a or Wnt5a ligand, with parental L-cell conditioned medium as a control.  
All three lines were cultured in DMEM (11966; Invitrogen) containing 4mM L-
glutamine, 4.5g/L glucose and 10% (v/v) FBS.  The antibiotic G418 was added 
to the medium to maintain selection pressure at the following concentration; 
Wnt3a L-cells 0.4mg/ml; Wnt5a L-cells 0.6mg/ml. 
2.6.4.4  Production of secreted Wnt 3a or Wnt 5a ligand  
Confluent cultures were split at a ratio of 1:15 into 10ml of fresh growth 
medium without antibiotics and incubated for 4 days at 37°C in 10% CO2 in air.  
Conditioned media was harvested (batch 1) and the growth medium was 
replenished.  Cells were then cultured for a further three days prior to 
harvesting of the second batch of conditioned medium and then discarded.  
Both batches of conditioned medium were mixed and filtered through a 0.2µm 
Tuffryn® filter (Acrodisc) prior to immediate use or storage at 4°C for up to 3 
months.  
2.6.4.5  RetropackTM PT67 Packaging Cell Line 
The Retropack PT67 cell line (Clontech) is a NIH3T3 fibroblast derived cell line 
which has been genetically engineered to stably produce the retroviral gag, pol 
and env genes.  Once transfected with retroviral vector, cells produce a 
replication-defective retrovirus, with a broad (amphotrophic) mammalian host 
range.  Cells were routinely cultured in DMEM supplemented with 10% (v/v) 
FBS and were passaged as for UC cell lines.  Cells were split at a ratio of 
between 1:5-1:15.  Prior to transfection, cells were subjected to Hypoxanthine 
Aminopterin Thymidine (HAT; Invitrogen) medium re-selection as 
recommended by the supplier.  PT67 cells were firstly cultured in normal 
growth medium supplemented with 100nm aminopterin for 5 days, and then 5 
days in DMEM-HAT medium (30nm hypoxanthine, 1M aminopterin, 20mM 
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thymidine), and then finally 5 days in DMEM-HT medium (30mM hypoxanthine, 
20mM thymidine).  Immediately after HAT re-selection, PT67 cells were either 
cryo-preserved or transfected.   
2.6.4.6  Cryo-preservation and thawing of cell lines 
Cells were cryo-preserved and stored in liquid nitrogen in a Statebourne storage 
dewar at -196°C.  For cryopreservation of cell lines, cultures were harvested as 
for passaging and collected by centrifugation.  The cell pellet was resuspended 
in the appropriate ice-cold growth medium containing 10% (v/v) FBS and 10% 
(v/v) dimethylsulphoxide (DMSO) at a cell density not less than 1x106 cells/ml.  
Cells were aliquoted into 1ml polypropylene cryovials (Greiner) and transferred 
to an ice-cold “Mr Frosty” (Nalgene) containing 250ml of isopropanol (SLS) to 
control the cooling rate to 1°C per minute.  The cells were then placed within a 
-80°C freezer for 4-6 hours prior to transfer to liquid nitrogen.  Cells were 
thawed rapidly at 37°C and 5mls of pre-warmed growth medium was 
immediately added.  Cells were centrifuged at 400g for 5 minutes and then 
plated as required.  
2.6.5  Mycoplasma testing 
Mycoplasma spp. contamination is a huge problem in eukaryotic cell culture and 
can lead to unreliable experimental results (98).  All cell lines were routinely 
tested for intracellular bacteria Mycoplasma spp. prior to cryopreservation.  The 
presence of extra-nuclear staining with the DNA-intercalator bisbenzimide 
(Hoechst 33258) is highly suggestive of Mycoplasma spp. contamination and 
was employed as a simple screening tool for such infection.  Autoclaved 12-well 
Teflon-coated glass slides (Hendley-Essex) were placed into the chambers of a 
sterile Hereaus box (Sartorius).  Cells were seeded at a density of 1x104 cells 
per well and allowed to attach for 4 hours at 37°C.  Each chamber was flooded 
with 5ml of complete growth medium and the cells were then left to grow 
overnight at 37°C.  Medium was removed and slides were washed with 5ml of 
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PBS prior to fixing in methanol:acetone (50:50) for 30 seconds and air drying.  
Cells were stained with Hoechst 33258 (0.1µg/ml (w/v) in PBS) for 5 minutes in 
the dark, washed in PBS, air-dried and mounted in DABCO/glycerol antifade 
(appendix II).  Once dry, slides were examined using an Olympus BX60 
microscope using epifluorescence and the appropriate filter set. 
2.6.6  Genotyping 
Cross-contamination of cell lines is a serious and costly problem in today’s 
laboratory and can lead to confusion in the literature as well as retraction of 
previously published manuscripts (reviewed by (98)).  To reduce the chances of 
this, strict tissue culture practice was adhered to as well as routine 
authentication of each cell line prior to use.  Cell lines were genotyped using a 
PCR-based short tandem repeat (STR) analysis system to verify cell line 
pedigree.  STR’s are distributed throughout the genome and are highly 
polymorphic in number.  By counting the number of alleles for 9 different loci, 
one can determine with a high degree of certainty whether two cell lines are of 
the same origin.  The Powerplex® 1.2 system (Promega) allows identification 
of 9 independent loci (Penta E, D18S51, D21S11,TH01, D3S1358, FGA, TPOX, 
D8S1179 and vWA) from freshly isolated genomic DNA.  
2.6.6.1  Isolation of genomic DNA from cultured cells 
Genomic DNA (gDNA) was purified from cultured cells using a DNeasy Blood 
and Tissue Kit (Qiagen).  1x106 cells were collected into a universal, centrifuged 
at 400g for 5 minutes and resuspended in 200µl of PBS prior to genomic DNA 
extraction as recommended by the manufacturer (Qiagen).  In brief, samples 
were lysed using proteinase K and the genomic DNA (gDNA) was bound to a 
DNeasy mini column.  Each column was then washed to remove contaminants 
and the resulting gDNA eluted in 200µl of AE buffer (Qiagen).  DNA was 
quantified using a NanodropTM ND-1000 spectrophotometer (Thermo Fisher) 
and stored at 4°C until use. 
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2.6.6.2  STR genotyping using the Powerplex® 2.1 System (Promega) 
Genomic DNA was diluted to 0.4ng/µl using nuclease free water (Promega).  A 
PCR reaction was assembled on ice in a thin-walled 0.5ml PCR tube containing 
2.5µl of test gDNA (1ug), 2.5µl of Powerplex 1.2® 10x primer pair mix, 0.45µl 
of AmpliTaq Gold® DNA polymerase I and 17.05µl of nuclease free water.  A 
positive PCR reaction containing 1µg of K562 DNA was also assembled along 
with a no template negative control.  The PCR was then cycled in a GeneAmp® 
PCR system 9700 (Applied Biosystems) as described by the manufacturer  To 
each sample 9µl of Hi-Di™ formamide (Applied Biosystems) and 1µl internal 
lane standard (Promega) was added and mixed by vortexing.  10µl was then 
added to a well of a 96-well optical plate (Applied Biosystems) and was sealed 
with optical adhesive tape.  The sample was injected into a Beckman CEQ 8000 
fragment analyzer capillary electrophoresis system along with an Allelic ladder 
(Promega).  Results were analysed using GeneMapper® 4.0 software (Applied 
Biosystems) and the STR profile for each sample was compared to that found 
on the Health Protection Agency Culture Collection (HPACC) or American Type 
Culture Collection (ATCC) website (Appendix IV). 
2.7 Molecular Biology 
2.7.1  General 
All microbiological culture work was undertaken using aseptic technique and 
within the guidelines set out by the University of York for Good Microbiological 
Practice.  Before and after use, benches were cleaned with 2% (w/v)Virkon® 
and then 70% (v/v) ethanol (Fisher).  Waste cells and growth medium were 
treated with 2% (w/v) Virkon® overnight prior to disposal down the sink.  
Contaminated glassware was completely immersed in 2% (w/v) Virkon® 
overnight, after which it was rinsed and washed as normal.  Contaminated 
solids were autoclaved prior to disposal. 
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2.7.2  Plasticware 
Liquid cultures were grown overnight in 500ml glass Buchner flasks containing 
Luria Broth (LB; Appendix II).  Luria-Broth Agar plates (LBA; Appendix II) were 
poured into 9cm UV-irradiated Petri dishes and allowed to set prior to use.  
Sterilin single use inoculating loops and T-shaped spreaders were purchased 
from VWR. 
2.7.3  Plasmids 
Full details including vector map can be found in the appropriate section of use. 
Table 2-4 outlines all plasmids used in this study and the relevant supplier.  
Vector name Supplier Size 
(Kb) 
Promoter Use 
pSIREN- RetroQ Clontech 6.4 U6 shRNA knock-down 
(section 2.7.6 ) 
TOPFLASH Millipore 5.5 TK and TCF  Firefly luciferase reporter 
(section 2.10.3) 
FOPFLASH Millipore 5.5 TK and mutant 
TCF 
Firefly luciferase reporter 
(section 2.10.3) 
pRL-CMV Promega  4.1 CMV Renilla luciferase reporter 
(section 2.10.3) 
pBabe-EGFP Gift from Dr. 
N.Georgopoulos  
5.0 LTR Cell sorting-FACS analysis 
(section 2.10.4) 
Table 2-4 Plasmids 
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2.7.4  Amplification of plasmid DNA 
2.7.4.1  Transformaton of competent E-coli cells 
Amplification of previously established plasmid DNA: 20ng of plasmid DNA was 
transformed into a 50µl aliquot of DH5αTM ultracompetent E.coli cells 
(genotype: F- mcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74 recA1 ara139 (ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG>) (Invitrogen).  Plasmid was gently 
mixed with cells and incubated on ice for 30 minutes.  Cells were then heat 
shocked at 42°C for 30 seconds and returned to ice for 2 minutes.  250µl of 
S.O.C medium (Invitrogen) was added and the cells were incubated in an 
orbital shaker at 225rpm for 1 hour at 37°C.  100µl of the cell suspension was 
spread onto an LBA plate (appendix II) containing 100µg/ml ampicillin and 
incubated, inverted at 37°C, overnight.  A single colony was picked using a 
sterile single use loop and used to inoculate 5ml of LB containing 100µg/ml 
ampicillin and incubated at 37°C with shaking at 225rpm for 4 hours.  The 
culture was then used to inoculate a further 50ml of LB containing 100µl/ml 
ampicillin and incubated for 16 hours at 225rpm, 37°C. 
Amplification of ligated product (section 2.7.5.5): 5µl of ligated product was 
added to one 50µl thawed vial of TOP10® E.coli (genotype: F- mcrA Δ(mrr-
hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 
galE15 galK16 rpsL(StrR) endA1 λ-). DNA and bacteria were gently mixed and 
incubated on ice for 30 minutes prior to heat-shocking at 42°C for 30 seconds. 
Bacteria were then placed on ice for 2 minutes. 250µl of pre-warmed (37°C) 
S.O.C medium was added and the cell suspension was incubated at 37°C with 
shaking (220rpm) for 1 hour.   Between 20-200µl of cell suspension was then 
spread onto an LBA plate (appendix II) containing 100µg/ml ampicillin and 
incubated, inverted at 37°C, overnight.  Single colonies were picked using a 
sterile single use loop and used to inoculate 5ml of LB containing 100µg/ml 
ampicillin and incubated at 37°C with shaking at 225rpm for 16 hours.   
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2.7.4.2 Purification of plasmid DNA 
Plasmid DNA was recovered from overnight cultures using a Midi Endotoxin-free 
plasmid extraction kitTM (Qiagen).  Bacteria were harvested from the overnight 
cultures by centrifugation at 4000g for 10 minutes at 4°C.  The pellet was 
resuspended in 4ml of P1 buffer (50 mM Tris-Cl [pH 8.0], 10mM EDTA, 
100µg/ml RNase A) and vortexed until in suspension.  4ml of buffer P2 (200mM 
NaOH, 1% SDS) was added, inverted 6 times and incubated at ambient 
temperature for 5 minutes.  4ml of chilled buffer P3 (3.0 M potassium acetate, 
pH 5.5) was added and inverted several times to stop the lysis reaction.  The 
lysate was poured into the barrel of a QIAfilter cartridge and left for 10 minutes 
at ambient temperature to settle.  The cap was removed from the QIAfilter and 
the plunger was gently depressed.  The resulting flow through was collected 
into a 50ml polypropylene centrifuge tube and 1ml of ER buffer (proprietary 
recipe; Qiagen) was added, inverted ten times and then incubated on ice for 30 
minutes.  A Qiagen tip-100 was equilibrated by adding 10ml of QBT buffer 
(750mM NaCl, 50mM MOPS [pH 7.0], 15% isopropanol, 0.15% Triton X-100) 
and allowed to flow through under gravity.  The chilled lysate was added to the 
filter and allowed to enter the resin via gravity flow and then washed twice with 
10ml of QC buffer (1.0M NaCl, 50mM MOPS [pH 7.0], 15% (v/v) isopropanol).  
DNA was eluted into an autoclaved Corex 30ml tube (Gentaur) using 5ml of QF 
buffer (1.25 M NaCl, 50mM Tris-Cl [pH 8.5], 15% isopropanol).  DNA was 
precipitated by adding 3.5ml of isopropanol, mixed and centrifuged at 15000g 
for 30 minutes at 4°C.  The resulting DNA pellet was washed in 5ml of 
70%(v/v) ethanol, air dried and resuspended in nuclease free water.  Plasmid 
DNA was quantified using a NanodropTM Spectrophotometer and stored at  
-20°C. 
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2.7.4.3  Glycerol stocks 
Glycerol stocks were made from overnight LB cultures.  750µl of culture was 
aliquoted into a 1.5ml cryovial® and 250µl of sterile 80% (v/v) glycerol was 
added and mixed prior to long term storage at -80°C.  To recover bacteria, 5µl 
was streaked onto an LBA plate containing 100µg/ml ampicillin and incubated 
overnight at 37°C. 
2.7.5  Molecular cloning 
2.7.5.1  Restriction enzyme digestion 
Plasmid DNA was restriction enzyme digested to check for the presence of 
insert DNA.  Restriction enzyme digestion was typically carried out in a total 
volume of 20µl.  5µl (2-3µg) of DNA was digested with 5 units of restriction 
enzyme (New England Biolabs) in the appropriate buffer and at the temperature 
recommended by the supplier for 1-2  hours. 
2.7.5.2  Preparation of analytical agarose gels 
A clean plastic gel rig (100mm x 100mm) was sealed at the ends with autoclave 
tape to form a mould.  Combs were inserted into appropriate slots in the gel 
rig.  500mg of high purity agarose (Invitrogen) was mixed with 50ml of TBE 
buffer (Appendix II) and was heated in a microwave oven for 2 minutes, or 
until all of the agarose had dissolved.  The solution was then allowed to cool to 
around 45°C, after which, 1.2µl of ethidium bromide solution (5mg/ml) was 
added and mixed gently.  The solution was carefully poured into the gel rig and 
all bubbles were removed with a pipette tip.  The gel was allowed to set for at 
least 30 minutes prior to the combs and tape being carefully removed.  The gel 
rig was lowered into an Horizon® 58 electrophoresis gel tank (Gibco®; 
Invitrogen) with enough TBE buffer (appendix II) to cover the gel by about 3-
5mm. 
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2.7.5.3  Agarose gel electrophoresis 
DNA samples were diluted in 6x loading buffer (Blue:orange loading dye; 
Promega) and loaded into the wells of a pre-cast agarose gel.  5µl of 
Hyperladder I (Bioline) was loaded alongside.  DNA fragments were resolved by 
applying a voltage of 100V for approximately 45 minutes and visualised using a 
Gene Genius bio-imaging system and Genesnap 7.07 software (Syngene).   
2.7.5.4  Annealing of oligonucleotides 
10µl of each oligonucleotide at a concentration of 100pmol/µl were mixed in a 
microcentrifuge tube and the volume made up to 20µl with nuclease-free water.  
The mixture was heated to 95°C for 30 seconds, 72°C for two minutes, 37°C 
for two minutes, 25°C for two minutes and then cooled on ice.  Annealed oligo 
pairs were either used immediately for ligation or stored at -20°C. 
2.7.5.5  Ligation 
Ligations were typically carried out in a total volume of 20µl.  50µl of pre-cut 
vector was ligated with 3x (w/w) of insert DNA.  2µl of 10x ligation buffer 
(50mM Tris-HCl [pH7.8], 10mM MgCl2, 20mM dithiothreitol, 10mM ATP, 
50mg/ml of bovine serum albumin; Promega) was used per ligation, together 
with 1µl (200 units) of T4 DNA ligase (Promega).  The reaction was incubated 
at ambient temperature for 3 hours prior to transformation into One 
Shot®TOP10 E.coli . 
2.7.5.6  Sequencing 
Dye terminator cycle sequencing was undertaken by Cogenics (Beckman 
Coulter).  The resulting sequences were viewed using Chromas v1.45 
(Technelysium Pty Ltd) and were aligned using Fasta3 and the EMBL library. 
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2.7.6  Genetic manipulation of NHU cells  
2.7.6.1  Retroviral transduction 
The infection efficiency of retroviruses can be employed to rapidly and stably 
express a transgene of interest within a population of mitotically active cells.  
Transduction is much more efficient than many transfection protocols as it 
results in less cellular stress and subsequent cell death and is thus the method 
of choice when using finite cell lines. 
2.7.6.2  RNAi delivery plasmid 
RNAi ready pSIREN RetroQ (Clontech) is a self-inactivating retroviral expression 
vector designed to express shRNAs via a U6 promoter.  The vector encodes a 5’ 
long terminal repeat (LTR) containing a cytomegalovirus type 1(CMV) enhancer 
region and a mouse sarcoma virus (MSV) promoter to drive transcription of the 
RNA packaging signal Ψ+, shRNA of interest and puromycin resistance cassette 
in eukaryotic cells.  When expressed in the packaging cell line, PT67, the 
plasmid produces infectious but replication-incompetent viral particles, which 
can infect a wide host range but cannot replicate (Figure 2-1). 
2.7.6.3  shRNA design 
shRNA sequences were designed using the Clontech online design tool and 
incorporating BamHI and EcoR1 overhangs as well as an internal MluI 
restriction site to aid in selection of positive clones. 
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Figure 2-1 pSIREN RetroQ plasmid 
pSIREN RetroQ plasmid is based on the Moloney mouse leukemia virus (MMLV) and can be 
used for targeted gene silencing using RNAi.  Oligonucleotides encoding short-hairpin RNA 
sequences can be cloned between the BamHI and EcoRI restriction enzyme sites.  Plasmid  is 
then propagated in competent E.coli bacteria using the ColE1 origin of replication (ColE1ori) and 
successfully transformed cells are selected via expression of the ampicillin resistance gene 
(Ampr). Upon transfection into the packaging cell line, PT67, the RNA packaging signal (Ψ+), 
shRNA of interest and puromycin resistance cassette (Puror) is transcribed via a 5’ long terminal 
repeat (LTR) containing a cytomegalovirus type 1(CMV) enhancer region and a mouse sarcoma 
virus (MSV) promoter.  During reverse transcription of the retroviral RNA, the 3' LTR is copied 
and replaces the 5' LTR, resulting in inactivation of the 5' LTR CMV enhancer sequences.  
Vector is then packaged and the resulting retroviral particles can be utilised to infect a variety 
of mammalian cells.  In target cells, expression of the short hairpin RNA and Puror is driven via 
a U6 promoter, an RNA Polymerase III-dependent promoter.  Image reproduced from the 
Clontech pSIREN RetroQ manual PT3737-5.  
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2.7.6.4  Transfection of the packaging cell line PT67 
All procedures involving transfected PT67 cells were carried out in a class II 
externally vented tissue culture hood.  The packaging cell line PT67 was 
maintained in DMEM (Invitrogen) supplemented with 10% (v/v) FBS and 1% 
(v/v) L-glutamine until 60% confluent.  Cells were transfected using Effectene 
(Qiagen), a lipid-based transfection reagent according to the manufacturer’s 
instructions.  In brief, 5µg of endotoxin-free plasmid DNA was mixed with 150µl 
of buffer EC and 40µl of enhancer, vortexed for one second and incubated at 
ambient temperature for 5 minutes.  50µl of Effectene transfection reagent was 
added, vortexed for 10 seconds and incubate at ambient temperature for a 
further 10 minutes.  To this, 1ml of complete growth medium (DMEM with 10% 
(v/v) FBS and 1% (v/v) L-glutamine) was added, gently mixed and then added 
drop-wise to the flask.  A negative control culture where the plasmid DNA was 
omitted was included in all experiments.  Cultures were incubated for 16 hours, 
after which the medium was replaced with fresh, pre-warmed complete growth 
medium and the cells were left to reach confluence.  At confluency, the 
transfected PT67 cells and negative control flask were harvested as with routine 
passaging and reseeded at a split ratio of 1:2 into complete medium 
supplemented with 4ug/ml of puromycin (Autogen Bioclear).  A 100% stably 
transfected cell population was assumed in the test flask when all cells in the 
untransfected negative control flask had perished.  Transfected PT67 cells were 
maintained under puromycin selection pressure until viral particles were 
harvested. 
2.7.6.5  Retroviral transduction of urothelial cells 
Stably transfected PT67 cells were grown to 100% confluence when the 
medium was changed to 10ml DMEM:RPMI (50:50) supplemented with 5% 
(v/v) FBS (no antibiotics) for 16 hours.  Conditioned virus-containing medium 
was  harvested and filtered through a 0.45µm Tuffryn® filter (Acrodisc) to 
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remove any cellular debris and 8µg/ml polybrene (Sigma) was added.  Medium 
was removed from 2 T75 flasks of passage 1 (P1) NHU cell cultures at 
approximately 50% confluence.  8ml of virus-containing medium was added to 
one culture. The remaining culture was treated with 8mls of DMEM:RPMI 
(50:50)+5% (v/v) FBS to serve as an negative control.  Both cultures were then 
incubated at 37ºC for 4-6 hours after which the medium was replaced with 
15ml KSFMc.  At 48 hours post transduction, both cultures were trypsinised and 
passaged 1:3 into KSFMc supplemented with 2mg/ml puromycin.  A 100% 
stably transduced cell population was assumed in the test flask when all cells in 
the untransduced negative control flask had perished.  Puromycin selection 
pressure was then maintained at a reduced concentration of 0.5mg/ml. 
2.8 Gene Expression Analysis 
2.8.1 General 
Before working with RNA, all surfaces and pipettes were cleaned with RNase 
Zap® (Ambion).  Glassware and 13ml polypropylene tubes and caps (Starstedt) 
were incubated at ambient temperature, overnight with 0.1% (v/v) diethyl 
pyrocarbonate (DEPC) (Sigma) to inactivate RNase activity.  Glass and 
plasticware was then autoclaved and air-dried prior to use.  Only DNase and 
RNase free pipette tips (Axygen;Fisher Scientific) and nuclease-free 
microcentrifuge tubes (Ambion) were used.  RNA was reconstituted in nuclease-
free H2O (Promega). 
2.8.2  RNA Extraction 
Cell lysates were prepared from cultures in situ using TRIzolTM reagent 
(Invitrogen).  Growth medium was removed and the cell monolayer was 
washed in 10ml of PBSc.  5ml of TRIzolTM was added for 5 minutes on a rotary 
shaker and lysates were collected into 13ml polypropylene tubes using a cell 
scraper (Greiner) and either extracted as outlined below or stored at -80°C.  
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Frozen lysates were thawed on ice and total RNA was extracted by the addition 
of 1ml of chloroform (BDH).  Tubes were vortexed for 15 seconds and 
incubated for 5 minutes at ambient temperature prior to centrifugation at 
12,000g, 4°C in a refrigerated centrifuge (Sorvall RC-5, Du-Pont) for 15 
minutes.  The upper aqueous phase was carefully removed to a fresh 13ml tube 
and the RNA was precipitated using an equal volume of isopropanol for 10 
minutes at ambient temperature.  Precipitate was collected by centrifugation at 
12,000g for 10 minutes at 4°C and was washed with 5ml 70% (v/v) ethanol.  
The resulting pellet was air-dried and resuspended in 30µl of nuclease–free H2O 
prior to transfer into a 0.5ml nuclease-free tube. 
2.8.3  DNase treatment of RNA 
Residual genomic DNA contamination was removed by DNase I digestion.  RNA 
was incubated with 1µl of DNase I (DNA-freeTM; Ambion) and an appropriate 
volume of 10x DNase I buffer for 30 minutes at 37°C.  5µl or 1/10th  volume 
(whichever was greater) of DNase inactivating reagent was added to terminate 
the reaction.  After a 2 minute incubation at ambient temperature, the DNase 
inactivating reagent was removed by centrifugation at 10,000g for 1 minute.  
RNA supernatant was collected and transferred to a fresh nuclease-free tube 
and stored at -80°C.  RNA quality and quantity was assessed using a 
NanodropTM ND-1000  Spectrophotometer (Thermo Fisher). 
2.8.4  RNA precipitation using sodium acetate 
To remove contaminants such as ethanol and salt (evident by a low 
260nm:230nm ratio), RNA was cleaned using alcohol and salt precipitation.  
1/9th volume of 3M Sodium Acetate and 2.5 x volume of ethanol was added, 
vortexed, and left at -80°C for at least 16 hours.  Tubes were centrifuged at 
maximum speed in a benchtop refrigerated centrifuge (Hettich; SLS) for 30 
minutes at 4°C and washed with 500µl of 70% (v/v) ethanol, air-dried and 
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resuspended in an appropriate volume of nuclease-free H2O.  RNA was then re-
quantified using a Nanodrop spectrophotometer and stored, aliquoted at -80°C. 
2.8.5  Reverse Transcriptase Polymerase Chain Reaction  
RT-PCR is a powerful technique used to detect the presence of a specific mRNA 
transcript in a population of cells.  RT-PCR involves two steps; the reverse 
transcription of mRNA and subsequent PCR amplification.  mRNA transcripts are 
converted to complementary DNA (cDNA) using RNA-dependant DNA 
polymerase.  The resulting thermostable cDNA is then used as a template for 
PCR amplification using specific primers targeted to the gene of interest.  The 
amplified product can then be visualised using agarose gel electrophoresis. 
2.8.6  First-strand cDNA synthesis - Reverse transcription (RT) 
cDNA was synthesised using 1µg of total RNA, 50ng of random hexamer 
primers and a SuperscriptTM II first-strand cDNA synthesis kit (Invitrogen).  
After incubation at 65°C for 10 minutes the RNA/hexamer mix was snap-cooled 
on ice for 1 minute and 7µl of a “master mix” containing the following was 
added to each reaction: 2µl of Reverse transcription buffer, 2µl of 25mM MgCl2, 
2µl of 0.1mM Dithiothreitol (DTT) and 1µl of 10µM dinucleotide triphosphate 
(dNTP) mix.  Tubes were gently mixed and incubated at 25°C for 2 minutes 
prior to addition of 1 unit of SuperscriptTM II reverse transcriptase enzyme.  
Samples were incubated at 25°C for 10 minutes prior to transfer to a 42°C 
heatblock for 50 minutes.  The reaction was then inactivated at 70°C for 10 
minutes and the resulting cDNA was stored at -20°C until use.  For each RNA 
sample a negative control reaction was included where the reverse transcription 
enzyme was omitted (RT negative). 
 
Chapter 2 
76 
 
2.8.7  Primer design for PCR  
mRNA coding sequences for genes of interest were obtained from the Ensembl 
database (99).  Where more than one transcript variant was found, the 
sequences were aligned and primers designed to regions of homology.  Primers 
of between 18-27bp in length were designed using Primer3 version 04.0 
software (Whitehead Institute for Biomedical Research, USA) and default 
parameters, except GC content was restricted to between 40-60%, and melting 
temperature (Tm) was set to between 56-63°C.  Amplicon size was restricted to 
300-400bp and was always within one exon.  Primers were selected against 
primer dimer formation or strong secondary structure.  Specificity was checked 
using an NCBI primer BLAST® search prior to ordering (Eurofins).  On arrival, 
primers were reconstituted in nuclease free H2O to a concentration of 100mM 
and stored at -20°C.  Primer sequences are detailed in Appendix V. 
2.8.8  PCR primer testing 
Primer binding efficiency and optimal annealing temperatures for each primer 
set were determined using a gradient PCR.  A 10-reaction master mix was 
assembled on ice as follows: 50µl of 20ng/µl human genomic DNA (Promega), 
25µl of 10x reaction buffer (Agilent), 2µl of dNTP mix (25mM each dATP, dCTP, 
dGTP, dTTP; Invitrogen), 10μl of each primer (10mM stock), 2µl (1 Unit) 
SureStart Taq DNA Polymerase (Agilent) and 151µl of nuclease-free H2O.  8 x 
25µl reactions were then assembled in thin-walled PCR tubes (Axygen;Fisher 
Scientific) and subjected to the following PCR conditions with a gradient 
annealing temperature present across the PCR block (Left-Right); 9 minutes at 
94ºC, 26 cycles of denaturation for 30 seconds at 94ºC, annealing for 30 
seconds at 50-60ºC and a 1 minute extension at 72ºC.  A final elongation phase 
of 10 minutes at 72ºC was then followed by a 4ºC hold.  10µl of each PCR 
reaction was analysed via agarose gel electrophoresis.  The annealing 
temperature which produced the strongest band at the expected size was then 
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chosen for RT-PCR.  If specific product yield was poor or secondary bands were 
present, primers were redesigned. 
2.8.9  PCR 
All PCR reactions were undertaken in thin-walled 8-well strip PCR tubes 
(Axygen; Fisher Scientific) using a PCR Express thermocycler (Hybaid).  For 
each experiment a PCR mastermix was prepared on ice to minimise pipetting 
error.  Each reaction contained as follows: 5µl of cDNA (or 5µl of 20ng/µl 
human genomic DNA (Promega)), 2.5µl of 10x reaction buffer (Agilent), 0.2µl of 
dNTP mix (25mM each dATP, dCTP, dGTP, dTTP; Invitrogen), 1μl of each 
primer (10mM stock), 0.2µl (1 Unit) SureStart® Taq DNA Polymerase (Agilent) 
and 15.1µl of nuclease-free H2O.  Each experiment included the following 
controls: an RT negative control for each test sample to assess for genomic 
DNA contamination, a genomic DNA positive control (100ng) to verify the PCR 
reaction had been successful and a β-actin control PCR for each test sample to 
verify the integrity of the cDNA.  A hotstart Taq polymerase was used in all 
experiments to reduce background noise and increase efficiency.  cDNA 
template was denatured and Surestart® Taq polymerase activated with a 9 
minute, 94ºC pre-heat step.  This was followed by 30 cycles of denaturation at 
94ºC for 30 seconds, annealing for 30 seconds at 50-55ºC (depending on 
primer pair) and a 1 minute/Kb extension at 72ºC.  A final elongation phase of 
10 minutes at 72ºC was then followed by a 4ºC hold.  PCR products were 
analysed using agarose gel electrophoresis.  
2.8.10 Quantitative Polymerase Chain Reaction (qPCR) using 
SYBR® -Green I technology 
Quantitative PCR (qPCR) measures the accumulation of PCR products over time 
and allows the measurement of amplicon product throughout the experiment 
not just at a predetermined end-point.  This is achieved by addition of SYBR®-
Green I Dye, a DNA intercalator which binds to double stranded DNA formed 
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during the PCR reaction.  Once bound to DNA, SYBR® -Green I emits a 
fluorescent signal which is proportional to the amount of PCR product present 
and can be excited using a tungsten halogen lamp or argon laser (at 488nm) 
and detected using a charged coupled device (CCD) image sensor.  A well 
optimised reaction is essential for accurate results, as SYBR®-Green I dye will 
bind to all double stranded DNA including non-specific product.  Therefore it 
was essential that all primer pairs were tested for specificity as outlined in 
section 2.8.12. 
2.8.11 Primer design for qPCR  
Primes were designed using Primer Express Software v.3 (Applied Biosystems) 
and default parameters.  Primers were of 16-27bp in length with an optimal Tm 
of 58-60°C.  Amplicons were of 100-150bp in length and were always within an 
exon.  Specificity was checked using NCBI primer BLAST® prior to ordering from 
Eurofins.  Primers were reconstituted in nuclease free H2O and stored frozen at 
-20°C.  All Primer sequences can be found in appendix V. 
2.8.12 qPCR primer testing 
RTqPCR primers were tested for specificity and primer binding efficiency prior 
to use.  A dissociation curve or melt curve was used to determine the number 
of products generated within a reaction.  dsDNA product was melted into ssDNA 
by an increase in temperature over time.  The magnitude of the reduction in 
fluorescence at each increment was then plotted as a dissociation curve.  For 
each dissociation curve, an RT negative and water only control was included.  If 
more than one major peak (one PCR product) was detected, primers were 
redesigned.  Dissociation plots for primer pairs can be found in appendix VI. 
2.8.13 qPCR  
Reactions were prepared with SYBR-Green I PCR Master mix (Applied 
Biosystems) containing the SYBR-Green I Dye, AmpliTaq Gold DNA 
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polymerase, dNTPs, buffer components, and a passive ROX reference to allow 
for background correction.  Reactions were assembled as follows on ice in a 96-
well optical reaction plate (ABI): 5µl of template cDNA, 12.5µl of 2x SYBR-
green I PCR Master mix, 400nm of each primer and 5.5µl of nuclease free H2O.  
The plate was sealed with an optical adhesive cover (ABI) and run on an ABI 
7300 sequence detection system using the following thermal cycle profile: 2-
minute hold at 50°C, incubation at 95°C for 10 minutes, followed by 40 cycles 
of denaturation at 95°C for 15 seconds and elongation at 60°C for 1 minute.  
Each sample was run in triplicate alongside an RT negative control sample from 
which the reverse transcriptase enzyme had been omitted.  A water only (no 
template) control was included on each plate.  Loading controls targeted to 
GAPDH were included for each sample.  Data was collected using ABI Sequence 
detection software v1.2.3f2 and normalised against the passive reference 
fluorophore ROX.  Data was analysed using the comparative cycle threshold 
(CT) method as described by the manufacturer (100).  Thresholding was set in 
the region of exponential amplification and cycle threshold values (CT) were 
calculated as the cycle number required to cross the threshold. Data was 
expressed as relative quantification (RQ) using GAPDH as the loading control:  
Each sample was calculated relative to loading control to give ∆ CT; 
∆CT values (CT target-CT reference gene GAPDH) 
∆ CT was expressed as relative to the calibrator sample; 
∆∆CT values (∆CT test sample-∆CT calibrator) 
∆∆CT was converted to relative quantification; 
RQ=2-∆∆CT 
Results were then expressed as log (base2) from calibrator sample. 
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2.8.14 AffymetrixTM analysis 
Affymetrix .CEL files were analysed using ArrayassistTM 5.5.1 software (Agilent).  
Background was removed and chips were normalised using the Microarray suite 
5 (MAS5) algorithm before an absolute calls database was generated (101).  
Signal intensities were transferred to Excel® and Ingenuity® Pathway Analysis 
(IPA) software (Ingenuity Systems Inc) for further analysis. 
2.9 Protein Analysis 
2.9.1 Indirect immunofluorescent labelling of cultured cells 
Immunolabelling of cells uses the specificity of antibody-antigen interactions to 
visualise the distribution of a protein within a fixed cell population.  Indirect 
immunofluorescence uses two antibodies, the first or primary antibody targets 
the protein of interest, whereas the secondary antibody is conjugated to a 
fluorophore and binds specifically to the primary antibody.  The fluorophore can 
then be excited using an appropriate wavelength and the resulting emission 
visualised using a fluorescent microscope. 
2.9.1.1  Slide preparation 
Teflon® coated 12-well multispot slides (CA Hendley) were wiped with 70% 
(v/v) ethanol and autoclaved prior to use.  Slides were placed into a sterile  
4-chambered Hereaus box using sterile forceps.  Cells in culture were seeded at 
a density of 5x103 – 2x104 cells/well, depending on the experiment.  Slides 
were then incubated at 37°C for 3 hours to allow cell attachment prior to 
flooding with 5ml of the appropriate medium.  At designated time points, cells 
were fixed using either methanol:acetone (50:50) or 10% (v/v) formalin 
depending on the antigen of interest. 
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2.9.1.2 Methanol:Acetone fixation  
Cells were fixed by immersion in 5ml of 50:50 (v/v) methanol:acetone  for 30 
seconds, air dried and stored desiccated at -20°C until required.  Once thawed 
to ambient temperature, wells were delineated using a delineating pen 
(DakoCytomation). 
2.9.1.3  Formalin fixation  
Slides were fixed in 10% (v/v) formalin in PBSC for 15 minutes and then 
washed with PBS for 5 minutes.  Cells were permeabilised and blocked with 
0.5% (v/v) Triton-X + 5% (v/v) FBS in PBS for 1 hour at ambient temperature.  
Wells were then delineated using a delineating pen.  
2.9.1.4  Fluorescent immunolabelling of cultured cells 
50µl of primary antibody at a predetermined dilution was added to each well 
and incubated for 16 hours at 4°C.  No primary antibody negative controls (TBS 
only) were included in each experiment.  Slides were washed 3x in TBS 
(appendix II) for 5 minutes.  50µl of appropriate Alexa 488/Alexa 594-
conjugated secondary antibody was applied to each well and incubated in the 
dark, at ambient temperature for 1 hour.  Slides were then washed five times 
with TBS on an orbital shaker for five minutes each.  To aid visualisation, the 
cell nuclei were stained with Hoechst 33258 (0.1µg/ml) in the penultimate 
wash.  Slides were air-dried, mounted in DABCO/glycerol antifade (appendix II) 
to reduce photo-bleaching and sealed with nail varnish. 
2.9.1.5  Photomicroscopy of immunofluorescent labelled cells  
Cells were visualised on an Olympus BX60 microscope under epifluorescent 
illumination using x20, x40 and x60 oil immersion objectives.  The microscope 
was equipped with the appropriate excitation and emission filters for 
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bisbenzimide, dual and specific filters for FITC and Texas Red.  Images were 
taken using an Olympus DP50 digital camera and analysed with Image-Pro® 
Plus software (MediaCybernetics) and Photoshop CS4 (Adobe) as outlines in 
section 2.9.1.6.  
2.9.1.6 Calculating nuclear and cytoplasmic protein expression from 
immunofluorescent images  
Nuclear and cytoplasmic labelling was quantified using Photoshop CS4 (Adobe) 
as described by Kirkeby and colleagues (102).  In brief, Hoechst images were 
superimposed onto the adjacent fluorescent image to be quantified.  
Background labelling was normalised and the Hoechst image was used as a 
mask to calculate mean nuclear intensity from the histogram.  Selection was 
then inversed to give cytoplasmic and membrane labelling intensities.  One 
should note that if images are over-saturated PhotoshopTM will not be able to 
make any distinction between saturated and over-saturated pixels and 
inaccuracies in the quantification of mean nuclear intensity will result.   
2.9.2  Western blotting 
Western blotting is a powerful and widely used analytical technique to detect 
specific proteins within a cell lysate.  The principle of western blotting involves 
size fractionation of a cell lysate using gel-electrophoresis and subsequent 
transfer onto a solid membrane prior to addition of an antibody specific to the 
target protein of interest.  A near-infrared (NR) fluorphore-conjugated 
secondary antibody raised against the primary antibody is then added to the 
membrane and the membrane is scanned using an infrared scanner.  
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2.9.2.1  Protein extraction 
Cell cultures were lysed in situ at approx 70% confluence unless otherwise 
stated.  Medium was aspirated and cell sheets were washed 2x in ice-cold D-
PBS (Appendix II).  100µl of 2x sodium dodecyl sulphate (SDS) buffer 
(appendix II) containing 2mg/ml DTT and 0.2%(v/v) protease inhibitor cocktail 
set 3 (Calbiochem) was pipetted onto the cell monolayer and the cells were 
scraped using a cell scraper (Greiner) into a chilled microcentrifuge tube.  
Samples were sonicated using an ultrasonic probe (Jencons Scientific) for three 
10-second bursts and then rested on ice for 30 minutes.  The lysates were 
centrifuged at 18,500g, 4°C for 30 minutes to pellet the insoluble material 
before aliquoting the supernatant and storing at -20°C.  
2.9.2.2  Protein Quantification 
Total protein content of each sample was determined using a Coomassie 
protein reagent assay kit (Pierce).  Samples were diluted 1:12.5 in dH2O and 
10µl was aliquoted in duplicate into a 96-well flat bottomed plate.  A seven 
point standard curve of 0-1mg/ml BSA (Pierce) was included on each plate.  
200µl of ambient temperature Coomassie reagent was added to each well and 
mixed gently by pipetting.  Absorbance was measured using a Multiskan 
Ascent® V1.25 plate reader (Thermo Fisher) at 570nm (test) and 630nm 
(reference) against a dH2O control.  Ascent software 2.6 (Thermo Fisher) was 
used to plot a standard curve for the BSA and to estimate the protein 
concentration for each lysate. 
2.9.2.3  SDS-Polyacrylamide gel Electrophoresis (SDS-PAGE) 
20µg of protein lysate was made up to 13µl with 2x SDS-lysis buffer.  5µl of 4x 
lithium dodecyl sulfate sample buffer (LDS; Invitrogen) and 2µl of 10x reducing 
agent (Invitrogen) was added and the sample denatured by heating to 70°C for 
10 minutes in a heatblock.  10-well NuPAGETM Novex electrophoresis pre-cast 
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gels (Invitrogen) were placed into an Xcell SurelockTM mini-cell upright 
electrophoresis tank (Invitrogen).  200ml and 600ml of 1x NuPAGETM SDS 
running buffer (Invitrogen) was poured into the inner and outer chambers, 
respectively.  500µl of NuPAGETM antioxidant (Invitrogen) was added to the 
inner chamber prior to loading of the samples.  5µl of All-Blue Precision Plus 
ProteinTM standard (Bio-Rad) was loaded alongside as a marker of protein size 
and the gel was run at 150V for 90 minutes. 
2.9.2.4  Electrophoretic membrane transfer 
Electrophoretically-seperated proteins were transferred onto Immobilon-PTM 
polyvinylidine difluoride membrane (PVDF; Millipore) using an Xcell IITM blot 
module (Invitrogen).  PVDF membrane was dipped in methanol, rinsed in dH2O 
and then soaked in 0.5x “Towbin” transfer buffer with 20% (v/v) methanol 
(appendix II) along with the required number of blotting pads and WhatmanTM 
filter paper (SLS) for 30 minutes.  The gel membrane sandwich was assembled 
cathode to anode as follows; 2x blot pads, filter paper, gel, PVDF membrane, 
filter paper, 2x blot pads.  The blot module was secured into the Xcell 
SureLockTM Mini-Cell and filled with transfer buffer.  The outer chamber was 
filled with dH2O and the transfer was performed at 25V for 2 hours on ice.  
2.9.2.5  Ponceau Red staining 
Protein transfer was visualised on the PVDF membrane by reversible Ponceau 
red staining.  The PVDF membrane was soaked in 42mM Ponceau red in 3% 
(v/v) trichloroacetic acid for 5-seconds and then washed in dH2O.  
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2.9.2.6  Immunolabelling of PVDF membrane using Li-Cor Odyssey 
To minimise non-specific binding, membranes were blocked in 50:50 (v/v) 
Odyssey blocking buffer (Li-Cor):10mM TBS pH 7.6 at ambient temperature on 
an orbital shaker for 1 hour.  Membranes were then probed for 16 hours at 4°C 
with 5-8ml of pre-titrated primary antibody diluted in 50:50 Odyssey blocking 
buffer:TBS+0.2% (v/v)Tween-20 (Table 2-1).  Membranes were washed 5x 5 
minutes in TBS+0.1% (v/v)Tween-20 prior to addition of 5ml of appropriate 
Alexa Fluor® -conjugated secondary antibody (Table 2-2) for 1 hour at ambient 
temperature with shaking.  Membranes were washed as for primary antibody 
and then washed 1x for 5 minutes with TBS prior to visualisation using an 
OdysseyTM Infra-red Imaging system (Li-Cor).  Equal loading was verified using 
an antibody raised against the house keeping gene, β-actin.  Densitometry was 
performed using Odyssey V1.1 software (Li-Cor) and protein expression was 
normalised relative to β-actin.  
2.9.2.7  Membrane stripping and re-probing 
PVDF Membranes were incubated in 5mls of 1x western blot recycling reagent 
(Autogen Bioclear) for 20-30 minutes at ambient temperature on an orbital 
shaker.  Membranes were then washed in TBS, re-blocked with 50:50 (v/v) 
Odyssey blocking buffer:TBS and re-probed up to 4 times.  
2.10 Cell based assays 
2.10.1 Cell viability assay 
Cell viability was measured using a Methylthiazolyldiphenyl-tetrazolium bromide 
(MTT) assay.  MTT is reduced to an insoluble formazan purple crystal by the 
activity of the mitochondrial enzyme, dehydrogenase.  The amount of formazan 
purple crystal produced over a set time period can be measured by dissolving in 
a suitable solvent and performing a spectrophotometric analysis.  The amount 
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of formazan crystal produced is generally proportional to the amount of 
mitochondrial activity and is assumed to be comparable to viable cell number.  
NHU cells were seeded into a 96-well PrimariaTM plate at a density of 2x103 cells 
per well in 200µl of KSFMc and were incubated for 24 hours at 37°C (day - 1). 
Plates were treated with inhibitors in triplicate wells (day 0) and assayed at day 
0,1, 3 and 6.  A solvent balanced control was included at each timepoint.  To 
assay, medium was removed and 200µl of 0.5mg/ml MTT was incubated on the 
cells for 4 hours at 37°C.  MTT solution was then removed and the resulting 
formazan crystals were dissolved in 200µl of spectrophotometric grade DMSO.  
Absorbance was measured at 570nm (test) and 630nm (reference) against a 
DMSO control using a Multiskan Ascent® V1.25 plate reader (Thermo Fisher) 
and Ascent software 2.6 (Thermo Fisher).  Absorbance is directly proportional 
to mitochondrial activity in each sample, which in turn is assumed to be 
proportional to viable cell biomass and cell number. 
2.10.2 Luciferase Reporter assays 
Reporter assays are used to assess the activity of a signal transduction pathway 
by assessing the functional status of the downstream transcription factor (TF).  
Luciferase (Luc) reporter constructs contain the TF binding site of interest, 
upstream of a luciferase reporter gene.  The vector can be transfected into cells 
and the activity of the reporter gene measured using a chemiluminescent assay. 
2.10.2.1 TOPFLASH/FOPFLASH TCF reporter plasmids 
TOPFLASH TCF reporter plasmid (Millipore) is a luciferase reporter of β-catenin 
mediated transcription first described by Korinek and colleagues (103).  
Activation of the three TCF-binding sites upstream of a thymidine kinase (tk) 
minimal promoter leads to transcription and translation of the encoding Firefly 
luciferase (Photinus pyralis) gene (Figure 2-2) and can be quantified via a dual 
luciferase reporter assay (section 2.10.3.6). The negative control plasmid, 
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FOPFLASH (Figure 2-2), has an identical backbone and minimal promoter but 
contains a mutated TCF binding site which does not bind TCF transcription 
factor and is used to assess basal activity from the minimal promoter. 
 
Figure 2-2 TOPFLASH/FOPFLASH vectors 
Schematic representation of the luciferase reporter constructs TOPFLASH and FOPFLASH used 
for assessing TCF trancription factor activity.   In bacteria, plasmid is replicated using the ColE1 
origin of replication (ColE1Ori) and successfully transformed cells are selected via expression of 
the ampicillin resistance casette (Ampr).  In mammalian cells, Firefly luciferase expression is 
driven via the thymidine kinase minimal promoter (TK prom.) and potential TCF binding sites.  
Image reproduced from Millipore catalogue number 1-285. 
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2.10.2.2 pRL-CMV internal control plasmid 
The pRL-CMV vector (Figure 2-3; Promega) is a normalising transfection control 
reporter for use in combination with the Firefly luciferase reporter construct, 
(TOPFLASH/FOPFLASH).  pRL-CMV contains a CMV promoter to drive high-level 
expression of Renilla luciferase (Renilla Reniformis) which can be measured in 
conjunction with Firefly luciferase using a Dual luciferase reporter assay. 
 
Figure 2-3 pRL-CMV reporter construct 
pRL-CMV is intended for use as an internal control reporter vector in combination with a Firefly 
luciferase reporter vector such as TOPFLASH/FOPFLASH.  pRL-CMV Vector can be propagated in 
competent E.coli bacteria using the ColE1 origin of replication (Ori). Successfully transformed 
cells can be selected via expression of the ampicillin resistance gene (Ampr).   pRL-CMV 
contains the cytomegalovirus (CMV) immediate/early enhancer/promote to drive high-level 
expression of Renilla luciferase (Rluc) in mammalian cells. An SV40 Late Polyadenylation Signal 
(SV40 late poly(A)) enhances RNA stability and translation via the addition of a poly A-tail. 
Image reproduced from catalogue E2261 (Promega). 
2.10.2.3 Transfection 
The transfection of NHU cells using liposome-based gene transfer was 
optimised using a GFP reporter plasmid and analysis by flow cytometry (FSC vs. 
SSC plots and histograms can be found in Appendix VII).  Five different 
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transfection reagents were tested in parallel on NHU cells, alongside a non-
transfected control to assess toxicity.  Each reagent was tested at the 
manufacturer’s recommended ratio of lipid to DNA.  Of the five reagents tested, 
Fugene®HD (Roche) was chosen as the most effective reagent for liposome 
mediated gene delivery as it was tolerated well by NHU cells and yielded the 
highest transfection rate (Appendix VII).   
2.10.2.4 Transfection of NHU cells with Fugene®HD transfection 
reagent 
NHU cells were seeded into a 24-well plate in KSFMc at a concentration of 
4x104 cell/well and incubated overnight at 37°C in 5% CO2 in air.  The following 
day, 0.5µg of either TOPFLASH or FOPFLASH along with 0.01µg of pRL-CMV 
plasmid was mixed in 40µl of serum-free medium (Optimem; Invitrogen) 
containing 3µl of Fugene® HD transfection reagent and incubated at ambient 
temperature for 30 minutes.  KSFMc was removed from the 24-well plate and 
replaced with 0.5ml of Optimem medium.  DNA:Fugene complex was added 
dropwise to each well and gently mixed by rocking.  The transfection was 
incubated at 37°C with 5% CO2 in air for 16 hours, after which the medium was 
replaced with normal growth medium and the cells were treated with Wnt 
ligand or GSK3β inhibitor for 24-72 hours. 
2.10.2.5 Cell lysis 
Medium was removed and cells were rinsed in 1ml of PBS per well.  100µl of 1x 
passive lysis buffer (Promega) was incubated in each well for 15 minutes with 
gentle agitation.  Lysate was transferred to a 1.5ml autoclaved microcentrifuge 
tube and stored at -20°C for no more than 2 weeks before analysis. 
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2.10.2.6 Dual luciferase reporter assay 
All reagents were prepared as described by the manufacturer (Promega).  In 
short, lyophilised Firefly luciferase assay substrate was reconstituted in 10ml of 
luciferase assay buffer II (LARII).  Stop and GloTM reagent was prepared by 
mixing 1:50 Stop and gloTM buffer to 50x Stop and GloTM substrate.  Both 
reagents were kept out of the light and on ice.  20µl of each sample to be 
tested was dispensed into a black flat-bottomed 96-well plate in triplicate.  
100µl of LARII was dispensed into each well and luminescence from Firefly 
luciferase was measured using a BMG Labtech POLARstar Optima plate reader.  
100µl of Stop and GloTM reagent was then added to extinguish Firefly luciferase 
activity and activate Renilla luciferase.  Luminescence from Renilla luciferase 
was recorded and used to normalise the experimental data for differences in 
transfection efficiency (Figure 2-4). 
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Figure 2-4 Dual Luciferase reporter assay 
Schematical representation of a dual luciferase assay to measure Wnt signalling and 
downstream TCF activity.  Adapted from Promega technical manual TM040.  
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2.10.3 Flow Cytometry 
NHU Cells were harvested as for routine passaging, washed and re-suspended 
in 100µl of FACS buffer (PBS with 1% (v/v) FBS) prior to analysis on a Beckman 
Coulter Epics XL FACS machine.  Untransfected cells were used as a control to 
gate the live cell population.  Cells treated with transfection reagent alone (no 
plasmid) were used as a negative control.  A total of 10,000 live cells were 
collected per analysis.  Side scatter (SSC) was plotted against forward scatter 
(FSC) and GFP fluorescence was measured in the FITC channel.  Scatter plots 
and histograms were analysed using Summit Software v4.3 (DakoCytomation). 
2.11  Statistical analysis 
Data was represented graphically using either Excel® (Microsoft) or Sigmaplot 
11.0 (Systat Software).  Where possible, data was presented as the mean of all 
replicates with error bars representing ± one standard deviation.  Statistical 
analysis was performed using GraphPad InStat software V3.05 (GraphPad) 
when at least three data points were obtained, in which case, the data were 
confirmed to be drawn from Gaussian distribution.  One-way analysis of 
variance (ANOVA) tests were used to compare three or more sample means, 
along with the appropriate post-test.  Bonferroni multiple comparison post-tests 
were used to test which treatments were significantly different from each other.  
A two-tailed, unpaired t-test was used to compare two sample means.  Levels 
of significance are cited in the text and assumed to be significant where 
P<0.05. 
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3 Screening for components of the canonical Wnt 
pathway in Normal Human Urothelial cells 
 
3.1 Aims 
The aims of this chapter were: 
 To determine if fundamental components of the canonical Wnt signalling 
pathway were present at the mRNA level in NHU cells.  
 To investigate the hypothesis that Wnt signalling is involved in the 
development and maintenance of the proliferative phenotype important 
in urothelial repair and regeneration.  
Specific objectives of this sub-chapter were: 
 To use mRNA AffymetrixTM genechip expression data to assess the 
presence of essential components of the canonical Wnt signalling 
cascade in proliferating NHU cells in vitro.   
 To compare the mRNA expression profile of Wnt signalling components 
during proliferation, when quiescent and after differentiation.  
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3.2 Experimental Design 
AffymetrixTM U133 plus 2 mRNA genechip files previously generated by Dr. J. 
Fleming (Jack Birch Unit; University of York) were used as a screening tool to 
assess the presence or absence of mRNA transcript from genes implicated in 
the Wnt canonical signalling cascade.  The data set consisted of a six day time 
course (6 hours, 24 hours, 72 hours, and 144 hours) from a bladder-derived 
NHU cell line (Y676) that had been treated as outlined below and in Figure 3-1: 
Maintained as a non-differentiated culture.  
Induced to differentiate with 1µM troglitazone (PPARγ agonist) and 
concurrent EGFR blockade using 1µM PD153035 (TZ/PD). 
Induced to differentiate with 5% (v/v) adult bovine serum (ABS) and 2mM 
calcium chloride (ABS/Ca2+). 
Gene chip raw data files (.cel) were imported into Genespring GX v11.0.  
Background correction, normalisation and probe summarisation were performed 
using the MAS5 algorithm.  Internal hybridisation controls were checked to 
assess the reliability of the data from each chip and unreliable chips were 
removed from the analysis.  An absolute calls database was generated for each 
probe set using the background correction and MAS5 algorithm.  Probe sets 
were assigned an absent, marginal or present call using the standard 
thesholding criteria within the MAS5 algorithm.  Genes with no present call in 
any of the chips were omitted.  A list of probe sets with at least one present call 
was compiled and exported into Microsoft Excel® as well as IngenuityTM IPA 
software for further analysis. 
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Figure 3-1 Schematic representing the experimental design for the 
microarray time course experiment 
Bladder-derived NHU cell line (Y676) was passaged at a split ratio of 1:3 and grown as either a 
non-differentiated monolayer or induced to differentiate using two independent methods 
(TZ/PD or ABS/Ca2+).  RNA was extracted using TRIzol at 4 time points over the course of 6 
days to look at the changes in mRNA profile during the transition from proliferative to confluent 
monolayer, as well as during differentiation. 
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Each microarray was firstly interrogated for well-characterised markers of 
proliferation.  This was achieved by assessing the expression of a subset of 
genes involved in the cell cycle, known as the “proliferation signature” 
(reviewed by (115)).  Expression of the “proliferation signature” correlates well 
with the proliferation rate of cells in culture and can be used as a defined 
marker of cell cycle progression (115).  This signature can vary between cell 
types but there is a core set of genes whose highest expression always 
correlates with a rapid proliferation rate. These genes are PLK1, BUB1 and 
TOP2A (all genes which contain a FOXM1 transcription factor binding site) and 
are important in initiating the transition from G2 –M (Figure 3-2).  
 
Figure 3-2 Cell cycle and associated proliferation marker gene 
expression 
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If a marker was represented by more than one probe set, the most specific and 
sensitive probe set (as ranked by Geneannot Microarray Gene Annotation, 
Weizmann Institute of Science (116)) was plotted.  Each chip was ranked 
according to its expression of each proliferation marker.  Each differentiated 
time series was validated manually using specific markers of terminal urothelial 
differentiation and ranked accordingly.  The chip ranked as the most 
proliferative was then compared to the least proliferative (quiescent) and the 
most terminally differentiated.  Changes greater than 2-fold were exported into 
IngenuityTM IPA software and a gene ontology analysis was undertaken to 
establish which biological processes and signalling pathways were altered in the 
following scenarios: 
 Quiescent cells vs. proliferating cells 
 TZ/PD terminally differentiated cells vs. proliferating cells 
 ABS/Ca 2+ terminally differentiated cells vs. proliferating cells 
Specific changes in the Wnt pathway were interrogated manually using Excel®.  
Wnt ligands, receptors and downstream gene targets, as well as known 
agonists and antagonists were expressed as log2 fold change and represented 
in schematic as well as tabular form.  
Changes in gene expression were confirmed for 13 targets using RT-PCR and 
mRNA from the original Y676 cell line used to generate the Affymetrix 
Genechips.  RNA from uncultured stripped urothelium (Y1043) was used to 
assess the presence of transcript in vivo.  A genomic DNA positive control and a 
no template control were included in all experiments.  Reverse transcriptase 
negative samples were included to verify samples were free from genomic DNA 
contamination.  Primers targeted to UPK2 and MKI67 were used to assess 
differentiation and proliferation, respectively.  Expression changes were then 
validated on differentiated and undifferentiated cultures from three independent 
NHU cell lines (Y878, Y372 and Y387) using SYBR-green I RT-qPCR and the 
appropriate controls. 
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3.3 Results 
3.3.1  Quality control assessment 
Quality control analysis of the MAS5 normalised data was undertaken in 
Genespring GX v11.0.  Internal controls for housekeeping genes, GAPDH,  
β-actin, 18s rRNA and 28s rRNA were used to assess the quality of the 
hybridised cDNA by measuring the 3’ to 5’ ratio using C- and N-terminal probe 
sets.  A ratio greater than 3 indicated either RNA degradation prior to cDNA 
synthesis or incomplete cDNA synthesis during reverse transcription.  Two chips 
out of the 12 failed the acceptable 3-fold cut off for one gene (Table 3-1).  
These were data points TZ/PD 6h and TZ/PD 72 h. 
Log2 MAS5 normalised signal intensities for the externally spiked hybridisation 
controls; BioB, BioC, BioD (from the E.coli biotin synthesis pathway) and CreX 
(from the recombinase gene for P1 bacteriophage) were plotted and displayed 
as line graphs.  BioB, bioC, bioD and CreX signal intensities increased as 
expected indicating hybridisation was acceptable for all chips except TZ/PD 6h 
(Figure 3-3).  
Box and whisker plots were drawn from the median, 25th quartile and 75th 
quartile (Figure 3-4).  One chip had a significantly higher than average median 
and spread of data. This was data point TZ/PD 6h. To enable accurate 
comparison between chips, data must be similar in range and quality.  
Hybridisation problems and quality issues could skew the results but as there 
were no technical replicates (N=1) within the experiment, chip substitutions 
were not possible.  Time point TZ/PD 6h had quality control issues, signifying 
possible RNA degradation.  It also had a larger than average spread of data, 
indicating high levels of background which would produce a skewed distribution 
of expression (i.e., was not normally distributed).  Chip TZ/PD 6h was therefore 
removed from the data set and the data was normalised once again using the 
MAS5 algorithm.  
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Table 3-1 Affymetrix internal controls 
Table of 3’/5’ ratios for internal controls β-actin, GAPDH, 18S rRNA and 28S rRNA.  A ratio 
higher than 3 indicates RNA degradation.  Boxes highlighted in yellow indicate samples that 
failed the quality control check for RNA degradation. 
 
Figure 3-3 Spiked hybridisation controls 
Log2 normalised signal values for spiked biotin-labelled cRNA transcripts from bioB, bioC, bioD 
and cre at 1.5, 5, 25, and 100pm respectively.  All chips show a similar level of hybridisation 
except chip TZ/PD 6h (labelled in green) which has a lower normalised signal value for bioB 
indicating an issue with cRNA hybridisation. 
Chapter 3 
 
100 
 
 
Figure 3-4 Affymetrix array analysis box and whisker plots 
Normalised MAS5 intensity values for all probes within the U133 plus 2 chip were displayed as a 
box and whisker plot.  Blue boxes indicate the median, 25th and 75th quartile, whiskers indicate 
the 5th and 95th quartile. Points in red indicate outliers. Chip TZ/PD 6h had a higher than 
average median intensity as well as a larger spread of data. 
3.3.2  Assessment of the proliferation signature 
PLK1, TOP2A and BUB1 mRNA expression was higher in the non-differentiated 
time series compared to the TZ/PD and ABS/Ca2+ treated cells (Figure 3-5).  
Within the non-differentiated time series, mRNA expression peaked at 24 hours 
for all three markers (Figure 3-5).  MKI67 expression also correlated well, with 
its highest expression seen at the 24 hour time point (Figure 3-5).  The 24 hour 
time point scored the highest for all four markers and was ranked as the most 
proliferative.  The 144 hour time point was ranked as the least proliferative 
(Table 3-2). 
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Figure 3-5 Expression of proliferation markers 
AffymetrixTM mRNA microarray analysis of proliferation markers PLK1, TOP2A, BUB1 and MKI67 
in cultures of non-differentiated and differentiated NHU cells over a 6 day time course. Data is 
expressed as arbitrary MAS5 normalised signal intensities.  Black bars represent non-
differentiated NHU cultures.  Dotted bars represent NHU cultures induced to differentiate with 
the addition of TZ/PD.  Striped bars represent NHU cultures induced to differentiated with 
ABS/Ca2+. 
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Time point PLK1 TOP2A BUB1 MKI67 Score Rank 
6 +++ +++ +++ +++ 12 2nd 
24 ++++ ++++ ++++ ++++ 16 1st 
72 + ++ ++ ++ 7 3rd 
144 ++ + + + 5 4th 
 
Table 3-2 Ranking non-differentiated NHU cultures according to 
expression of proliferation markers 
Non-differentiated NHU cultures were ranked according to their expression of PLK1, TOP2A, 
BUB1 and MKI67 mRNA expression using AffymetrixTM microarray data from a 6 day time 
course. Key; + lowest expression over time, ++++ highest level of expression over time.   
3.3.3  Assessment of differentiation 
Each time series was assessed for markers of urothelial differentiation.  With 
both differentiation protocols UPK2 and UPK3a were seen to accumulate over 
time with the final time point of 144 hours expressing the highest amount of 
UPK2 and UPK3a mRNA (Figure 3-6).  Almost no UPK2 or UPK3 was detected in 
any of the non-differentiated cultures (KSFMc).  KRT7 expression increased 
over time in the TZ/PD model but was relatively unchanged in the ABS/Ca2+ 
model (Figure 3-6).  This was probably due to the fact that the ABS/Ca2+ 
cultures were pre-treated prior to commencement of the time course.  Pre-
treatment of cultures with 5% (v/v) ABS is a prerequisite to obtain a tight 
epithelial barrier in accordance with the published method (94).  Because of 
this, KRT7 up-regulation had probably already occurred (evident from the high 
KRT7 expression at 6h) and thus was not observed as a change in the dataset.  
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Cultures induced to differentiated using either method express urothelial 
terminal differentiation markers, but only the ABS/Ca2+ model is known to result 
in a functional barrier (94).  The factors that contribute to this are yet to be 
defined but both models are thought to activate the nuclear receptor PPARγ.  
For this reason each differentiation procedure was compared separately to the 
proliferating culture with common changes compiled at the end.  
CLDN4 expression varied significantly over the 144 hour time course with no 
real trend (Figure 3-6).  CLDN4 was seen to increase in the non-differentiated 
(KSFMc) cultures by > 5-fold between time points 24-72 hours.  Both systems 
of inducing differentiation were ranked according to expression of the four 
markers of urothelial differentiation.  For both systems, the final time point of 
144 hours was ranked the most “differentiated” within the data set (Table 
3-3,Table 3-4). 
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Figure 3-6 Expression of urothelial differentiation- associated markers 
Affymetrix mRNA microarray analysis of urothelial specific markers of differentiation UPK3a, 
KRT7, UPK2 and CLD4 in cultures of non-differentiated and differentiated NHU cells over a six 
day time course.  Data is expressed as arbitrary MAS5 normalised signal intensities.  Black bars 
represent non-differentiated NHU cultures.  Dotted bars represent NHU cultures induced to 
differentiate with the addition of TZ/PD.  Striped bars represent NHU cultures induced to 
differentiate with ABS/Ca2+. 
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Time point UPK2 UPK3a KRT7 CLDN4 Score Rank 
6 ND ND ND ND   N/A 
24 + + + + 4 3rd 
72 ++ ++ ++ +++ 9 2nd 
144 +++ +++ +++ +++ 11 1st 
Table 3-3 Ranking TZ/PD treated NHU cultures over time according to 
their expression of urothelial markers of terminal differentiation 
TZ/PD treated NHU cultures were ranked according to their expression of UPK2, UPK3a, KRT7 
and CLDN4 mRNA expression using AffymetrixTM microarray data from a 6 day time course. 
Key; + lowest expression over time, ++++ highest level of expression over time.  ND= no data 
as chip removed. 
Time point UPK2 UPK3a KRT7 CLDN4 Score Rank 
6 + + ++ ++++ 8 3rd/4th 
24 +++ ++ + ++ 8 3rd/4th 
72 ++ +++ +++ +++ 11 2nd 
144 ++++ ++++ ++++ + 13 1st 
 
Table 3-4 Ranking ABS/Ca2+ treated NHU cultures over time 
according to their expression of urothelial markers of terminal 
differentiation 
ABS/Ca2+ treated NHU cultures were ranked according to their expression of UPK2, UPK3a, 
KRT7 and CLDN4 mRNA expression using AffymetrixTM microarray data from a six day time 
course.  Note induction of differentiation procedure for ABS/Ca contains pre-treatment).  Key; + 
lowest expression over time, ++++ highest level of expression over time.   
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3.3.4  Ontology analysis 
20,490 genes were termed “present” from the MAS5 normalised proliferating 24 
hour time point. These genes were imported into ingenuity IPA software and a 
core functional analysis was undertaken.  The highest ranked functions were 
gene expression, cell cycle control, RNA post transcriptional modification and 
cell growth. 
Ontology analysis of the significant changes (2127 >2 fold) between quiescent 
and proliferating cultures revealed 18 signalling pathways significantly altered, 
of which Wnt was ranked 6th behind Notch, Sonic Hedgehog, mTOR, PTEN and 
p53 signalling (Figure 3-7).  Further analysis of the Wnt-specific changes, 
revealed 6 Wnt related genes were up-regulated and 4 were down-regulated 
(Table 3-5).  
Ontology analysis of the significant changes (2896 >2 fold) between TZ/PD 
differentiated and proliferating cultures revealed 22 signalling pathways were 
significantly altered of which Wnt signalling was ranked 17th (Figure 3-8).  In 
total, 23 Wnt related changes were found, 8 of which were up-regulated and 15 
down-regulated (Table 3-5). 
Ontology analysis of the significant changes (2187 >2 fold) between ABS/Ca2+ 
differentiated and proliferating cultures revealed 22 signalling pathways were 
significantly altered of which Wnt signalling was ranked 16th (Figure 3-9).  21 
Wnt pathway-associated changes were seen, with 9 components up-regulated 
and 12 down-regulated (Table 3-5). 
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  Quiescent TZ/PD ABS/Ca 2+ 
Wnt genes up-regulated (≥2 fold) 6 8 9 
Wnt genes down-regulated (≥2 fold) 4 15 12 
Total Wnt related changes (≥2 fold) 10 23 21 
Total gene changes across chip 
 ( ≥2 fold) 
2127 2896 2187 
Table 3-5 Number of Wnt related genes up- and down-regulated in 
quiescent and differentiated NHU cultures compared to proliferating 
NHU cell cultures 
Number of Wnt signalling components altered by at least 2-fold in quiescent, TZ/PD 
differentiated and ABS/Ca2+ differentiated cultures when compared to proliferating NHU cell 
cultures. 
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Figure 3-7 Ontologies of genes up- and down-regulated in quiescent 
NHU cells compared to proliferating NHU cells in vitro 
Genes involved in signal transduction with at least a 2-fold change in mRNA expression (total 
gene changes 2127) were categorised according to the pathway in which they function.  Up-
regulated genes are expressed as red bars and down regulated as green bars.  Signalling 
pathways were then ranked according to the percentage of gene altered within each pathway.  
Some genes may function in more than one pathway.  Bar charts were drawn using IngenuityTM 
IPA software. 
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Figure 3-8 Ontologies of genes up- and down-regulated in TZ/PD 
treated NHU cells compared to proliferating NHU cells in vitro 
Genes involved in signal transduction with at least a 2-fold change in mRNA expression (total 
gene changes 2127) were categorised according to the pathway in which they function.  Up-
regulated genes are expressed as red bars and down-regulated as green bars.  Signalling 
pathways were then ranked according to the percentage of gene altered within each pathway. 
Some genes may function in more than one pathway. Bar charts were drawn using IngenuityTM 
IPA software. 
Chapter 3 
 
110 
 
 
Figure 3-9 Ontologies of genes up- and down-regulated in ABS/Ca2+ 
treated NHU cells compared to proliferating NHU cells in vitro 
Genes involved in signal transduction with at least a 2-fold change in mRNA expression (total 
gene changes 2127) were categorised according to the pathway in which they function.  Up-
regulated genes are expressed as red bars and down-regulated as green bars.  Signalling 
pathways were then ranked according to the percentage of gene altered within each pathway.  
Some genes may function in more than one pathway.  Bar charts were drawn using IngenuityTM 
IPA software. 
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3.3.5  In depth analysis of Wnt associated genes 
Wnt pathway related mRNA transcripts were comprehensively analysed using 
the normalised MAS5 data imported into Excel®.  All fundamental components 
necessary for a functional Wnt cascade were present at the mRNA level in the 
proliferating NHU culture (Figure 3-10).  All constituents downstream from the 
frizzled receptor to TCF/Lef transcription factors were categorised as present 
using the calls database generated through MAS5. For several components, 
more than one gene was expressed at the mRNA level and thus to aid 
visualisation, data was interpreted as a schematical Wnt cascade with present 
transcripts detailed alongside each component (Figure 3-10).  Seven receptors, 
all of which were known to play a role in transducing the Wnt canonical signal, 
were present.  20 known transcriptional Wnt signalling targets were present in 
proliferating NHU cells.  A number of intracellular as well as extracellular Wnt 
signalling antagonists were also expressed at the mRNA level including DKK, 
Kremen, CBY, CTNNBIP and NLK.  mRNA transcript for four Wnt ligands were 
also present.  
Manual interrogation of the fold change values from the quiescent vs. 
proliferating chips revealed 13 significant (>2 fold) Wnt pathway changes 
(Figure 3-11).  Expression of four Wnt ligands significantly increased when the 
culture was quiescent. One Frizzled receptor, Fzd8 was also up-regulated in the 
quiescent population by 4.85-fold. Wif1, an extracellular Wnt signalling 
antagonist was up-regulated 6.53-fold in the quiescent population.  Five 
downstream Wnt gene targets were down-regulated in the quiescent population 
including Axin2 (down 2.38-fold), Twist (down 7.9-fold) and Survivin (BIRC5 
down 12.7-fold), although none are Wnt-specific.  
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Figure 3-10 Schematical representation of the components present 
from the canonical Wnt cascade in proliferating NHU cells 
All coloured components were classified as present from MAS5 normalised AffymetrixTM data 
taken from proliferating NHU cells in vitro.  Components in white with dashed borders were 
classed as absent in the proliferating NHU culture.  Components with more than one gene 
expressed are labelled at the side. 
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Figure 3-11 Schematical representation of the gene changes within 
the canonical Wnt pathway in quiescent NHU cells 
Genes with at least a 2-fold change in expression compared to the proliferative culture are 
labelled as either red (up-regulated) or green (down-regulated).  Actual changes in expression 
are detailed within the tables and are expressed as signal log ratios (log base 2). 
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Manual interrogation of the fold change differences between TZ/PD treated 
cultures and proliferating NHU cultures revealed 23 members of the Wnt 
pathway were significantly altered at the mRNA level.  These gene changes 
were displayed as an overlay on top of a schematic Wnt pathway along with 
log2 fold change values (Figure 3-12).  Immediate attention was drawn to the 
fact that two Wnt antagonists were significantly up-regulated in the TZ/PD 
treated culture compared to the proliferating culture, these were; sFrp1(up-
regulated 2.29 fold) which was classed as  absent at the mRNA level in the 
proliferating culture and Kremen1 which was up-regulated 3.23 fold.  
Noteworthy changes were also seen in four key Wnt pathway components, 
these were; Wnt7a (down-regulated 4.23 fold), Wnt7b (up regulated 2.64 fold) 
Fzd2 and Fzd4 (down-regulated 4.56 and 5-fold, respectively) as well as GSK3β 
(down regulated 4.2 fold).  Ten downstream Wnt targets were also significantly 
altered, with the majority down-regulated (7/10) (Figure 3-12). 
A comparative analysis of the ABS/Ca2+ treated culture vs. the proliferative NHU 
culture showed no up-regulation of Wnt antagonists.  One important difference 
between the TZ/PD and ABS/Ca2+ model is the need for a pre-treatment with 
5% (v/v) ABS prior to passage into medium containing 5% (v/v) ABS and 
2mMCaCl2 (94) and therefore there is a time difference between the two 
methods of differentiation which may account for the dissimilarity.  As with the 
TZ/PD model Fzd2 and Fzd4 were significantly down-regulated (3.92 and 3.41-
fold, respectively). Wnt5a was significantly up-regulated (4.54 fold) and has 
been implicated as both an activator and inhibitor of the canonical Wnt 
pathway.  Ten downstream targets were found to be significantly altered with 
the majority (7/10) down-regulated (Figure 3-13).  In total 23 genes involved in 
either transducing the Wnt signal or direct gene targets of TCF/β-catenin were 
significantly altered between the ABS/Ca2+ and the proliferating NHU cell 
cultures. 
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Figure 3-12 Schematical representation of the gene changes within 
the canonical Wnt pathway in TZ/PD differentiated cultures 
Genes with at least a 2-fold change in expression are labelled as either red (up-regulated) or 
green (down-regulated).  Actual changes in expression are detailed within the tables and are 
expressed as signal log ratios (log base 2). 
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Figure 3-13 Schematical representation of the gene changes within 
the canonical Wnt pathway in ABS/Ca2+ differentiated cultures 
Genes with at least a 2-fold change in expression compared to the proliferative culture are 
labelled as either red (up-regulated) or green (down-regulated). Actual changes in expression 
are detailed within the tables and are expressed as signal log ratios (log base 2).  
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To facilitate analysis of all culture conditions, fold-change data was summarised 
in a table (Table 3-6).  mRNA expression values for Wnt components within the 
quiescent and differentiated NHU cultures were compared to the proliferative 
culture and expressed as fold change.  Changes greater than two fold were 
represented as a colour; red for a significantly up-regulated gene and green for 
a significantly down-regulated gene. 
Different Wnt ligands were up and down regulated between the two methods of 
differentiation.  No similarity in expression profile was observed.  In the 
quiescent NHU cell culture, four Wnt ligands showed up-regulated expression.  
Fzd receptors showed a similar pattern of expression in the two differentiation 
methods.  In both the TZ/PD and ABS/Ca2+ cultures, Fzd1 expression increased 
when compared to the proliferative culture.  Both Fzd2 and Fzd4 were down-
regulated in the TZ/PD and ABS/Ca2+ cultures when compared to the 
proliferative culture.  Wnt signalling antagonists were seen to be altered in 
expression when NHU cells were differentiated with TZ/PD.  DKK3 was down 
regulated, whereas Kremen1 and sFrp1 were both up-regulated. Expression of 
Wnt signalling antagonists did not alter in the ABS/Ca2+ model.  Wif1 was up-
regulated in the quiescent culture compared to the proliferative culture.  
Several components important in transducing a Wnt signal changed in 
expression when NHU cells were induced to differentiate.  CBP, an important 
part of the β-catenin/TCF transcription complex increased in expression in both 
models of differentiation. Axin2, part of the destruction complex as well as a 
direct downstream target of the Wnt cascade, decreased in expression when 
cells were induced to differentiate, and also when the culture became 
confluent.  Several downstream targets of the Wnt cascade were altered in 
expression when cultures were differentiated as well as confluent.  Axin2, c-
Jun, CD44 and Survivin were down-regulated in all conditions when compared 
to the proliferative NHU cell culture.  Both TZ/PD and ABS/Ca2+ differentiation 
lead to expression changes in Fzd1, Fzd2, Fzd4 and CBY.  Changes in 
expression of these genes as well as three well-characterised antagonists 
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(DKK3, sFrp1 and Wif1) and three transcriptional targets (c-Jun, Axin2 and 
CyclinD1) were verified using RT-PCR on the same RNA used to undertake the 
AffymetrixTM analysis.  CyclinD1 expression was included in the panel of targets 
not because it showed any trend in expression in the AffymetrixTM analysis but 
because there is evidence of a correlation between β-catenin mutation in 
bladder cancer and over-expression of CyclinD1 (117).  Three canonical Wnt 
ligands (Wnt3, 5a and 7a) were also interrogated using RT-PCR.  Changes seen 
in the AffymetrixTM and RT-PCR were then verified using RT-qPCR on three 
independent cell lines. 
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Gene TZ/PD ABS/Ca2+ Quiescent 
Ligands 
Wnt2       
Wnt5a       
Wnt5b       
Wnt7a       
Wnt7b       
Wnt9a       
Wnt10a       
Receptors 
Fzd1       
Fzd2       
Fzd4       
Fzd8       
Antagonists 
DKK3       
Kremen1       
sFRP1       
Wif1       
Pathway components 
CBP       
Axin2       
TCF4       
CK1α       
DVL2       
TCF7L1       
Lrp5       
BCL9       
CK1ε       
GSK3β       
Adherens junction 
E-Cadherin       
P-Cadherin        
α-catenin       
p120       
N-cadherin       
Downstream targets 
Axin2       
c-Jun       
Sox9       
Twist       
MMP7       
EGFR       
CD44       
CLDN1       
Survivin       
Endothelin       
C-MYC       
PPARδ       
Cyclin D1       
SKP2       
Table 3-6 Summary of AffymetrixTM microarray results for changes in 
the canonical Wnt pathway 
Changes in mRNA expression are labelled as red (up-regulated >2-fold) or green (down-
regulated >2-fold). 
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3.3.6  RT-PCR analysis  
RT-PCR was used to verify the changes seen in the AffymetrixTM array analysis. 
UPK2 was only expressed in the ABS/Ca2+ treated NHU cell culture, TZ/PD 
treated culture and freshly isolated (P0) urothelium as expected (Figure 3-14).  
MKI67 was expressed in the proliferating NHU culture.  A faint band was also 
visualised in the freshly isolated urothelium.  RT-PCR confirmed the presence of 
Wnt3, Wnt5a and Wnt7a in proliferating culture, quiescent and both 
differentiation procedures.  Interestingly, both Wnt3 and Wnt7a were absent 
from freshly isolated urothelium.  Fzd1 did not appear to be expressed in 
culture with only a very faint product in the freshly isolated urothelium.  Fzd2 
expression matched that observed in the AffymetrixTM analysis: mRNA was 
detected in the proliferative and quiescent culture but was absent from 
differentiated cultures.  Fzd2 was also detected in the P0 urothelium.  Fzd4 was 
expressed in all samples and gave no hint of a possible down-regulation upon 
differentiation as observed in the AffymetrixTM array data.  DKK3 was expressed 
in all samples including the P0 urothelium.  sFrp1 was absent in all samples. 
Wif1 expression was very weak with only a very faint band visible in the 
quiescent culture. This agreed with the results obtained from the Affymetrix 
analysis.  Axin2 mRNA was found in the proliferative culture as well as the P0 
urothelium. A faint band for Axin2 was observed in the quiescent culture but no 
mRNA for Axin2 was observed in either model of differentiation.  Expression of 
CyclinD1 was evident in all culture conditions as well as in the P0 urothelium.  
c-Jun mRNA was expressed in all culture conditions but appeared to be down 
regulated upon differentiation.  CBY RT-PCR failed with the genomic DNA 
positive control and was therefore not taken forward. 
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Figure 3-14 mRNA expression of Wnt signalling components in NHU 
cells in vitro and in vivo 
RT-PCR analysis of Wnt signaling components from Y676 NHU cells grown in culture as a 
proliferative monolayer, quiescent culture or differentiated using TZ/PD or ABS/Ca2+as well as 
expression in uncultured stripped urothelium (Y1043).  Human genomic DNA was used as a 
template control.  Water only was used as a no-template negative control.  GAPDH was used as 
a positive control to verify intact cDNA.  RT negatives were included to verify lack of gDNA 
contamination in the cDNA. 
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Although the RT-PCR data was not quantitative, it provided back up data to the 
AffymetrixTM analysis and is summarised in table 3-7. From the RT-PCR and 
AffymetrixTM data, seven targets revealed a convincing change in expression 
between treatments and were taken forward for quantitative analysis on three 
independent NHU cell lines. These were Wnt3, Wnt5, Wnt7a, Fzd2, Fzd4 and 
Axin2.  
 
Table 3-7 Summary of AffymetrixTM microarray and RT-PCR results for 
changes in the canonical Wnt pathway 
Changes in mRNA expression are labelled as red (up-regulated) or green (down-regulated) in 
each of the labelled conditions. A=Absent transcript, P=Present transcript, ND=No data 
available.  
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3.3.7  RT-qPCR 
Quantitative PCR using SYBR-green was performed on three independent NHU 
cell lines (Y878, Y372 and Y387) to validate the changes in mRNA expression 
seen between proliferating, quiescent and differentiated NHU cultures using 
AffymetrixTM microarray analysis and RT-PCR.  RTq-PCR for UPK2 and UPK3a 
verified that the cultures treated with TZ/PD and ABS/Ca2+ were expressing 
markers of urothelial differentiation (P<0.001 and P<0.05, respectively for 
UPK2 as well as UPK3a;Figure 3-15).  MKI67 mRNA expression verified the 
confluent cultures had reduced expression of the proliferation marker (P<0.01) 
and were deemed quiescent (Figure 3-15).  Of the three Wnt ligands tested, 
only Wnt5a significantly changed in expression when proliferating and 
differentiated cultures were compared.  Changes in mRNA expression for Wnt5a 
were statistically significant when TZ/PD differentiated cultures as well as 
ABS/Ca2+ differentiated cultures were compared to proliferating NHU cultures 
(P<0.001 and P<0.01, respectively).  No significant change was observed with 
Wnt3 or Wnt7a.  Of the two Fzd receptors highlighted in the AffymetrixTM array 
analysis, Fzd2 was significantly down-regulated in TZ/PD treated cultures 
(P<0.05) agreeing with the results seen from the AffymetrixTM analysis and RT-
PCR.  Fzd2 appeared to be down regulated in the ABS/Ca2+ treated cultures 
too, with a median down-regulation of 2.4-fold, however, this was not 
statistically significant.  Fzd4 was unaffected by TZ/PD treatment or quiescence, 
but was down-regulated in the ABS/Ca2+ treated cultures (P<0.05). The Wnt 
antagonist, DKK3 was seen to be significantly up-regulated in the ABS/Ca2+ 
differentiated cultures (P<0.01) but remained unchanged in the TZ/PD and 
quiescent cultures.  Expression of the Wnt signalling downstream gene target, 
Axin2, was significantly altered in both differentiation procedures (<0.001), but 
remained unchanged in quiescent cultures. In summary, no opposing regulatory 
expression changes were observed between the AffymetrixTM /RT-PCR screen 
and the RT-qPCR analysis.   
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Figure 3-15 mRNA expression of Wnt components in proliferative, 
quiescent and differentiated NHU cultures 
Expression of Wnt components as assessed by SYBR-green RT-qPCR and normalised to GAPDH.  
Changes in expression were measured as fold-change compared to the proliferative culture and 
data represented as a box and whisker plot.  Boxes indicate the median, 25th and 75th quartile, 
whiskers denote the 5th and 95th quartile.  Red and green arrows indicate a statistically 
significant up- and down-regulation, respectively.  Statistical analysis was performed using a 
non-parametric ANOVA and Dunn’s multiple comparison post test.  *** indicate a P value of 
<0.001, ** indicate a P value of <0.01, * denotes a P value of <0.05.  NC=No change.  Data is 
from three independent NHU cell lines (Y878, Y372 and Y387) each assayed in technical 
triplicate (n=9).  
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3.4  Discussion  
AffymetrixTM microarray analysis is a powerful and convenient method of 
analysing relative changes in gene expression.  The dataset used in this study 
represented a differentiating time series and had been a widely used resource 
to study the vast but sometimes subtle changes that occur during in vitro 
urothelial differentiation over time (118).  In this study, the data was not 
classically interrogated using clustering but was used as a screening tool for 
investigating changes within a specific pathway.   
No technical replicates were present in the dataset (n=1).  A second time series 
using an independent cell line derived from ureter was available but was not 
used in this study because markers of urothelial differentiation were poorly 
expressed.  Technical replicates would have made the data more robust by 
compensating for anomalies in such things as hybridisation differences and 
background correction.  Unfortunately one chip out of the 12-chip dataset was 
shown to have issues with RNA quality and hybridisation.  As no technical 
replicates were available, this timepoint was removed from the dataset to 
prevent skewing of the results.  Although the dataset was incomplete it still 
contained a vast amount of information and was used as a screening tool to 
direct further investigations.  
As the canonical Wnt signalling pathway is important in driving proliferation one 
might expect components of the pathway as well as downstream targets to be 
expressed at a higher level in an actively dividing population than in a culture 
that was quiescent due to contact inhibition or differentiation.  One might also 
expect that if the Wnt pathway was important during proliferation, antagonists 
would be more transcriptionally-active in a contact-inhibited culture or upon 
differentiation.  
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3.4.1 Analysis of the proliferative NHU culture 
All components necessary for a functional Wnt cascade were present at the 
mRNA level in the proliferating NHU cell culture.  Four Wnt genes were also 
transcribed in proliferative culture, these were: Wnt3, Wnt5a, Wnt6 and Wnt7a.  
Wnt3 is a well characterised canonical Wnt ligand which has been found to be 
up-regulated in several cases of primary breast and rectal cancer (119) and  
signals via Fzd7 (120), which was also present.  Wnt7a has been found to drive 
proliferation in endometrial cells, the epithelial cells that line the uterus (121) 
and is thought to occur via binding to Fzd 5 (122) which was also present in the 
proliferating NHU cell culture.  Wnt5a was initially classified as a non-canonical 
Wnt ligand as it activates the RAC-1 cell motility pathway via Fzd2 and ROR1/2, 
however, when Fzd4 is present, Wnt5a can activate the classical β-catenin 
signalling cascade (123).  
Fzd receptor expression is an important regulator of the Wnt pathway.  Seven 
Fzd receptors were classified as present (Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7 
and Fzd10).  Fzd2 and Fzd4 are interesting as they can bind Wnt3 and may be 
an important component of a possible autocrine/paracrine Wnt signalling loop in 
NHU cells (explored in chapter 6).  Fzd7 was also a compelling target for further 
investigation because it also mediates the β-catenin/TCF canonical response via 
Wnt3 (120) and has been suggested as having an important role in the self-
renewal of embryonic stem cells (124). 
Several antagonists were transcriptionally-active in the proliferative culture 
including the Dickkopf (DKK) family of genes.  DKK proteins primarily act as 
antagonists of the Wnt canonical pathway by blocking access to the Wnt co-
receptor LRP5/6 and inducing endocytosis via Kremen (109, 110, 125).  The 
role of DKK1 and DKK3 as inhibitors of the Wnt pathway is well established, but 
not all DKK proteins are antagonists.  DKK2 was also present in the dataset and 
has been shown in the absence of Kremen2, to activate DVL via LRP6 and drive 
β-catenin mediated TCF transcription (126, 127).  In the proliferative culture, 
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Kremen2 was absent suggesting DKK2 could potentially act as a driver of  
β-catenin mediated proliferation in NHU cells. 
The fact that several Wnt extracellular antagonists such as Wif1 and sFrp were 
not transcribed in the proliferating culture was promising evidence for a 
functional cascade during urothelial regeneration.  The same was not true for 
several intracellular Wnt signalling antagonists.  Both Chibby (CBY), an 
intracellular trafficking molecule which shuttles β-catenin out of the nucleus 
(128) and ICAT, an inhibitor of β-catenin and TCF interaction (129) were 
present as transcripts in proliferating NHU cell cultures.  
Although the presence of mRNA for several antagonists was not an encouraging 
sight, many of these inhibitors require post-translational modification and 
therefore their transcription does not necessarily imply activity.  This is indeed 
the case for CBY which requires phosphorylation at serine 20 before it can form 
a tripartite bond between 14-3-3 ε/ζ and β-catenin (130). 
Several downstream Wnt signalling target transcripts were expressed in the 
proliferative NHU cell culture.  These included such targets as: Axin2, a 
feedback repressor of the Wnt pathway (131) and a downstream target of Wnt 
and pRB/E2F signalling (132, 133); Survivin (BIRC5)(134); Twist (135) and 
SKP2, a reported downstream target of the Wnt signalling pathway in bladder 
cancer cells (81).  Another potential Wnt-associated transcript, CyclinD1 (136) 
was also present, but its link to the Wnt pathway is debatable (137). 
3.4.2  Comparison between quiescent and proliferating NHU cells 
If Wnt signalling was important in driving proliferation one might expect a 
number of expression changes within the cascade when a culture reached 
confluency and entered G1 cell cycle arrest.  Indeed, several changes in the 
expression of Wnt pathway components were evident between the proliferative 
and confluent dataset.  The most interesting of these changes was the 
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induction of otherwise undetected Wnt2 and Wnt5b. The role of Wnt2 remains 
unclear but Wnt5b, a homologue of Wnt5a acts non-canonically in pre-
adipocytes to stimulate adipogenesis via PPARγ (138), the same type II nuclear 
receptor activated in urothelial differentiation (93, 95).  Wnt inhibitory factor 1 
(Wif1) was also an mRNA target not seen in the proliferative NHU dataset but 
present in confluent culture.  Wif1 is interesting as it is a potent extracellular 
antagonist of Wnt signalling and has been shown to be frequently 
hypermethylated in bladder tumours.  Knock-down of Wif1 in bladder cancer 
cells leads to an increase in cell proliferation rate, which is thought to be driven 
by the observed increase in c-MYC transcription and implies that Wif1 may 
regulate urothelial cell proliferation by inhibiting β-catenin/TCF-mediated 
transcription (79).  The results presented here suggest contact inhibited NHU 
cells may also up-regulate Wif1, possibly to inhibit further Wnt signalling and 
maintain tissue quiescence.  
3.4.3  The Wnt pathway in differentiated NHU cells 
Both systems for inducing urothelial differentiation result in the up-regulation of 
well characterised markers of urothelial terminal differentiation, but only the 
ABS/Ca2+ model results in a functional barrier (94).  The factors that contribute 
to this have yet to be defined, but both models are thought to result from the 
activation of the nuclear receptor PPARγ.  For this reason each model of 
differentiation was compared separately to the proliferative culture.  
A comparison between TZ/PD differentiated and proliferating NHU cultures 
revealed a down regulation in Wnt7a,  as well as a significant down-regulation 
in Fzd2 and Fzd4, both of which are important in transducing the signal from 
Wnt3 and Wnt5a (120, 123).  The fact that both of these receptors were down-
regulated along with Wnt7a implied that Wnt signalling (if active) would likely 
be diminished upon differentiation.  
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Analysis of the ABS/Ca2+ differentiated dataset revealed different changes in 
components of the Wnt pathway compared to the TZ/PD model.  After 
ABS/Ca2+ differentiation, Wnt5a ligand was seen to be significantly up-
regulated.  This increase in Wnt5a expression coincided with a reduction in its 
canonical receptor Fzd4, suggesting that in this situation, Wnt5a may be acting 
as an antagonist via ROR1/2. 
In summary, AffymetrixTM mRNA expression analysis of NHU cells under 
proliferative and differentiated conditions revealed several changes within the 
Wnt pathway.  In this study, previously generated microarray data was used as 
a screening tool to assess the presence of the Wnt canonical pathway at the 
mRNA level in NHU cells.  The results indicated that all components necessary 
for a functional cascade were present in proliferating NHU cells.   
In conclusion, analysis of the AffymetrixTM dataset provided preliminary 
evidence for a functional Wnt pathway during proliferation and suggested that 
it may be differentially regulated upon differentiation. 
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4 Pharmacological activation of the Wnt canonical 
cascade in Normal Human Urothelial cells 
4.1 Introduction 
GSK3 is a proline directed serine-threonine kinase that plays a crucial role in 
glycogen metabolism as well as other tissue-specific signalling roles throughout 
the human body.  GSK3 has two isoforms, α and β which are encoded on two 
separate genes at 19q13.2 and 3q13.3, respectively.  The two isoforms of GSK3 
share 98% amino acid homology within their kinase domain (139), but it 
remains unclear as to whether these isoforms are functionally interchangeable.  
Both α and β isoforms appear to have some overlapping roles in Wnt signalling. 
Over expression of GSK3α or GSK3β have both been shown to result in a 
reduction in β-catenin nuclear translocation and TCF activity (140) but, as 
demonstrated in the GSK3β embryonic lethal knock-out mouse, GSK3α and 
GSK3β are not functionally redundant (141, 142).    
Together, GSK3α and GSK3β are known to phosphorylate over 40 targets, 
including signalling proteins, transcription factors as well as structural proteins.  
Inhibitors of GSK3 are widely used as crude activators of the Wnt signalling 
cascade, even though they have the potential to affect several other signalling 
pathways.  
To date there are roughly 30 known inhibitors of GSK3 which are reviewed in 
detail elsewhere (143).  Most inhibitors are not GSK3-specific and affect the 
activity of other protein kinases at similar IC50 concentrations (e.g., 
hymenialdisine, flavopiridol and kenpaullone )(143).  
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4.2 Hypothesis 
The canonical Wnt pathway is functional in NHU cells and may be utilised to 
drive proliferation in vitro.  
4.3 Aim 
The aim of this chapter was to determine if the canonical Wnt pathway was 
functional in NHU cells and to assess its ability to initiate self-renewal.  
Specific objectives of this chapter were: 
 To inhibit the destruction complex using antagonists targeted to GSK3 
and assess activation of the Wnt cascade by monitoring active (non-
phosphorylated) β-catenin nuclear accumulation. 
 To assess the effect of pharmacological activation of the Wnt pathway 
on NHU cell morphology and proliferation.   
 To utilise the TOPFLASH TCF reporter assay in NHU cells to assess TCF 
transcription factor activity before and after GSK3 inhibition.  
 
4.4 Experimental Design 
Two GSK3β antagonists were used in this study: SB415286, a DMSO-soluble 
inhibitor with a published IC50 of 2.9µM (144) and LiCl salt, a widely used, 
water-soluble but less specific GSK antagonist with a published IC50 of between 
2mM-15mM (145).  Both inhibitors were titrated in the well-characterised Wnt-
responsive osteosarcoma cell line, SaOS-2 (146, 147) and in NHU cells.  
Cytotoxicity was assessed by comparison to vehicle control in a 6-day cell 
viability assay using MTT and by phase contrast photomicroscopy. 
The effect of GSK3 inhibition on β-catenin nuclear translocation was assessed 
using indirect immunofluorescence on formalin-fixed cultures. Nuclear and 
cytoplasmic signal intensities for β-catenin were quantified from each 
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micrograph using Hoechst 33258 stain to delineate the nucleus and Adobe® 
PhotoshopTM software as previously described (section 2.9.1.6).  
The effect of GSK3 inhibition on the TCF activity of NHU cells was assessed in 
triplicate cultures using the TOPFLASH Firefly luciferase reporter plasmid and a 
dual luciferase reporter kit.  NHU cells were cultured for 24-hours ± SB415286.  
SaOS-2 cells were included alongside as a positive Wnt-responsive control.  
Results were normalised to a constitutively-active Renilla luciferase loading 
control plasmid.  The mutant TCF Firefly luciferase plasmid, FOPFLASH was 
included to control for changes in TK minimal promoter activity.  
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4.5 Results 
4.5.1 Effect of GSK3 inhibitors on cull viabilty 
4.5.1.1  SB415286 
Incubation of SaOS-2 cells with up to 50µM SB415286 had no significant effect 
on culture biomass when compared to vehicle control at day 4 (Figure 
4-1;Figure 4-2).  When incubated with a concentration of 100µM, SaOS-2 
culture biomass remained static over the course of the experiment (Figure 4-1).  
At 200µM, culture biomass was seen to drop to levels below that observed at 
time point 0 (Figure 4-1). 
Concentrations of up to 12µM SB415286 had no effect on the culture biomass 
of NHU cells when compared to vehicle control at the same time point (Figure 
4-3).  Interestingly, a slight increase in cell biomass was seen with 5-10µM 
SB415286 when compared to vehicle control, but this was not statistically 
significant.  Concentrations of 15µM or higher significantly reduced NHU culture 
biomass (P<0.01; Figure 4-4).  
4.5.1.2  LiCl 
Up to 20mM LiCl did not affect the culture biomass of SaOS-2 cells compared to 
vehicle control at day 4 (Figure 4-7).  50mM and 100mM LiCl significantly 
reduced SaOS-2 culture biomass when compared to vehicle control (P<0.01, 
Figure 4-8). 
LiCl was not well tolerated by NHU cells (Figure 4-5).  By day 4, concentrations 
of 10µM and above resulted in a significant reduction in NHU culture biomass 
compared to vehicle control (P<0.01, Figure 4-6).  
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Figure 4-1 Effect of SB415286 on SaOS-2 cell viability 
MTT assay from SaOS-2 cells cultured in McCoy’s 5A + 15% (v/v) FBS + 0-200µM SB415286 for 
up to 6 days.  0.1% (v/v) DMSO was included in all cultures as the vehicle control.  Medium and 
inhibitors were replenished on day 3.  Data shows the mean absorbance at 570nm (±SD) of 6 
technical replicates.   
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Figure 4-2 SaOS-2 dose response curve to SB415286 
Mean absorbance from SaOS-2 cells after a 4-day incubation with 0-200µM SB415286 in 0.1% 
(v/v) DMSO.  Data shows the mean absorbance at 570nm (±SD) of 6 technical replicates.  ** 
p<0.01, one way ANOVA with Dunnett’s post-test.  
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Figure 4-3 Effect of SB415286 on NHU cell viability 
MTT assay from NHU cells (Y924 at P4) cultured in KSFMc + 0-30µM SB415286 for up to 6 
days.  0.1% (v/v) DMSO was included in all cultures as the vehicle control.  Medium and 
inhibitors were replenished on day 3.  Data shows the mean absorbance at 570nm (±SD) of 6 
technical replicates.   
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Figure 4-4 NHU dose response curve to SB415286 
Mean absorbance from NHU cells after a 4-day incubation with 0-30µM SB415286 in 0.1% (v/v) 
DMSO.  Data shows the mean absorbance at 570nm (±SD) of 6 technical replicates.  ** 
p<0.01, one way ANOVA with Dunnett’s post-test. 
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Figure 4-5 Effect of LiCl on NHU cell viability 
MTT assay from NHU cells (Y924 at P4) cultured in KSFMc + 0-25mM LiCl for up to 6 days.   
1% (v/v) PBS was included in all cultures as the vehicle control.  Medium and inhibitors were 
replenished on day 3.  Data shows the mean absorbance at 570nm (±SD) of 6 technical 
replicates.   
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Figure 4-6 NHU dose response curve to LiCl 
Mean absorbance from NHU cells after a 4-day incubation with 0-25mM LiCl in 1% (v/v) PBS.  
Data shows the mean absorbance at 570nm (±SD) of 6 technical replicates.  ** p<0.01, one 
way ANOVA with Dunnett’s post-test. 
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Figure 4-7 Effect of LiCl on SaOS-2 cell viability 
MTT assay from SaOS-2 cells cultured in McCoy’s 5A + 15% (v/v) FBS + 0-100mM LiCl for up to 
6 days.  1% (v/v) PBS was included in all cultures as the vehicle control.  Medium and inhibitors 
were replenished on day 3.  Data shows the mean absorbance at 570nm (±SD) of 6 technical 
replicates.   
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Figure 4-8 SaOS-2 dose response curve to LiCl 
Mean absorbance from SaOS-2 cells after a 4-day incubation with 0-100mM LiCl in 1% (v/v) 
PBS.  Data shows the mean absorbance at 570nm (±SD) of 6 technical replicates.  ** p<0.01, 
one way ANOVA with Dunnett’s post-test.  
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4.5.2 Effect of GSK3β inhibition on cell morphology 
No morphological differences were observed between SaOS-2 cells incubated 
with 10-20µM SB415286 and vehicle control (Figure 4-9A, B and C).  SaOS-2 
cell cultures incubated in the presence of 20mM LiCl appeared to be slightly less 
densely populated than vehicle control cultures, but cells still appeared phase-
bright (Figure 4-9D).  NHU cells treated with between 5-10µM SB415286 lacked 
any morphological changes compared to vehicle control (Figure 4-9 E,F,G and 
H).  
4.5.3 Effect of GSK3β inhibition on β-catenin localisation  
Labelling of SaOS-2 cells with anti- β-catenin antibody resulted in a diffuse 
cytoplasmic labelling pattern with no nuclear labelling visible (Figure 4-10 A).  
With 10-20µM SB415286 and 20mM LiCl, SaOS-2 cell nuclei were clearly 
labelled, signifying activation and translocation of β-catenin to the nucleus 
(Figure 4-10 A,B,C and D).  Mean nuclear pixel intensity was 2.3-fold higher 
after treatment with 10µM SB415286, 2.7-fold higher with 20µM SB415286 and 
2.9-fold higher with 20mM LiCl when compared to control (Figure 4-11).  By 
contrast, NHU cells (Figure 4-10 E,F,G and H) exhibited a large proportion of 
nuclear β-catenin in the untreated control culture and only developed a modest 
increase in nuclear labelling after treatment with 5, 7.5 and 10µM SB415286 
(1.1-fold, 1.2-fold and 1.4-fold vs. control, respectively;Figure 4-11).  This data 
inferred that NHU cells already had a pool of active β-catenin which was 
present in the nucleus. 
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Figure 4-9 Effect of GSK3 inhibitors on cell morphology of SaOS-2 and 
NHU cells in vitro 
 Phase micrographs of SaOS-2 and NHU cells after a 24 hour incubation with GSK3 inhibitors. 
(A-D) SaOS-2 cells cultured in McCoy’s 5A + 15% (v/v) FBS and treated with the following: 
(A) 0.1% (v/v) DMSO (solvent control); (B) 10µM SB415286; (C) 20µM SB415286; (D) 20mM 
LiCl. (E-H) Y924 P4 NHU cells cultured in KSFMc and treated with the following: (E) 0.1% 
(v/v)DMSO (solvent control); (F) 5µM SB415286; (G) 7.5µM SB415286; (H) 10µM SB415286. 
Scale bar: 50µm. 
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Figure 4-11 Nuclear translocation of β-catenin in SaOS-2 and NHU 
cells after GSK3 inhibition 
Mean nuclear pixel intensities from photomicrographs of β-catenin labelled cells after a 24-hour 
incubation ± GSK3 inhibitors (fig 4.10).  (A) SaOS-2 cells cultured in McCoy’s 5A + 15% (v/v) 
FBS; (B) Y924 NHU cells cultured in KSFMc. Vehicle control was 0.1% (v/v) DMSO in normal 
culture medium.  (** P<0.01, NS non-significant, one-way ANOVA with Dunnett’s post-test 
versus vehicle control).  (Mean nuclear pixel intensity calculated as described in section 
2.9.1.6).   
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4.5.4 Effect of GSK3 inhibitors on TCF transcription factor activity  
As expected, the positive control cell line, SaOS-2, had significantly higher 
luciferase expression when treated with either SB415286 or LiCl compared to 
vehicle only control.  Normalised TOPFLASH luciferase activity after SB415286 
treatment was 7.5-fold higher than vehicle control (P<0.05) and 12-fold higher 
after LiCl treatment (P<0.001).  This data verified that both compounds not 
only led to a nuclear translocation of β-catenin (Figure 4-12) but also activated 
TCF transcription factors and thus mimicked active Wnt signalling.  No 
significant change was observed in the FOPFLASH TCF-mutant control when 
SaOS-2 cells were incubated with GSK3 inhibitors. 
By contrast to the response seen in the SaOS-2 cells, no change in TOPFLASH 
luciferase activity was observed in the NHU cells after SB415286 treatment 
(Figure 4-13).  Interestingly, TOPFLASH and FOPFLASH luciferase activity was 
much higher in the NHU cells than in the SaOS-2 cells.  Basal luciferase activity 
from the TOPFLASH plasmid was 143-fold higher in the NHU cells compared to 
the SaOS-2 cells.  NHU FOPFLASH activity was 63-fold higher in the NHU cells 
compared to the SaOS-2 cells, and was most likely caused by differences in TK 
minimal promoter activity between the two cell lines.  Surprisingly, in NHU cells, 
normalised FOPFLASH luciferase activity was higher than TOPFLASH under all 
conditions, suggesting luciferase gene transcription was being driven via the 
mutant site in FOPFLASH.  To investigate the cause of this background 
transcription, both the TCF-binding promoter insert within TOPFLASH and the 
mutant non-TCF binding promoter insert within FOPFLASH (appendix VIII) were 
interrogated for potential transcription factor binding sites using MATinspector 
(Genomatix). 
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Figure 4-12 TCF transcription factor activity in SaOS-2 cells after 
GSK3 inhibition 
SAOS-2 cells were transfected 24-hours after seeding with either 0.5µg of TOPFLASH or 
FOPFLASH (negative control) plasmid along with 0.01µg pRL-CMV (loading control).  24 hours 
after transfection, SaOS-2 cells were treated with 20µM SB415286, 20mM LiCl or vehicle control 
for 24 hours.  A dual luciferase assay was performed on 3 biological replicates and data 
represents the mean luciferase activity after normalisation to loading control (±SD).  (*** 
P<0.001, ** P<0.01, * P<0.05, NS non significant using a one-way ANOVA with Dunnett’s 
multiple comparison post-test).   
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Figure 4-13 TCF transcription factor activity in NHU cells after GSK3 
inhibition 
Y924 NHU cells (at P3) were seeded into a 24-well Primaria® plate at 4x 104 cells/well and 
transfected 24-hours after seeding with either; 0.5µg TOPFLASH or FOPFLASH (negative 
control) plasmid along with 0.01µg loading control, pRL-CMV.  24 hours post-transfection, NHU 
cells were medium changed to KSFMc + 0.1% (v/v) DMSO with 0-10µM SB415286 for 24 hours.  
A dual luciferase assay was performed on 3 technical replicates and data represents the mean 
luciferase activity after normalisation to loading control (±SD).  (*** P<0.001, ** P<0.01, * 
P<0.05, NS non significant using a one-way ANOVA with Bonferroni multiple comparison post-
test).  Please note differences in the Y-axis scale bar between fig 4-12 and fig 4.13.  
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4.5.4.1 TOPFLASH promoter analysis 
Analysis of the TOPFLASH plasmid clearly showed four LEF1/TCF binding sites 
along with several other potential transcription factor binding sites, such as 
nuclear receptor sub-family 2 factors and GATA binding sites (Table 4-1).  
Unexpectedly, two of the four LEF1/TCF binding sites were present on the 
negative strand leaving only two on the template strand. 
Analysis of the mutant TCF binding site within the FOPFLASH vector exposed a 
plethora of potential binding sites.  Of notable interest were potential PPARγ 
binding sites, with 3 present on the template strand (Table 4-2). 
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Table 4-1 Potential transcription factor binding sites within the TCF 
promoter of TOPFLASH 
Transcription factor binding sites within the TCF-specific promoter of the TOPFLASH plasmid 
(Millipore) were analysed using MATinspector (Genomatix) and default parameters.  Matrix 
similarity score >0.8 are classed as potential binding sites.  Note the four LEF1/TCF binding 
sites, two of which are on the negative (-) strand. 
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Table 4-2 Potential transcription factor binding sites within the 
mutant TCF promoter of FOPFLASH 
Transcription factor binding sites within the mutant TCF promoter of the FOPFLASH plasmid 
(Millipore) were analysed using MATinspector (Genomatix) and default parameters.  Matrix 
similarity score >0.8 are classed as potential binding sites.  Note the five PPARγ binding sites, 
three of which are on the template (+) strand. 
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4.6 Discussion 
The aim of this study was to utilise pharmacological antagonists of GSK3 to 
inactivate the destruction complex and mimic canonical Wnt signalling in NHU 
cells.  
Two GSK3 inhibitors were used in this study: LiCl, a seminal GSK3 inhibitor 
which has a long history within the Wnt literature, and a relatively new drug, 
SB415286, a maleimide derivative developed by SmithKline Beecham (148).  
LiCl is an alkali metal chloride which inhibits the activity of GSK3 via two 
mechanisms: firstly, it acts as a competitive inhibitor of Mg2+, required for 
substrate phosphorylation (145, 149) and secondly, by inhibition of protein 
phosphatase 1, the enzyme which dephosphorylates and re-activates GSK3β at 
serine 9 (150).  LiCl is however not a specific GSK3 inhibitor; it has been shown 
to affect other kinases including casein kinase 2 (CK2 IC50 44mM), mitogen-
activated protein kinase-activated protein kinase 5 (PRAK IC50 56mM) and 
mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 IC50 
21mM)(151) and therefore data must be interpreted with caution.  SB415286 
inhibits GSK3 in an ATP competitive manner and has so far not been shown to 
significantly inhibit any other protein kinases when used at a concentration of 
10µM (tested against a panel of 24-protein kinases) (144, 148, 152).   Another 
maleimide derivative, SB216763 was not used in this study because of reported 
precipitation issues when incubated for periods greater than 90 minutes in 
aqueous solution (144). 
4.6.1 Toxicity of GSK3 inhibitors 
Up to 10µM SB415286 had no effect on NHU morphology or cell viability in 
culture.  LiCl on the other hand, was not well tolerated by NHU cells.  The 
reasons for this were not fully investigated in this study but could be linked to 
its effect not only on GSK3 but also on a variety of other protein kinases, 
included at least two involved in the p38 stress response pathway (151). 
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Ideally the effect of two structurally unrelated inhibitors of GSK3β would have 
been used throughout this study, but as LiCl was not suitable for use with NHU 
cells the remainder of this investigation was completed with SB415286 alone.  
4.6.2  β-catenin nuclear translocation 
Indirect immunofluorescence from SaOS-2 cells treated with LiCl or SB415286 
showed clear nuclear translocation of β-catenin and verified the efficacy of both 
inhibitors.  Surprisingly, when NHU cells incubated with vehicle alone were 
immunolabelled with anti-β-catenin antibodies, most of the cells already had a 
significant pool of nuclear β-catenin.  This suggested one of two things, either 
NHU cells were autocrine Wnt signalling; or the destruction complex was 
repressed in NHU cells, allowing non-phosphorylated β-catenin to accumulate 
and translocate to the nucleus. 
Treatment of NHU cells with GSK3 inhibitor resulted in a visual increase in 
nuclear β-catenin above that observed in vehicle control cultures.  This 
suggested that in control cultures there was still a pool of β-catenin that was 
being inactivated via GSK3 and implied that the destruction complex was 
present in NHU cells but was probably repressed either via signalling from Wnt, 
or by phosphorylation of GSK3 from another protein kinase.  
Previous data from chapter 3 indicated that proliferating NHU cells produced 
transcript for four Wnt ligands which suggests they may have the potential for 
autocrine Wnt signalling.  The production of functional Wnt ligand is known to 
involve several tiers of post-translational modification.  Once translated, Wnt 
protein is targeted to the endoplasmic reticulum (ER) where it undergoes 
glycosylation and palmitoylation (96, 97, 153).  Both modifications are 
fundamentally important and are reviewed in detail in chapter 6.  In brief, 
glycosylation is thought to be important in the secretory pathway and transfer 
from the ER to the trans Golgi network (TGN) (154-157), whereas 
palmitoylation is thought to be important for Wnt bioactivity (157, 158).  For 
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production and secretion of active Wnt ligand in vitro, Willert and colleagues 
have shown that serum is required and have postulated this to be because of 
the need for palmitic acid (96).  NHU cells are cultured in a serum–free medium 
(KSFMc) with no palmitic acid present in the medium (Invitrogen; personal 
communication), therefore it is unlikely that the pool of nuclear β-catenin seen 
in proliferating NHU cells is the result of autocrine Wnt signalling.  The role of 
palmitic acid in Wnt secretion and autocrine signalling of NHU cells could be of 
significance during urothelial regeneration and is explored further in chapter 6. 
As mentioned above, there are several cell-specific mechanisms that can 
regulate the activity and subsequent nuclear translocation of β-catenin. Growth 
factors such as epidermal growth factor (EGF), hepatocyte growth factor (HGF) 
and insulin-like growth factor-1 (IGF-1) have all been shown to regulate the 
activity of β-catenin (159, 160).  This type of intersection between mitogen-
activated pathways is termed pathway crosstalk and potentially could be an 
important regulator of β-catenin/TCF signalling in NHU cells and is explored in 
chapter 5.  
4.6.3  TCF activity 
Results from the SaOS-2 cell line verified both the integrity of the GSK3 
inhibitors and the DLA assay.  No significant increase in luciferase activity was 
seen in NHU cells after treatment with SB415286.  This lack of a response could 
mean one of two things: either NHU cells already have active TCF-transcription 
factor, or the action of β-catenin on TCF is blocked via an antagonist such as 
CBY, ICAT or NLK, all of which are expressed at the mRNA level in proliferating 
NHU cells. 
Both TOPFLASH and FOPFLASH are manufactured from the same vector 
backbone; the only difference is the presence of TCF-binding sites within 
TOPFLASH and mutated sites in FOPFLASH.  It was therefore surprising to find 
a higher basal level of luciferase activity in NHU cells transfected with 
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FOPFLASH compared to TOPFLASH.  A published report by Da Costa and 
colleagues has also shown similar findings in other epithelial cell lines.  
Unfortunately, no explanation of the cause of this TCF-independent activity was 
reported by the investigator (161).  FOPFLASH contains a mutated TCF binding 
site and is used to control for changes in minimal promoter (TK) activity.  Closer 
inspection of the mutant TCF binding domain revealed several potential binding 
sites for other transcription factors including PPARγ, which has been shown to 
be active in proliferating NHU cells (personal communication; P. Rubenwolf).  
This questions the usefulness of the FOPFLASH plasmid as a negative control.  
4.6.4  Conclusions 
NHU cells have a high level of endogenous active β-catenin that is nuclear in 
location.  The action of this endogenous nuclear β-catenin in proliferating NHU 
cells remains unclear.  Background activity with the FOPFLASH plasmid suggest 
that it is not a good negative control in this cell system and thus the results 
from the TCF reporter assay are inconclusive. Data from chapter 3 showed 
proliferating NHU cells expressing transcript from several Wnt target genes and 
thus suggests TCF transcription factors are active when NHU cells are 
proliferating in culture. 
Chapter 5 
156 
 
5 The interrelationships of different signalling 
mechanisms and cell:cell contact in modulating 
urothelial tissue homeostasis 
5.1 Rationale 
The dynamics between growth factor signalling and cell:cell contact play an 
important role in regulating self-renewal mechanisms, but to date, it remains 
unclear how this is properly coordinated.  Research has focused on proteins 
that localise to both sites of cell contact and to the nucleus in the hope of 
finding the key mediators of this process.  Proliferating NHU cells contain 
nuclear as well as cytoplasmic and membrane bound pools of β-catenin 
(chapter 4).  These data would suggest that β-catenin is important in both NHU 
cell signalling and cell contact and therefore could be an important player in the 
proliferative/quiescent switch seen during urothelial regeneration.  
In culture, NHU proliferation is driven via autocrine/juxtacrine activation of the 
EGFR family of receptors.  This chapter aims to address whether EGFR cell 
signalling and cell:cell adhesion (adherens junction formation) modulate the 
activity of β-catenin and whether the dynamics between them is important in 
maintaining NHU tissue homeostasis.  
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To fully address this aim and for ease of reading this chapter is divided into 3 
sections: 
Section 1: EGFR signalling and its effect on β-catenin localisation and 
activity; the potential role of signalling crosstalk in Wnt-independent β-
catenin activation.   
 
Section 2: The effect of culture confluence and cell:cell contacts on  
β-catenin localisation; the role of contact inhibition. 
 
Section 3: The role of β-catenin in NHU cell proliferation. 
 
Each section contains its own short introduction, aims, objectives, experimental 
design and results section. A comprehensive discussion of all the data can be 
found at the end of the chapter.  
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5.2 Wnt-independent β-catenin activation: The role of 
pathway crosstalk 
5.2.1 Signalling Crosstalk 
At any one time, a cell may be bombarded with many extracellular cues and 
must take into account all of them to elicit the appropriate cellular response.  
Many such signals may be contradictory, while others intersect and override 
one another.  Intersection between pathways is known as signalling crosstalk 
and is thought to add robustness and adaptability to the system, allowing a cell 
to respond quickly and effectively to important cues for such things as repair 
and cell cycle arrest, where lack of tight regulation could result in failure to 
repair or unwarranted proliferation.  
5.2.2  Crosstalk with the Wnt pathway 
Crosstalk between the Wnt pathway and other signalling pathways is well 
documented and can be characterised as either GSK-dependent or GSK-
independent.  
5.2.3  GSK-dependent crosstalk mechanisms 
GSK proteins are unlike most protein kinases in that they are constitutively-
active and are regulated primarily through phospho-inhibition of their activity 
(serine 21 in GSK3α or serine 9 in GSK3β (162, 163)).  Several serine/threonine 
kinases have been suggested as effectors of this, including: p38 MAPK, P90RSK 
and P70 S6 (effectors of MAPK and ERK signalling) as well as AKT/PKB (PI3K 
signalling) (162-166).  A plethora of research articles linking mitogen-activated 
protein kinases and Wnt pathway activation have been published and have 
demonstrated crosstalk at the level of GSK3 via such growth factors as IGF-1, 
insulin (159, 167), IGF-II (167) EGF via ERK/MAPK (168-171), EGF via 
PI3K/PKB (172) but disputed by (173), HGF (170), TGFβ (174) and FGF (175).  
The impact of the above crosstalk mechanisms could be substantial and if 
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correct would suggest that the Wnt cascade is not as exclusive as was originally 
thought.  One paper has however shed doubt on the importance of GSK3 
phospho-inhibition in Wnt-driven β-catenin activation.  McManus and colleagues 
have shown in the transgenic mouse that conversion of GSK3β serine 9 to an 
alanine had no effect on the release of β-catenin from the destruction complex 
upon Wnt3a stimulation and thus implied that destruction complex inhibition did 
not mediate β-catenin release (176).  
5.2.4  GSK-independent crosstalk mechanisms 
GSK-independent crosstalk is mainly composed of mechanisms that release 
sequestered β-catenin from the adherens junction and is reviewed and 
addressed in section 5.3.2.  
5.2.5 Rationale 
Cell signalling pathways were once viewed as distinct and independent 
transduction cascades.  Evidence however now suggests many points of 
convergence may exist between cascades and therefore cell signalling studies 
should not focus solely on one particular pathway but should be investigated as 
a single global network (177).  This sub-chapter will address the role of 
pathway crosstalk in modulating the sub-cellular location and activity of  
β-catenin and will investigate the mechanism(s) regulating the expression of 
Wnt-independent nuclear β-catenin seen in cultured NHU cells. 
5.2.6 Hypothesis 
In NHU cells, β-catenin activity is modulated via EGFR signalling crosstalk. 
5.2.7 Aim 
The aim of this sub-chapter was to ascertain if signalling crosstalk between the 
downstream EGFR pathways and β-catenin was present in NHU cells.  
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5.2.8 Objectives 
Specific objectives of this sub-chapter were: 
 To use EGFR, PI3K and MAPK antagonists to block all or part of the EGFR 
signalling cascade and assess whether this affects the phosphorylation 
status and location of β-catenin as well as expression of β-catenin 
transcriptionally regulated gene targets (Objective 1). 
 
 To determine if NHU cells respond to pharmacological GSK3β inhibition 
when EGFR signalling was blocked and to assess the importance of active 
β-catenin alone in driving NHU cell proliferation (Objective 2). 
 
5.2.9 Experimental Design (Objective 1) 
NHU cells were cultured for up to 72 hours in KSFMc containing 1µM PD153035 
(EGFR tyrosine kinase inhibitor), 5µM U0126 (MEK1/MEK2 inhibitor) or 5µM 
LY294002 (PI3K inhibitor).  DMSO was kept at a concentration of 0.1%(v/v) in 
all cultures and controls.  At 24 intervals, parallel cultures were treated as 
follows (Figure 5-1  
 Formalin-fixed on 12-well Teflon®-coated multi-spot slides to allow 
indirect- immunofluorescence photomicroscopy to be performed.  
Changes in the amount and sub-cellular location of β-catenin was 
visualised using the anti β-catenin antibody (clone C2206) and anti-
active β-catenin antibody (ABC; clone 8E7).  Nuclear and cytoplasmic 
signal intensities for active β-catenin were quantified from 
photomicrographs all taken at the same exposure, as previously 
described (section 2.9.1.6). 
 Lysed in situ using 2x SDS lysis buffer to produce whole cell lysates.  
Western blot was employed to verify that the applied antagonists had 
been effective.  Changes in the relative expression of active β-catenin, as 
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well as the phosphorylation status of GSK3β over the 72 hour time 
course were investigated.  
 Scraped in situ into TRIzol® reagent.  The effect of EGFR, MAPK and 
PI3K inhibition on mRNA expression of three downstream targets of  
β-catenin/TCF mediated transcription (Axin2 c-MYC and Lef1), as well as 
one negatively regulated target (CDH1) were quantified using SYBR® 
Green I qPCR. 
 
NHU cells were also cultured in KSFM with BPE and cholera toxin but minus 
exogenous rhEGF to assess the effect of autocrine EGFR signalling on β-catenin 
activation.  
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Figure 5-1 Experimental design used to assess potential EGFR and  
β-catenin crosstalk 
One ureteric NHU cell line (Y919) was seeded onto 12-well multispot slides and T25 Primaria 
flasks at a cell density of 2.5 x 104 cells/cm2.  Cells were allowed to adhere and then cultured 
with inhibitors or 0.1% (v/v) DMSO vehicle control.  At 24, 48 and 72 hours, cells were 
harvested and the effect of EGF inhibition on β-catenin nuclear translocation and β-catenin/TCF 
driven transcription was assessed. 
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5.2.10 Results (Objective 1) 
5.2.10.1 Manipulation of the EGFR signalling cascades and its effect 
on active β-catenin expression and sub-cellular location 
The amount of active β-catenin contained within the nucleus of NHU cells 
cultured without inhibitors was seen to fluctuate over the 72 hour time course.  
Nuclear labelling for active β-catenin was most intense 48 hours post seeding, 
after which it was seen to reduce (Figure 5-2A-C).  This change in nuclear β-
catenin labelling was also seen with the anti-total β-catenin antibody (C2206; 
Figure 5-2G-I).  Photoshop quantification of the nuclear fluorescent signal 
affirmed the visual change across the course of the experiment (Figure 5-4).  
Cytoplasmic labelling for active β-catenin remained constant over the 72 hour 
time-course.  Parallel cultures grown without exogenous rhEGF also had high 
levels of nuclear-active β-catenin at 48 hours post-seeding and like the cultures 
grown in KSFMc, they exhibited a reduction in nuclear labelling 72 hours post 
seeding (Figure 5-3).  Results thus implied that the fluctuation of nuclear-active 
β-catenin was not caused by the addition and subsequent exhaustion of 
exogenous rhEGF in the medium, but was more likely due to alternative factors, 
such as the density of the culture.  
Western blot data from parallel cultures corroborated the immunofluorescence 
findings (Figure 5-5).  Densitometry confirmed peak expression of active  
β-catenin to be 48 hours post-seeding.  Relative active β-catenin expression 
(active/total) was calculated as being 0.61, 1.55 and 1.22 at 24, 48 and 72 
hours, respectively. Interestingly, relative phospho-ERK expression was also 
seen to peak 48 hours post-seeding (Figure 5-5B/D).  To investigate whether 
this increase in active β-catenin expression was due to a change in the activity 
of the destruction complex, an antibody targeted to the inactive (phospho 
serine 9) form of GSK3β was used.  Results revealed that the increase in 
relative active β-catenin expression seen at 48 hours post-seeding was 
accompanied by an increase in phospho-GSK3β (Figure 5-5F).  These data thus 
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indicated that β-catenin activity was being modulated via a Wnt-independent 
GSK3β-dependent mechanism.  
 
Figure 5-2 Expression and localisation of β-catenin in NHU cells 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 
0.1%(v/v) DMSO.  Slides were formalin-fixed and immunolabelled with active β-catenin 
antibody (8E7) and rabbit anti-mouse IgG-Alexa 594 secondary antibody or total β-catenin 
(C2206) and goat anti-rabbit IgG Alexa 488 secondary antibody.  All slides were stained with 
Hoechst 33258 to delineate the nucleus and labelling was visualised under epi-fluorescent 
illumination.  Scale bar: 100µM. Micrographs are representative of two technical replicates 
(N=2). Arrow denotes strong punctate nuclear active β-catenin labelling at 48 hours post-
seeding and indicates activation of the Wnt pathway changes over time.   
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Figure 5-3 Expression and localisation of β-catenin when NHU cells 
were cultured without exogenous rhEGF 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFM + BPE + 
Cholera toxin + 0.1% (v/v) DMSO (KSFM-rhEGF).  Slides were formalin-fixed and 
immunolabelled with active β-catenin antibody (8E7) and rabbit anti-mouse IgG-Alexa 594 
secondary antibody or total β-catenin (C2206) and goat anti-rabbit IgG Alexa 488 secondary 
antibody.  All slides were stained with Hoechst 33258 to delineate the nucleus and labelling was 
visualised under epi-fluorescent illumination.  Scale bar: 100µM. N=1. Data implies the 
fluctuation in nuclear active β-catenin seen over the course of 72 hours is not caused by 
exogenous EGF depletion but more likely due to culture confluence. 
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Figure 5-4 Quantification of nuclear and cytoplasmic active β-catenin 
over 72 hours in normal growth medium (KSFMc) and without 
exogenous rhEGF 
Line graph represents nuclear and cytoplasmic active β-catenin pixel intensities and standard 
deviations as quantified from each micrograph (fig 5-2 A-C and fig 5.3 A-C) using Adobe 
Photoshop® software.  
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Figure 5-5 Wnt-independent expression of β-catenin via inhibition of 
GSK3β 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 0.1% 
(v/v) DMSO prior to lysis in 2X SDS-lysis buffer.  20µg of each protein lysate was subjected to 
SDS-PAGE within a 4-12% (w/v) Bis-Tris gel under denaturing conditions and immunoblotted 
onto PVDF membrane.  The PVDF membranes were blocked and then probed for 16 hours with 
antibodies raised against E-cadherin (A), active β-catenin (B), total β-catenin (C), phospho-ERK 
(D),total ERK (E), phospho-GSK3β (serine 9) (F) and β-actin to control for equal lysate loading 
(G, H).  Membranes were incubated for 1 hour with either goat anti-mouse IgG Alexa 680 or 
goat anti-rabbit IgG Alexa 800 depending on the antigen and primary antibody used.  Antibody 
binding was visualised by scanning at 700 and 800nm.  Densitometry results were represented 
graphically relative to the appropriate loading control. N=1. Note how the pattern for active β-
catenin, phospho-ERK and phospho-GSK3β expression is all similar.  Whole blots for each 
antibody can be found in appendix IX. 
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Parallel cultures incubated in the presence of PD153035 and labelled with active  
β-catenin antibody (8E7) demonstrated weak nuclear and cytoplasmic signal 
over the time course of the experiment, with very little nuclear labelling visible 
by 72 hours (Figure 5-6).  Quantification estimated there to be a 43.6% 
reduction in signal intensity between the 24 and 72 hour culture (Figure 5-7).  
Cytoplasmic active β-catenin labelling was also seen to reduce over the 72 hour 
time course (37.4% reduction; Figure 5-7).  
Densitometry analysis of western blots from parellel cultures showed no 
significant change in expression of active β-catenin over the course of the 
experiment (Figure 5-8B/C).   Expression of P-ERK was also low confirming the 
efficacy of the EGFR tyrosine kinase inhibitor (Figure 5-8D/E).  Expression of 
inactive-GSK3β (phosphorylated on serine 9) was low throughout the 72-hour 
time course suggestive of an active destruction complex.  
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Figure 5-6 Expression and localisation of active β-catenin in NHU cells 
after EGFR tyrosine kinase inhibition 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 1µM 
PD153035.  Slides were fixed and immunolabelled with active β-catenin antibody (8E7) and 
rabbit anti-mouse IgG-Alexa 594 secondary antibody or total β-catenin (C2206) and goat anti-
rabbit IgG Alexa 488 secondary antibody.  All slides were stained with Hoechst 33258 to 
delineate the nucleus and labelling was visualised under epi-fluorescent illumination. Scale bar: 
100µM. Micrographs are representative of two technical replicates (N=2). Note the low nuclear 
labelling with both the active and total β-catenin antibodies over the 72 hour time course.   
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Figure 5-7 Quantification of nuclear and cytoplasmic active β-catenin 
in NHU cells when cultured with EGFR tyrosine kinase inhibitor 
Line graph represents nuclear and cytoplasmic active β-catenin pixel intensities and standard 
deviations as quantified from each micrograph (fig 5-.6 A-C) using Adobe Photoshop® software. 
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Figure 5-8 Effect of EGFR tyrosine kinase inhibition on expression of 
Wnt signalling components 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 1µM 
PD153035 prior to lysis in 2X SDS-lysis buffer.  20µg of each protein lysate was subjected to 
SDS-PAGE within a 4-12% (w/v) Bis-Tris gel under denaturing conditions and immunoblotted 
onto PVDF membrane.  The PVDF membranes were blocked and probed with antibodies raised 
against E-cadherin (A), active β-catenin (B), total β-catenin (C), phospho-ERK (D), total ERK 
(E), phospho-GSK3β (serine 9) (F) and β-actin antibodies to control for equal lysate loading (G, 
H).  Membranes were incubated for 1 hour with either goat anti-mouse IgG Alexa 680 or goat 
anti-rabbit IgG Alexa 800 depending on the antigen and primary antibody used.  Antibody 
binding was visualised by scanning at 700 and 800nm.  Densitometry results were represented 
graphically relative to the appropriate loading control. N=1. Note the low expression of active  
β-catenin, phospho-ERK and phospho-GSK3β in comparison to fig 5-5. Whole blots for each 
antibody can be found in appendix IX. 
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Inhibition of MEK1/MEK2 with U0126 resulted in a reduced nuclear active β-
catenin expression compared to the solvent balanced control culture at both the 
24 hour and 48 hour time points (Figure 5-2 vs. Figure 5-9).  Signal intensity 
for both nuclear and cytoplasmic active β-catenin was reduced, but was not as 
striking as with PD153035 treatment (Figure 5-6).  Western blot using an 
antibody targeted to P-ERK (p42/44) verified the efficacy of the MEK1/MEK2 
inhibitor (Figure 5-10).  Densitometry revealed no change in the relative 
expression of active β-catenin over the time course of the experiment (Figure 5-
10).  Expression of P-GSK3β was low over the entire course of the experiment 
(Figure 5-10). 
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Figure 5-9 Expression and sub-cellular location of active β-catenin 
after MEK1/MEK2 inhibition 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 5µM 
U0126.  Slides were fixed and immunolabelled with active β-catenin antibody (clone ABC; 8E7) 
and rabbit anti-mouse IgG-Alexa 594 and stained with Hoechst 33258.  Antibody binding was 
visualised under epi-fluorescent illumination.  Scale bar: 100µM. Micrographs are representative 
of duplicate experiments (N=2). Line graph represents nuclear and cytoplasmic active β-catenin 
pixel intensities and standard deviations as quantified from each micrograph using Adobe 
Photoshop® software.  Note the low expression of active β-catenin over the course of the 
experiment. 
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Figure 5-10 Effect of MEK1/MEK2 inhibition on components of the 
Wnt signalling pathway 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 5µM 
U0126 prior to lysis in 2X SDS-lysis buffer.  20µg of each protein lysate was subjected to SDS-
PAGE within a 4-12% (w/v) Bis-Tris gel under denaturing conditions and immunoblotted onto 
PVDF membrane.  The PVDF membranes were blocked and then probed for 16-hours with 
antibodies raised against E-cadherin (A), active β-catenin (B), total β-catenin (C), phospho-ERK 
(D), total ERK (E), phospho-GSK3β (serine 9) (F) and anti β-actin antibodies to control for equal 
lysate loading (G, H).  Membranes were incubated for 1-hour with either goat anti-mouse IgG 
Alexa 680 or goat anti-rabbit IgG Alexa 800 depending on the antigen and primary antibody 
used.  Antibody binding was then visualised by scanning at 700 and 800nm.  Densitometry 
results were represented graphically relative to the appropriate loading control. N=1.  Active β-
catenin expression as well as phospho-GSK3β and phospho-ERK remained low over the 72 hour 
time course. Whole blots for each antibody can be found in appendix IX. 
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NHU cell cultures treated with 5µM LY294002 and labelled with active β-catenin 
antibody (8E7) showed strong nuclear labelling which peaked at 48 hours post-
seeding (Figure 5-11).  This coincided with a reduction in the intensity of 
cytoplasmic labelling at the same time point (Figure 5-11).  Interestingly, some 
cells had membrane localised labelling, which was not evident in the solvent 
balanced control cultures (Figure 5-11 white arrow heads vs. Figure 5-2).   At 
72 hours post-seeding, nuclear labelling for active β-catenin was variable with 
some cells showing intense nuclear labelling and others with very little (Figure 
5-11).  The efficacy of the PI3K inhibitor, LY294002 was verified by western 
blot from parallel cultures using an anti phospho-AKT antibody (S473; D9E; 
Figure 5-12).  Densitometry results showed an increase in relative active β-
catenin expression over the course of the experiment with the highest 
expression observed at 72 hours post-seeding (Figure 5-12).  P-GSK3β labelling 
was intense at both the 24 hour and 48 hour time points but surprisingly had 
disappeared completely by 72 hours (Figure 5-12).   
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Figure 5-11 Expression and localisation of active β-catenin in NHU 
after treatment with LY294002 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 5µM 
LY294002.  Slides were fixed and immunolabelled with active β-catenin antibody (clone ABC; 
8E7) and rabbit anti-mouse IgG-Alexa 594 and stained with Hoechst 33258.  Antibody binding 
was visualised under epi-fluorescent illumination.  Scale bar: 100µM. N=1.  Arrow heads 
indicate membrane labelling.  Line graph represents nuclear and cytoplasmic active β-catenin 
pixel intensities and standard deviations as quantified from each micrograph using Adobe 
Photoshop® software. 
Chapter 5 
177 
 
Figure 5-12 Effect of PI3K inhibition on components of the Wnt 
signalling pathway 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc + 5µM 
LY294002 prior to lysis in 2X SDS-lysis buffer.  20µg of each protein lysate was subjected to 
SDS-PAGE within a 4-12% (w/v) Bis-Tris gel under denaturing conditions and immunoblotted 
onto PVDF membrane.  The PVDF membranes were blocked and then probed for 16 hours with 
antibodies raised against E-cadherin (A), active β-catenin (B), total β-catenin (C), phospho-ERK 
(D), total ERK (E), phospho-GSK3β (serine 9) (F), phospho-AKT (S473) (G), total AKT (H) and 
anti β-actin antibodies to control for equal lysate loading (I, J).  Membranes were incubated for 
1 hour with either goat anti-mouse IgG Alexa 680 or goat anti-rabbit IgG Alexa 800 depending 
on the antigen and primary antibody used.  Antibody binding was visualised by epi-fluorescence 
illumination at 700 and 800nm. N=1.  Densitometry results are graphically represented relative 
to the appropriate loading control.  Whole blots for each antibody can be found in appendix IX. 
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5.2.10.2  Effect of EGF signalling inhibition on β-catenin/TCF 
mediated transcription  
Expression of three direct targets of β-catenin/TCF transcription (Axin2, c-MYC 
and LEF1), as well as one negatively-regulated target (CDH1) were quantified 
after incubation with EGFR signalling inhibitors.  Expression of Axin2 was 
significantly down-regulated (> 2-fold) after 24, 48 and 72 hours in culture with 
1µM PD153035 and implies inhibition of EGFR signalling reduces TCF-mediated 
transcription (Figure 5-13).  Treatment with U0126 also reduced the expression 
of Axin2 by more than 2-fold at both the 24 and 48 time point but not at the 72 
hour timepoint (Figure 5-13).  LY294002 did not significantly alter the 
transcription of Axin2 (Figure 5-13).  Expression of c-MYC was significantly 
down regulated when NHU cells were incubated with PD153035 or U0126 at the 
48 hour timepoint only.  Quantification of LEF1 expression was hampered by 
low expression and resulted in high standard deviation.  CDH1 mRNA 
expression was significantly higher in the PD153035-treated culture at 48 and 
72 hours post-seeding when compared to the solvent balanced control at the 
same time point (Figure 5-13).  Neither U0126, nor LY294002 treatment 
affected the mRNA expression of CDH1 (Figure 5-13). 
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Figure 5-13 Effect of EGF signalling on β-catenin/TCF mediated 
transcription 
NHU cells (Y919) at P4 were cultured for 24, 48 and 72 hours in KSFMc with 0.1% (v/v) DMSO, 
1µM PD153035, 5µM U0126 or 5µM LY294002.  Cells were solubilised in situ with Trizol® 
reagent and the total RNA content from the culture was extracted.  All samples were subjected 
to DNAse I digestion to remove residual gDNA prior to first-strand cDNA synthesis using 1ug of 
template mRNA and random hexamers.  Quantitative RT-PCR was performed for three direct 
downstream β-catenin/TCF targets: Axin2, c-Myc and LEF1. The repression of E-cadherin mRNA 
expression was also quantified.  Data was normalised to GAPDH and expressed relative to 
solvent balanced control.  Data represents the log2 mean expression of three-technical 
replicates with the corresponding standard deviation.  Red and green lines represent 2-fold 
up/down regulation. 
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5.2.11  Summary 
 Labelling intensity for nuclear active β-catenin was not constant over 
time in culture.  Nuclear labelling using two different antibodies raised 
against active and total β-catenin both labelled much more intensely 48 
hours post-seeding than at any other time point.  After 72 hours in 
culture, nuclear labelling had reduced, indicating a possible link between 
β-catenin release and culture confluence/contact inhibition.  Nuclear 
accumulation of β-catenin was not affected by the omission of 
exogenous rhEGF but was reduced by the addition of PD153035 to the 
growth medium. 
 
 Western blot from parallel cultures revealed a correlation between active 
β-catenin expression, high phospho-ERK and inhibition of GSK3β by 
phosphorylation at serine 9.  Inhibition of the EGFR pathways with 
PD153035 reduced the amount of active β-catenin and also led to a 
reduction in phospho-GSK3β indicating a link between the pathways 
downstream of EGFR and β-catenin. 
 
 Treatment of NHU cells with MEK1/MEK2 inhibitor reduced the nuclear 
labelling intensity for active β-catenin but not to the extent seen with 
PD153035.  Western blot data corroborated this reduction in active  
β-catenin expression after MEK1/MEK2 inhibition and indicated that the 
MAPK pathway may be important in the regulation of β-catenin. 
 
 Treatment with the PI3K inhibitor, LY294002, increased the nuclear 
labelling intensity seen with the active β-catenin antibody (8E7).  
Western blot data verified this increase in active β-catenin.  Phospho-
GSK3β (serine 9) expression was high with LY294002 treatment but 
disappeared completely by the 72 hour time-point.   
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 Quantitative RT-PCR revealed a significant decrease in Axin2 expression 
when NHU cells were cultured in the presence of PD153035 compared to 
solvent balanced control cultures at the same time-point and iplies a 
reduction in TCF-mediated transcription. 
 
5.2.12 Experimental design (Objective 2)   
NHU cells were pre-treated for 24 hours in KSFMc containing 0.1% (w/v) DMSO 
(vehicle control), 1µM PD153035, 5µM U0126 or 5µM LY294002 to block all, or 
specific parts of the EGF signalling cascade.  After pretreatment, NHU cells were 
cultured in KSFMc ±5-10µM SB415286 GSK3β inhibitor in the continued 
presence of fresh EGF signalling inhibitors for up to 5 days to determine 
whether NHU cells respond to pharmacological inhibitors when EGFR signalling 
was blocked.  The following experiments were undertaken to assess the effects 
on β-catenin sub-cellular location, TCF-mediated transcription and NHU cell 
growth (Figure 5-14): 
 Morphology: NHU cells were visualised by phase contrast microscopy and 
representative photomicrographs were taken to allow comparison.  
 Indirect immunofluorescence microscopy: NHU cells were formalin-fixed 
24 hours after the addition of SB415286 and immunolabelled with active 
β-catenin antibody (ABC; clone 8E7).  The nuclear signal intensity for 
active β-catenin was quantified from photomicrographs taken at the 
same exposure using Hoechst 33258 to delineate the nucleus. 
 Cell viability assays: viable cell biomass was measured using MTT assays 
over a 5 day time course to assess proliferation rate.  
 TOPFLASH dual luciferase assay: NHU cells were lysed 24 hours after 
treatment with SB415286.  TCF activity was assessed in triplicate wells 
using the TOPFLASH dual luciferase reporter assay.  Results were 
normalised to constitutively active Renilla luciferase and compared to 
those obtained with the negative control plasmid, FOPFLASH. 
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Figure 5-14 Experimental design to assess the effect of combined EGF 
and GSK3 inhibition on β-catenin signalling 
Ureteric NHU cell line (Y924) was cultured in KSFMc with 0.1% (v/v) DMSO (vehicle control), 
1µM PD153035, 5µM U0126 or 5µM LY294002 to inhibit all or specific parts of the EGFR 
signalling cascade (day 0).  After 24 hours, the medium and EGF signalling inhibitors were 
replenished and cultures were incubated with 0-10µM SB415286 (day 1).  DMSO was kept 
constant at 0.1% (v/v) in all experiments and controls.  To assess the effect of EGF and GSK3 
inhibition on cell proliferation, MTT assays were performed on days 2, 4 and 6 with medium and 
inhibitors replenished on day 3.  Cell morphology, TCF activation and β-catenin nuclear 
translocation were assessed at day 2 (24 hours post SB415286). 
Chapter 5 
183 
 
5.2.13 Results 
5.2.13.1 The effect of combined EGFR pathway and GSK3 inhibition 
on NHU morphology 
When cultured in normal growth medium + 0.1% (v/v) DMSO, NHU cells were 
small in size (~20µm in diameter) with phase-bright cell borders (Figure 5-15).  
Cells formed a non-stratified monolayer with typical epithelioid pavement 
morphology (Figure 5-15). 
In the presence of 1µM PD153035, NHU cells were seen to adopt an enlarged 
and flatter appearance (Figure 5-15;white arrow).  Cell borders were not phase-
bright.  10µM SB415286 in combination with PD153035 had little effect on cell 
morphology compared to PD153035 alone (Figure 5-15).  Both cultures 
appeared to be quiescent, with no mitotic figures apparent. 
When applied alone, 5µM U0126 reduced the culture density and individual cell 
size compared to solvent balanced control (Figure 5-15).  A proportion of highly 
elongated cells were evident throughout the culture (Figure 5-15 black arrows).  
Co-treatment with 10µM SB415286 and 5µM U0126 reduced the cell density 
further, while cell morphology remained the same (Figure 5-15). 
Treatment with 5µM LY294002 had little effect on cell morphology or culture 
density when compared to solvent balanced control (Figure 5-15).  Co-
treatment with SB415286 and LY294002 had no visible effect on cell 
morphology compared to LY294002 alone (Figure 5-15). 
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Figure 5-15 Effect of combined EGFR and GSK3 inhibition on 
morphology 
Phase contrast micrographs of Y924 (P3) NHU cells after a 24-hour incubation with EGFR 
signalling inhibitors and a further 24 hour incubation with EGFR inhibitors ±10µM SB415286.  
White arrow denotes flat and enlarged cells.  Black arrows highlight elongated cells.  Scale bar: 
100µm.  
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5.2.13.2 The effect of combined EGFR pathway and GSK3 inhibition 
on active β-catenin expression and localisation 
Nuclear labelling intensity for active β-catenin was dramatically reduced in the 
PD153035-treated culture compared to vehicle control (Figure 5-16).  Co-
treatment with SB415286 and PD153035 resulted in a more intense and 
punctate/granular nuclear labelling than with PD153035 alone and was possible 
the result of aggregate formation. Hoechst 33258 staining revealed nuclei to 
also be enlarged (Figure 5-16).  NHU cells co-treated with PD153035 and 
SB415286 also showed cytoskeletal distribution of β-catenin (Figure 5-16; white 
arrow).  A comparison of the mean nuclear pixel intensities obtained from 
PD153035-treated cells (110.8± 11.7 SD) and PD153035 plus SB415286 treated 
cells (143± 25.0 SD) revealed a statistically significant difference between the 
two cultures (P <0.01; Figure 5-17).   
With U0126 treatment alone, active β-catenin expression was seen to be more 
diffuse with both nuclear and cytoplasmic labelling visible.  Nuclear labelling 
appeared less intense than in the vehicle control.  In a large proportion of cells, 
active β-catenin labelling was also evident at the cell membrane (Figure 5-16; 
grey arrow).  No profound change in the expression or localisation of active  
β-catenin was noticeable when U0126 pre-treated NHU cells were cultured in 
medium containing both U0126 and SB415286 (Figure 5-16).   
Treatment with LY294002 did not affect the expression or localisation of active  
β-catenin.  No difference was observed in expression or localisation of β-catenin 
when cells were co-treated with SB415286 and LY294002 (Figure 5-16).  
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Figure 5-17 Quantification of nuclear active β-catenin in NHU cells 
treated with combined EGFR signalling and GSK3 inhibitors 
Bar chart represents nuclear active β-catenin as assessed from the pixel intensities of each 
micrograph in fig 5-16 using Adobe Photoshop® software.  Error bars represent standard 
deviations obtained from 20 randomly picked cells selected from the Hoechst 33258 image.  
(*** p<0.001, ** p<0.01, NS not significant, Tukey-Kramer multiple comparisons test). 
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5.2.13.3 Cell viability assays  
PD153035-treated cultures were severely growth retarded when compared to 
vehicle control cultures at the same timepoint (Figure 5-18A).  Cultures treated 
with 1µM PD153035 and 5µM SB415286 showed no statistically significant 
difference in growth rate compared to cultures treated with PD153035 alone.  
On the other hand, cultures co-treated with 7.5-10µM SB41528 and PD153035 
had a statistically significant higher proliferation rate when compared to 
PD153035 alone(Figure 5-18B;P<0.05).  This indicated that treatment with 
SB415286 was able to alleviate the proliferative block seen with PD153035 
alone and implied that β-catenin was able to drive NHU cell proliferation alone. 
NHU cells incubated with U0126 also had a reduced proliferation rate compared 
to control cultures at the same timepoint (Figure 5-19A).  However, addition of 
5-10µM SB415286 did not significantly alter the proliferation rate of U0126 
treated cells (Figure 5-19B).  
Cultures incubated in 5µM LY294002 had a reduced growth rate compared to 
control cultures, but not to the extent observed with 1µM PD153035 or 5µM 
U0126 (Figure 5-20A).  Addition of 5-10µM SB415286 had no effect on the 
growth rate of LY294002 treated NHU cells (Figure 5-20B).    
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Figure 5-18 Effect of combined EGFR and GSK3 inhibition on NHU cell 
viability 
MTT assays were performed on NHU cells (Y911) at P3 on days 0, 1, 3 and 6.  On day 0, cells 
were cultured in KSFMc ± 1µM PD153035.  On day one, PD153035 was replenished and the 
medium was supplemented with 0-10µM SB415286 where indicated.  A) Data shows the mean 
absorbance at 570nm (±SD) of 3 technical replicates.  B) Bar graph and statistical analysis from 
day 6 only.  Each data point is the average of 3 technical replicates ± SD.  (*** p<0.001, * 
p<0.05, one way ANOVA with multiple comparisons post-test).  
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Figure 5-19 Effect of combined MEK1/MEK2 and GSK3 inhibition on 
NHU cell viability 
MTT assays were performed on NHU cells (Y911) at P3 on days 0, 2, 4 and 6.  On day 0, cells 
were cultured in KSFMc ± 5µM U0126.  On day one, U0126 was replenished and the medium 
was supplemented with 0-10µM SB415286 where indicated.  A) Data shows the mean 
absorbance at 570nm (±SD) of 3 technical replicates.  B) Bar graph and statistical analysis 
from day 6 only.  Each data point is the average of 3 technical replicates ± SD.  (*** p<0.001, 
* p<0.05, one way ANOVA with multiple comparisons post-test).  
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Figure 5-20 Effect of combined PI3K and GSK3 inhibition on NHU cell 
viability 
MTT assays were performed on NHU cells (Y911) at P3 on days 0, 2, 4 and 6.  On day 0, cells 
were cultured in KSFMc ± 5µM LY294002.  On day one, LY294002 was replenished and the 
medium was supplemented with 0-10µM SB415286 where indicated.  A) Data shows the mean 
absorbance at 570nm (±SD) of 3 technical replicates.  B) Bar graph and statistical analysis from 
day 6 only.  Each data point is the average of 3 technical replicates ± SD.  (*** p<0.001, one 
way ANOVA with multiple comparisons post-test).  
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5.2.13.4 Assessing the effect of EGFR signalling and GSK3 inhibition 
on TCF activity 
NHU cell cultures treated for 24 hours with 0-10µM SB415286 did not show any 
change in TCF activity (Figure 5-21).  Normalised luciferase activity 
(Firefly/Renilla) in the TOPFLASH assay was in fact less than in the negative 
FOPFLASH control assay (Figure 5-21A).  Treatment with 1µM PD153035 
reduced the luciferase activity in both the TOPFLASH and FOPFLASH assay, 
indicating a possible reduction in the activity of the TK minimal promoter 
(Figure 5-21B).  When 10µM SB415286 was added to PD153035 pre-treated 
cultures, TOPFLASH normalised luciferase activity significantly increased, but 
FOPFLASH activity did not, indicate any increase in TCF mediated transcription 
(P<0.01; Figure 5-21B).  
Addition of 7.5-10µM SB415286 to NHU cultures pretreated for 24 hours with 
5µM U0126 slightly elevated the mean TOPFLASH luciferase activity above that 
obtained with the FOPFLASH negative control but this was not statistically 
significant (Figure 5-21C). 
Pre-treatment of NHU cultures for 24 hours with 1µM LY294002 prior to the 
addition of 7.5-10µM SB415286 had no effect on TCF activity (Figure 5-21D).  
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Figure 5-21 TCF transcription factor activity after co-treatment with 
EGFR signalling and GSK3 inhibitors 
NHU cells (Y924) were seeded into a 24-well Primaria® plate at 4 x104 cells/well and 
transfected with either 5µg of TOPFLASH or FOPFLASH plasmid along with 0.01µg of pRL-CMV 
(loading control).  16 hours after transfection, NHU cells were pre-treated with 0.1% (v/v) 
DMSO (A), 1µM PD153035 (B), 5µM U0126 (C) or 5µM LY294002 (D) in KSFMc for 24 hours 
and then incubated for a further 24 hours with 0-10µM SB415286 in the continued presence of 
EGFR signalling inhibitors.  A dual luciferase assay was performed on 3 technical replicates and 
data represents the mean luciferase activity after normalisation to loading control ± SD.  (** 
p<0.01, NS not significant, one-way ANOVA with Bonferroni multiple comparisons post test).  
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5.2.14 Summary 
 Addition of 1µM PD153035 to the culture medium of NHU cells 
significantly reduced the nuclear labelling intensity of active β-catenin 
indicating active β-catenin is regulated by signalling downstream of 
EGFR.  This reduction in nuclear active β-catenin could be partially 
restored by the addition of 10µM SB415286 . 
 
 Incubation with either EGFR (1µM PD153035) or MAPK inhibitor (5µM 
U0126) severely retarded the proliferation rate of NHU cells.  Addition of 
10µM SB415286 to PD153035 treated cells increased the viable cell 
biomass of the culture indicative of an increase in cell proliferation and 
suggests active β-catenin can drive proliferation in NHU cells.  SB415286 
had no effect on the proliferation rates of NHU cells treated with 
MEK1/MEK2 or PI3K inhibitors.  
 
 Incubation with 10µM SB415286 led to an increase in TCF transcription 
factor activity but only when all downstream signalling via the EGFR was 
blocked. 
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5.3 The role of cell:cell contacts in modulating β-catenin 
activity  
5.3.1 Cell:cell interactions 
Intercellular or cell:cell junctions are classified into three main types: the tight 
junction, which has an important role in barrier function, the communication or 
gap junction and the anchoring junctions, which are composed of adherens 
junctions and desmosomes (Figure 5-22).  
 
Figure 5-22 Cell:cell junctions 
Schematic illustrating the four types of cell:cell junctions found between epithelial cells: tight 
junctions, adherens junctions, desmosomes and gap junctions. 
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5.3.1.1  Tight junctions 
Tight junctions (TJ) can be found between the lateral membranes of two 
adjacent cells and limit para-cellular diffusion of water and solutes by bringing 
together the cell membranes of adjacent cells and sealing the paracellular space 
(reviewed by (20)).  TJ are multi-protein junctions composed of up to 40 
different proteins that show tissue-specific distributions. Three main groups of 
proteins are recognised:   
 Integral TJ proteins that bridge the intercellular space and include the 
occludins (178), claudins (179) and junctional adherens molecule (JAM-
1)(180). 
 Adaptor proteins which cluster and anchor the integral TJ proteins to the 
cytoskeleton and include zonular occludens (ZO-1, -2, -3), member of 
the membrane-associated guanylate kinases (MAGUK), which bind to 
claudins via their PDZ domain (181). 
 A miscellaneous group which are composed of cytosolic proteins.  Tight 
junctional complexes not only regulate polarity and barrier function but 
have been shown to be involved in cell proliferation and tumour 
suppression by recruiting such molecules as pTEN (182) and 
transcription factors such as cold shock domain protein A (CSDA alias 
Zonab (183).  
 
5.3.1.2  Communication junctions 
Gap junctions are channels directly connecting the cytoplasm of two adjacent 
cells and allow intracellular communication via the passage of small molecules up 
to 1KDa in size such as K+ ions, Ca2+ ions, ATP and glucose (reviewed by (184)).  
Each channel is composed of two end-to-end hemi-channels which are 
themselves composed of a hexamer (connexon) of transmembrane proteins 
called connexins (Cxs).  Gap junctions can be homotypic (composed of the same 
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connexon unit) or heterotypic (composed of 2 differing connexon units) which 
affects the selectivity and functional properties of the channel.  In humans there 
are 24 connexin genes, but to date, the expression profile in human urothelium 
is unknown.  
5.3.1.3  Anchoring junctions 
In epithelia, adherens junctions (AJ) are the principal form of intercellular 
adhesion and are important in the organisation and stratification of the tissue.  
Adherens junctions form between adjacent cells via calcium-dependent, 
homophilic engagement of E-cadherin molecules (Figure 5-23)(69).  The amino 
(N)-terminal extracellular domain of E-cadherin is composed of five domains 
(EC1-EC5), four of which bind Ca2+ ions and are necessary for adherens 
junctions to form (185-187).  The intracellular cytoplasmic tail of E-cadherin 
complexes directly with two members of the catenin family, β-catenin and P120 
and forms a stabilising bridge with α-catenin and vinculin to the actin 
cytoskeleton (Figure 5-23) (186, 188-190).    
  
Chapter 5 
198 
 
 
 
Figure 5-23 Schematic representation of an adherens junction 
between two adjacent cells 
The adherens junction (AJ) is a calcium-dependent cell:cell adhesion junction composed of a 
complex of cadherins (E-cadherin) and catenins (P120, β-catenin and α-catenin) which form a 
bridge via vinculin to the actin cytoskeleton.  
5.3.2  β-catenin sequestration at the adherens junction 
When bound as an intracellular component of the adherens junction, β-catenin is 
spatially separated from the soluble cytoplasmic pool and is unable to translocate 
to the nucleus.  In sub-confluent cultures, β-catenin is found to be tyrosine 
phosphorylated at its C-terminal domain and does not interact with the 
components of the adherens junction (191-193).  Examples of tyrosine (tyr) 
phosphorylation events which disrupt the adherens junction include 
phosphorylation of β-catenin at tyr-654 by Src or EGFR (disrupting the 
cadherin/β-catenin complex) and tyr-142 phosphorylation by Fer or Fyn 
(abrogating β-catenin interacting with α-catenin) (193-198).  In contrast to this, 
confluent cultures have been shown to mainly express non-tyrosine 
phosphorylated, serine/threonine phosphorylated β-catenin which localises at the 
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membrane as an intrinsic component of the adherens junction (191-193).  
Tyrosine phosphatase (PTPase) which stabilise the adherens junction complex 
and thus increase cell:cell adhesion include, PTP1B and PTPmu (199-201).   
Other mechanisms that may affect the formation of the adherens junction 
independently of β-catenin include: threonine phosphorylation of E-cadherin by 
CKII (202), E-cadherin endocytosis (108) and E-cadherin transcriptional 
repression by Snail (203). 
In certain situations, modulation of the membrane-bound pool of β-catenin has 
been reported to result in increased TCF transcription activity.  For example, in 
one study, short-term exposure of A431 human epidermoid cancer cells, A549 
human small cell lung carcinoma cells and DU145 prostate cancer cells to 
exogenous EGF was shown to induce calveolae-mediated E-cadherin 
endocytosis and subsequent release of β-catenin.  Most importantly, this study 
also showed that long-term EGF exposure increased E-cadherin repression by 
β-catenin/TCF-mediated expression of the transcriptional repressors, Snail and 
Twist, suggesting a positive feedback mechanism between the two pathways 
(168, 203).  Other mitogen-activated pathways which have been implicated in 
the same positive feedback loop include: FGFR1(204) and TGFβ1 (205). 
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5.3.3 Rationale 
Active β-catenin can be sequestered at adherens junctions resulting in a 
coordinated reduction in β-catenin-regulated gene expression and increased 
cell:cell adhesion.  This sequestration of β-catenin may be antagonised by a 
number of growth factor signalling mechanisms which either disrupt the 
adherens junction or down-regulate E-cadherin expression and lead to a 
reduction in cell:cell contact coupled with an increase in TCF-mediated gene 
transcription.  The literature suggests that β-catenin may be a key mediator in 
overseeing the close coordination of growth factor-induced proliferation with 
cell:cell adhesion. This chapter will explore the dynamics between adherens 
junctions and β-catenin/TCF-mediated gene transcription as a potential 
mechanism controlling NHU cell proliferation. 
5.3.4  Hypothesis 
Cell:cell contact and the sequestration of β-catenin at the adherens junction is 
an important means of curtailing β-catenin/TCF-mediated transcription and cell 
proliferation.   
5.3.5  Aim 
To ascertain whether increased cell adhesion reduces the availability of active 
β-catenin, in order to test the hypothesis that cell:cell contact and  
β-catenin signalling act cooperatively in switching urothelial cells between a 
proliferative and quiescent state. 
 
5.3.6 Objectives 
 To assess the effect of culture confluence on the translocation of β-
catenin to the nucleus.  
 To employ a calcium switch approach (sub- to near-physiological Ca2+ 
concentrations) to prohibit or permit the formation of adherens junctions 
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respectively, in order to assess whether their formation modulated  
β-catenin activity and TCF- mediated transcription.  
 
5.3.7 Experimental design 
The effect of culture confluence on active β-catenin expression and localisation 
was assessed in NHU cells (Y919) at P4.  Cells were plated at low (1.25 x 104 
cells/cm2) and high (5 x 104 cells/cm2) seeding densities and then formalin-fixed 
and detergent-permeabilised at 24, 48, 72 and 144 hours post-seeding.  
Cultures were immunolabelled for active and total β-catenin.  The proportion of 
nuclear to cytoplasmic β-catenin was visualised by immunofluorescence photo-
microscopy and quantified from photo-micrographs captured at constant 
exposure. 
The regulation of β-catenin activity by sequestration at adherens junctions was 
investigated by modulating the extracellular calcium concentration.  NHU cells 
were cultured in either low calcium conditions (0.09mM CaCl2) which restricted 
the formation of adherens junctions, or with 2mM CaCl2 for up to 72 hours.  At 
24 hour intervals, parallel cultures were: formalin-fixed and immunolabelled for 
active β-catenin, total β-catenin and E-cadherin; used to generate whole cell 
lysates in 2x SDS lysis buffer or; lysed in Trizol® reagent for subsequent 
extraction of mRNA.  The sub-cellular location of β-catenin and E-cadherin was 
determined by immunofluorescence photo-microscopy and the relative 
expression of active and total β-catenin was assessed by western blot.  
Downstream targets of β-catenin signalling were quantified by SYBR® Green I 
RT-qPCR. 
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5.3.8 Results 
5.3.8.1  The effect of cell density   
Seeding NHU cells at a low density (1.25 x 104 cells/cm2) prolonged the length 
of time β-catenin was present in the nucleus (Figure 5-24 vs. Figure 5-2 for 
comparison).  Strong β-catenin nuclear labelling was present for at least 72 
hours when NHU cells were seeded at 1.25 x 104 cells/cm2 (Figure 5-24A-C and 
I-K).  A reduction in the nuclear β-catenin pool was seen 144 hours post 
seeding (Figure 5-24). Coincidently, quantification of the cytoplasmic signal 
displayed the opposite effect, with weak labelling seen up to 72 hours and then 
a sharp increase 144 hours post-seeding (Figure 5-25). 
Seeding NHU cells at a higher plating density of 5 x 104 cells/cm2 did not 
completely ablate the nuclear translocation of active β-catenin but did reduce 
the labelling intensity (Figure 5-26 vs. fig Figure 5-2). Quantification of the 
nuclear localised active β-catenin signal was verified as being lower in the 
higher density culture compared to the lower density culture (111 vs. 171 
arbitrary units; Figure 5-27 vs. Figure 5-25).  
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Figure 5-24 Expression and localisation of β-catenin in NHU cells over 
time when seeded at low plating density 
NHU cells (Y919) at P4 were seeded at 1.25 x 104 cells/cm2 and cultured for 24 hours, 48 
hours, 72 hours and 144 hours in KSFMc.  Medium was replaced every 3 days to replenish 
growth factors.  Slides were fixed and immunolabelled with active β-catenin antibody (8E7), 
total β-catenin (C2206) or E-cadherin antibody (HECD1).  All slides were stained with Hoechst 
33258 to delineate the nucleus and labelling was visualised under epi-fluorescent illumination.  
Photo-micrographs are of NHU cells labelled with anti-active β-catenin (A-D), total β-catenin (I-
L) and E-cadherin (M-P) with matched Hoechst 33258 staining underneath. Scale bar:100µM. 
N=1.  β-catenin was present in the nucleus of NHU cells  for longer when seeded at a lower 
plating density.   
Chapter 5 
204 
 
 
Figure 5-25 Quantification of nuclear and cytoplasmic active β-catenin 
in NHU cells over time when seeded at low density  
Line graph represents nuclear and cytoplasmic active β-catenin pixel intensities and standard 
deviations as quantified from each micrograph (fig 5-24A-D) using Adobe Photoshop® software. 
Note inverse relationship between nuclear and cytoplasmically localised β-catenin.  
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Figure 5-26 Expression and localisation of β-catenin in NHU cells over 
time when seeded at high plating density 
NHU cells (Y919) at P4 were seeded at 5 x 104 cells/cm2 and cultured for 24 hours, 48 hours 
and 72 hours.  Slides were fixed and immunolabelled with active β-catenin antibody (8E7), total  
β-catenin (C2206) or E-cadherin antibody (HECD1).  All slides were stained with Hoechst 33258 
to delineate the nucleus and labelling was visualised under epi-fluorescent illumination.  Photo-
micrographs are of NHU cells labelled with anti-active β-catenin (A-C), total β-catenin (G-I) and 
E-cadherin (J-L) with matched Hoechst 33258 staining underneath.  Scale bar: 100µM. N=1.  
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Figure 5-27 Quantification of nuclear and cytoplasmic active β-catenin 
in NHU cells over time when seeded at high plating density 
Line graph represents nuclear and cytoplasmic active β-catenin pixel intensities and standard 
deviations as quantified from each micrograph (fig 5.26 A-C) using Adobe Photoshop® software.   
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5.3.8.2 The impact of adherens junction formation on sequestration of 
active β-catenin from the nucleus  
The addition of physiological calcium concentrations to the growth medium of 
NHU cells stimulated the formation of adherens junctions.  By 48 hours, E-
cadherin and β-catenin could clearly be seen at the membrane (Figure 5-28A-C 
and J-L). β-catenin was seen to enter the nuclear compartment 48 hours post 
seeding and was cytoplasmically localised by 72 hours; the same pattern of 
expression seen with NHU cells cultured in low calcium (Figure 5-2).  
Quantification verified the observed increase in nuclear-localised active  
β-catenin at 48 hours post seeding.  The nuclear-active β-catenin signal was 
seen to increase from a pixel intensity of 87.8 ± 20.9SD (arbitrary units) at 24 
hours post seeding to 150.6 ± 34.6SD at 48 hours (Figure 5-29) and was thus 
similar to that observed in low calcium conditions.  Sequestration of β-catenin 
at points of cell:cell contact via inclusion into calcium-dependent adherens 
junctions was not seen to inhibit the translocation of β-catenin to the nucleus.   
Western blot data from parallel cultures revealed a 2.5 fold increase in active 
β-catenin (Figure 5-30) between the 24 hour and 48 hour time points and was 
thus similar to that observed in low calcium conditions.  This increase in active 
β-catenin coincided with when P-ERK signalling was at its most active (Figure 5-
30) and was accompanied by an 11-fold increase in P-GSK3 (serine 9) at the 
same time point (Figure 5-30).   
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Figure 5-28 Expression and localisation of β-catenin in NHU cells over 
a 72 hour time course in KSFMc supplemented with physiological 
calcium 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc+2mM 
CaCl2.  Slides were fixed and immunolabelled with active β-catenin antibody (8E7), total  
β-catenin (C2206) or E-cadherin antibody (HECD1).  All slides were stained with Hoechst 33258 
to delineate the nucleus and labelling was visualised under epi-fluorescent illumination.  Photo-
micrographs are of NHU cells labelled with anti-active β-catenin (A-C), total β-catenin (G-I) and 
E-cadherin (J-L) with matched Hoechst 33258 staining underneath.  Scale bar: 100µM. N=1. 
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Figure 5-29 Quantification of nuclear and cytoplasmic active β-catenin 
in NHU cells over time when cultured in KSFMc supplemented with 
physiological calcium concentrations 
Line graph represents nuclear and cytoplasmic active β-catenin assessed from the pixel 
intensities.  Error bars represent standard deviations as quantified from each micrograph (fig 5-
28 A-C) using Adobe Photoshop® software.  
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Figure 5-30 Effect of calcium on components of the Wnt signalling 
pathway 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc+2mM 
CaCl2 prior to lysis in 2X SDS-lysis buffer.  20µg of each protein lysate was separated by SDS-
PAGE onto 2 duplicate 4-12% (w/v) Bis-Tris gels under denaturing conditions and 
immunoblotted onto PVDF membranes.  PVDF membranes were probed for 16 hours with 
antibodies raised against E-cadherin, active β-catenin, total β-catenin, phospho-ERK, total ERK, 
phospho-GSK3β and β-actin to control for equal lysate loading.  Membranes were incubated for 
1 hour with either; goat anti-mouse IgG Alexa 680 or; goat anti-rabbit IgG Alexa 800 depending 
on the antigen and primary antibody used.  Antibody binding was visualised by epi-fluorescent 
illumination at 700 and 800nm.  Densitometry results are represented graphically normalised to 
the appropriate loading control. 
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5.3.8.3  Assessing the effect of adherens junction formation on 
sequestration of β-catenin and subsequent TCF activity 
Expression of Axin2 was less in high calcium (2mM CaCl2) compared to low 
calcium (0.09mM CaCl2) at both the 48 and 72 hour time points  but the 
observed down-regulation did not meet the 2-fold change threshold and was 
therefore deemed insignificant (Figure 5-31).  E-cadherin and c-MYC expression 
did not change (Figure 5-31).  LEF1 mRNA expression was the only  
β-catenin/TCF-mediated downstream target to alter when compared to control 
(low calcium; 0.09mM). However, expression of LEF1 mRNA was low in both 
conditions and thus standard deviations were seen to be high (Figure 5-31).  
Addition of 2mM CaCl2 to the growth medium of NHU cells was deemed to not 
affect β-catenin/TCF-mediated transcription. 
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Figure 5-31 Effect of adherens junction formation on β-catenin/TCF-
mediated transcription 
NHU cells (Y919) at P4 were cultured for 24, 48 and 72 hours in KSFMc or KSFMc+ 2mM CaCl2. 
Cells were solubilised in situ with TRIzol® reagent and the total RNA content from the culture 
was extracted.  All samples were subjected to DNAse I digestion to remove residual gDNA prior 
to first-strand cDNA synthesis using 1ug of template mRNA and random hexamers.  
Quantitative RT-PCR was performed for three direct downstream β-catenin/TCF targets (Axin2, 
LEF1 and c-Myc) using SYBR-green I.  The repression of E-cadherin transcription (assumed to 
be via Twist) was also quantified.  Data was normalised to GAPDH and expression was 
quantified relative to KSFMc (low calcium; 0.09mM CaCl2) at the same time point.  Data 
represents the log2 mean expression of three-technical replicates with the corresponding 
standard deviation.  Red and green lines represent significant 2-fold change in expression.  
Addition of 2mM CaCl2 to the growth medium of NHU cells was seen to not affect 
β-catenin/TCF-mediated transcription. 
Chapter 5 
213 
 
5.3.9  Summary 
 Seeding NHU cells at a lower plating density prolonged the length of time 
active β-catenin was visible in the nucleus of NHU cells by at least 24 
hours. 
 
Seeding NHU cells at a higher than normal plating density did not 
completely ablate nuclear translocation of β-catenin but did reduce it by 
~35%. Data thus suggests that cell density regulates β-catenin activity. 
 
 In the presence of near physiological calcium concentrations that 
promoted formation of adherens junctions, β-catenin was still seen to 
translocate to the nucleus with strong nuclear labelling visible at 48 
hours post seeding.  This coincided with high MAPK activity and high  
P-GSK3β at the same time point.  At 72 hours post seeding, β-catenin 
was lost from the nucleus and relocalised to the membrane. Data thus 
suggests that cell:cell contacts may act to sequester β-catenin away 
from the nucleus. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
214 
 
5.4 The role of β-catenin signalling in NHU cell proliferation 
5.4.1 Rationale 
Data from section 5.2 showed that signalling downstream of EGFR could 
regulate the localisation and activity of β-catenin and lead to Wnt ligand-
independent TCF-mediated transcription.  To determine if this crosstalk was 
important in inducing/maintaining the proliferative phenotype of NHU cells, 
EGFR and β-catenin signal transduction cascades would need to be 
disentangled.   
5.4.2 Aim 
To determine if β-catenin signalling via pathway crosstalk was important 
in human urothelial proliferation. 
 
5.4.3 Objectives 
 To generate and validate a stable urothelial cell line expressing either an 
shRNA targeted to β-catenin (termed βCATKD cells) or a scrambled shRNA 
control. 
 
 To investigate the consequential changes of β-catenin knock-down on 
urothelial cell morphology and proliferation in vitro. 
 
 To investigate if there were any consequential changes to the MAPK and 
PI3K signalling when β-catenin signalling was reduced. 
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5.4.4 Experimental design   
A validated and published β-catenin siRNA (206) was modified to produce an 
shRNA hairpin and ligated into the retroviral vector, pSIREN-RetroQ via the 
EcoRI and BamHI restriction sites (Appendix X).  The resulting plasmid was 
transformed into E.coli and insertion of the shRNA sequence was confirmed by 
MluI digestion (Appendix XI).  PT67TM packaging cells were transfected with 
plasmid containing either the β-catenin shRNA (βCATKD) or with a scrambled 
shRNA control (developed by Clontech) and selected for stable expression using 
4µg/ml puromycin.  NHU cells (Y970) at low passage (P1) were transduced with 
retrovirus containing either the β-catenin KD shRNA or scrambled control shRNA 
and subjected to antibiotic selection (2µg/ml puromycin) prior to use in the 
following experiments: 
 Both sub-lines were cultured in complete growth medium and visualised 
using phase-contrast microscopy.  Representative photomicrographs 
were taken to allow morphological comparison between βCATKD and 
control cells.  
 Cells were cultured in KSFMc ± 2mM CaCl2 and lysed in situ in 2x SDS 
(electrophoresis sample buffer) during exponential growth phase.  
Western blotting studies were performed to verify β-catenin knock-down.  
Changes in the relative expression of active β-catenin, total β-catenin 
and E-cadherin were quantified alongside phospho-ERK and phospho-
AKT.  β-actin was used as a loading control in all experiments.  
 Cells were seeded onto 12-well multispot slides and incubated for 24 
hours in KSFMc ± 2mM CaCl2.  Slides were fixed in the appropriate 
fixative for the antigen of interest and immunolabelled with the 
following: active β-catenin antibody and total β-catenin to assess  
β-catenin expression and sub-cellular location, P-ERK and P-AKT to 
assess MAPK and PI3K signalling status.  Hoechst 33258 staining was 
included to allow delineation of the nuclear compartment. 
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 Sub-lines were seeded into 96-well plates and cultured in KSFMc ± 2mM 
CaCl2.  The viable cell biomass of the culture was determined over a 6-
day time course to assess the effect of β-catenin knock-down on 
proliferation.  
 Transduced sub-lines were seeded into 96-well plates and cultured in 
KSFMc ± 2mM CaCl2 with 1µM PD153035, 5µM U0126 or 5µM LY294002 
for 6 days.  The viable biomass of the culture was measured on days 1, 
4 and 6 to determine the sensitivity of each sub-line to EGFR, MAPK and 
PI3K inhibition. 
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5.4.5 Results 
5.4.5.1  Morphology 
Following retroviral transduction, stable sub-lines expressing either β-catenin 
(βCATKD) or scrambled shRNA were established by antibiotic selection with 
2µg/ml puromycin.  A non-transduced isogenic control culture selected at the 
same time and with the same concentration of antibiotic had perished by 48 
hours and thus clearly demonstrated the toxicity of the antibiotic when NHU 
cells did not possess the resistance gene (Figure 5-32C).  At 48 hours post 
selection, both the scrambled control and βCATKD cultures still contained viable 
cells which were resistant to the effects of puromycin (Figure 5-32A/B).  
Percentage survival was estimated to be slightly higher in the scrambled control 
culture compared to the βCATKD culture at the same time point.  At 96 hours 
post selection, both the scrambled control and βCATKD cultures had 
successfully recovered from antibiotic selection and grew as a monolayer 
culture with typical epithelioid pavement morphology (Figure 5-32D/E). The 
majority of cells in both cultures had phase-bright intracellular borders.  A small 
proportion of rounded (possibly mitotic) cells were evident (Figure 5-32D/E; 
black arrow heads).  Both cultures reached confluence and were passaged 
successfully without significant cell loss.  
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Figure 5-32 Morphological characteristics of β-catenin knock-down 
cells after antibiotic selection 
NHU (Y970) at P1 were transduced with retrovirus containing β-catenin-targeted shRNA 
(βCATKD) or scrambled control.  48 hours post transduction, cultures were trypsinised, split 1:3 
and allowed to attached to the tissue culture flask prior to addition of 2mg/ml puromycin.  A 
100% stably transduced cell population was assumed when all cells in the nontransduced 
control flask had perished.  Phase contrast images were taken at 48 hours and 96 hours post 
selection.  (A-C) 48 hours post-selection, (D-F) 96 hours post-selection.  Note the lack of cells 
in both (C) and (F) verifying a successful selection with puromycin.  Black arrow heads denote 
rounded (possibly mitotic) cells seen after antibiotic selection.  
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5.4.5.2  Validating β-catenin knock-down in urothelial cells 
Whole cell lysates from βCATKD and scrambled control sub-lines were probed 
for expression of active and total β-catenin (Figure 5-33A).  Normalised 
densitometry results demonstrated a substantial decrease in active β-catenin as 
well as total β-catenin expression in the βCATKD culture compared to control 
(Figure 5-33B).  Transformation of the normalised densitometry data revealed a 
66% reduction in active β-catenin protein expression and a 58% reduction in 
total β-catenin expression in the βCATKD culture compared to control (Figure 5-
33D). 
Formalin-fixed cultures of βCATKD and scrambled control sub-lines were probed 
for active and total β-catenin expression. Signal intensities for active and total 
β-catenin were clearly reduced in the βCATKD cultures compared to control 
when photomicrographs were taken at the same exposure (Figure 5-33C).  
Both nuclear and cytoplasmic labelling was visibly reduced in the βCATKD 
culture. 
5.4.5.3  Effect of β-catenin knock-down on urothelial cell viability 
Human urothelial cell biomass was determined by MTT assay after 1, 4 and 6 
days in culture with KSFMc ± 2mM CaCl2.  In KSFMc alone, both cultures 
entered a lag phase for the first 24 hours, after which, cell biomass was seen to 
increase at an exponential rate until the end of the time course.  By day six, the 
biomass of the control culture was seen to be significantly greater than the 
biomass of the βCATKD culture (Figure 5-34; p<0.001).  When cultured in the 
presence of 2mM calcium, both sub-lines proliferated at a greater rate than 
there KSFMc only counterpart (Figure 5-34).  Scrambled control cultures was 
once again seen to obtain a greater biomass at day six compared to the 
βCATKD culture indicating a potential growth disadvantage with knock-down of  
β-catenin (Figure 5-34, p<0.001). 
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Figure 5-33 Effect of β-catenin shRNA on β-catenin protein expression 
and localisation in HU cells 
(A) Y970 NHU cells expressing either β-catenin shRNA (βCATKD) or scrambled control shRNA 
were lysed and 20µg of each protein lysate was subjected to SDS-PAGE within a 4-12% (w/v) 
Bis-Tris gel followed by immunoblotted onto PVDF membrane.  Membranes were probed for 
active β-catenin (8E7), total β-catenin (C2206), and β-actin (to control for equal lysate loading) 
along with the appropriate secondary antibody.  (B) Signal intensities were normalised relative 
to β-actin control and represented graphically as bar charts.  (C) Data was transformed and 
expressed as percentage change vs. scrambled control.  (D) βCATKD and control sub-lines 
were labelled with active β-catenin (8E7) and total β-catenin (C2206) antibodies.  All slides 
were stained with Hoechst 33258 to delineate the nucleus and visualised under epi-fluorescent 
illumination. Photo-micrographs were taken at identical exposures for comparison. Micrographs 
and western blots are representative of duplicate experiments. Note the reduction in active  
β-catenin in the βCATKD cells compared to the control.  
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Figure 5-34 Effect of β-catenin knock –down on NHU cell viability 
β-catenin knock-down cells (βCATKD) and scrambled control from the NHU cell line Y970 were 
seeded at 2x 103 cells/well into a 96-well plate and grown for up to 6 days in complete growth 
medium ± 2mM CaCl2.  (A) MTT assays were performed on days 0, 1, 4 and 6 with KSFMc and 
CaCl2 replenished on day 3.  Each data point is the average of 6 biological replicates ± SD.   
(B) Transformed data from day six (*** p<0.001, unpaired t-test.).  Note the reduced 
absorbance obtained from the βCATKD sub-line compared to control at the same time point. 
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5.4.5.4  Assessing the effect of β-catenin knock-down on EGFR 
signalling 
When βCATKD and scrambled control were cultured in normal growth medium 
(KSFMc; 0.09mM CaCl2) both sub-lines appeared morphologically normal but 
the βCATKD culture appeared to have a reduced proliferation rate (Figure 5-
34).  Immunofluorescence labelling of both sub-lines with the proliferation 
marker MKi67 revealed a lower proportion of cells in the βCATKD culture (66%) 
were in the cell cycle compared to control (84%; Figure 5-35).  To investigate 
the effects of β-catenin knock-down on pathways downstream of EGFR 
signalling, immunofluorescence microscopy and immunoblotting were utilised.  
Immunofluorescent labelling of the two sub-lines highlighted an increased 
expression of phospho-AKT in the βCATKD cells (Figure 5-35).  Immunoblotting 
from parallel cultures quantified this change in P-AKT expression as being a 
2.16 fold increase over the scrambled control, implying that knock-down of β-
catenin increased activity of the PI3K pathway (Figure 5-36).  By contrast, 
expression of P-ERK was seen to be reduced by 80% in the βCATKD culture 
(Figure 5-36).  E-cadherin expression was increased by 2.7 fold in the βCATKD 
culture.  
When cultured in the presence of 2mM CaCl2, both sub-lines appeared to form 
calcium-dependent E-cadherin-mediated adherens junctions at the cell 
membrane (Figure 5-37).  Nuclear expression of MKI67 was similar to that 
observed in the KSFMc cultures, with 54% of cells in the βCATKD culture 
expressing the proliferation marker and 75% in the scrambled control (Figure 5-
37).  When cultured in physiological calcium, shRNA-mediated knock-down of 
β-catenin resulted in a significant reduction in both P-AKT and P-ERK expression 
relative to scrambled control (Figure 5-37).   Scrambled control cultures clearly 
showed nuclear expression of both P-ERK and P-AKT, whereas βCATKD cultures 
showed weak perinuclear localisation of both P-ERK and P-AKT (Figure 5-37).  
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Figure 5-35 Effect of β-catenin knock-down on the localisation of  
P-ERK and P-AKT in human urothelial cells 
NHU cells (Y970) expressing either β-catenin shRNA (βCATKD) or a scrambled control shRNA 
were methanol:acetone (50:50) fixed and labelled with the following primary antibodies:  
E-cadherin antibody (HECD1), MKi67 (MM1), P-ERK (D13.14.4E) and P-AKT (D9E).  Slides were 
stained with Hoechst 33258 to delineate the nucleus and visualised under epi-fluorescent 
illumination. Photomicrographs are representative of duplicate experiments (N=2). All 
photomicrographs with the same primary antibody were taken at the same exposure.  Note the 
increase in P-AKT expression in the βCATKD cells vs. the scrambled control.   
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Figure 5-36 Effect of β-catenin knock-down on the expression of  
P-ERK, P-AKT and E-cadherin in human urothelial cells 
NHU cells (Y970) expressing either β-catenin shRNA or scrambled control were lysed and 20µg 
of each was subjected to SDS-PAGE within a 4-12% (w/v) Bis-Tris gel under denaturing 
conditions.  (A) PVDF membranes were probed for E-cadherin, phospho-ERK, total ERK, 
phospho-AKT, total AKT and β-actin (to control for equal lysate loading). Membranes were 
incubated for 1 hour with either goat anti-mouse IgG Alexa 680 or goat anti-rabbit IgG Alexa 
800 and visualised by epi-fluorescent illumination at 700 and 800nm.  (B) Densitometry results 
were represented graphically as bar charts. Signal intensities were normalised relative to the 
appropriate loading control.  (C) Transformed densitometry data expressed as percentage 
change vs. scrambled control. Note the decrease in P-ERK and increase in P-AKT and  
E-cadherin expression in the βCATKD cells compared to control.  Representative micrographs 
from duplicate experiments shown. 
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Figure 5-37 Effect of β-catenin knock-down on the localisation of  
P-ERK and P-AKT in human urothelial cells when cultured in 2mM 
CaCl2 
NHU cells (Y970) expressing either β-catenin shRNA (βCATKD) or a scrambled control shRNA 
were incubated for 24 hours in KSFMc + 2mM CaCl2 prior to Methanol:acetone (50:50) fixation 
and labelling with the following primary antibodies: E-cadherin antibody (HECD1), Ki67 (MM1), 
P-ERK (D13.14.4E) and P-AKT (D9E). All slides were stained with Hoechst 33258 to delineate 
the nucleus and labelling was visualised under epi-fluorescent illumination. Representative 
photo-micrographs were taken at the same exposure for each antibody.  N=1. Note the 
reduced expression of nuclear P-ERK and P-AKT in the βCATKD cell culture.   
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5.4.5.5  Cell viability in the presence of EGFR signalling inhibitors 
To ascertain whether P-AKT was important in maintaining the proliferative 
phenotype of the βCATKD sub-line, both cultures were incubated in the 
presence of EGFR, PI3K and MAPK -specific signalling inhibitors.   
When cultured in KSFMc + 0.1%(v/v) DMSO, the βCATKD culture was seen to 
contain a significantly smaller viable biomass compared to scrambled control by 
day 6 (Figure 5-38, p<0.001).  In the presence of 1µM PD153035, proliferation 
was severely attenuated in both cultures, no significant difference in culture 
biomass was observed between the two sub-lines (Figure 5-38).  In the 
presence of 5µM U0126, the viable cell biomass of the βCATKD cell culture was 
seen to reduce over the 6 day time course, indicating a possible increase in cell 
death (Figure 5-39). This was seen regardless of whether the culture had been 
incubated in 0.09mM or 2mM CaCl2.  Viable biomass of the scrambled control 
culture remained constant over the course of the experiment, indicating either 
growth arrest or an increase in cell death (Figure 5-39).  When βCATKD 
cultures were grown in the presence of the PI3K inhibitor, LY294002, viable 
biomass was significantly reduced compared to scrambled control (p<0.001; 
Figure 5-40, Figure 5-41) and implied PI3K signalling was driving proliferation in 
the βCATKD cell culture but not in the scrambled control.  
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Figure 5-38 Effect of EGFR tyrosine kinase inhibition on the viability of 
human urothelial with reduced β-catenin expression  
β-catenin knock-down cells (βCATKD) and scrambled control cells were seeded at a density of 
2x 103 cells/well into a 96-well plate and grown for up to 6 days in either A) KSFMc ±1µM 
PD153035 or B) KSFMc + 2mM CaCl2 ±1µM PD153035. MTT assays were performed on days 0, 
1, 4 and 6 with growth medium and inhibitor replenished on day 3.  Each data point is the 
average of 6 biological replicates ± SD.  
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Figure 5-39 Effect of MEK1/MEK2 inhibition on the viability of human 
urothelial cells with reduced β-catenin expression 
β-catenin knock-down (βCATKD) cells and scrambled control cells were seeded at a density of 
2x 103 cells/well into a 96-well plate and grown for up to 6 days in either A) KSFMc ± 5µM 
U0126 or B) KSFMc + 2mM CaCl2 ±5µM U0126.  MTT assays were performed on days 0, 1, 4 
and 6 with growth medium and inhibitor replenished on day 3.  Each data point is the average 
of 6 biological replicates ± SD. 
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Figure 5-40 Effect of PI3K inhibition on the viability of human 
urothelial ells with reduced β-catenin expression 
β-catenin knock-down cells (βCATKD)  and scrambled control cells were seeded at a density of 
2x 103 cells/well into a 96-well plate and grown for up to 6 days in either A) KSFMc ± 5µM 
LY294002 or B) KSFMc + 2mM CaCl2 ± 5µM LY294002. MTT assays were performed on days 0, 
1, 4 and 6 with growth medium and inhibitor replenished on day 3.  Each data point is the 
average of 6 biological replicates ± SD.  Note the recovery of scrambled control cells in the 
presence of LY294002 as previously seen in (207) . 
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Figure 5-41 Effect of EGFR, MAPK and PI3K inhibitors on the viable 
biomass of βCATKD cells 
Mean absorbance from β-catenin knock-down (βCATKD) cells and scrambled control cells after 
6 days in culture with (A) KSFMc supplemented with 0.1% (v/v) DMSO, 1µM PD153035, 5µM 
U0126 or 5µM LY294002.  (B)  KSFMc + 2mM CaCl2 supplemented with 0.1% (v/v) DMSO, 1µM 
PD153035, 5µM U0126 or 5µM LY294002.  Each data point is the average of 6 biological 
replicates ± SD. (*** p<0.001, * p<0.05, one way ANOVA with multiple comparisons post-
test). Note the significant difference in biomass between βCATKD and scrambled control cells 
when cultured in LY294002 or U0126 but not in PD153035. Data is derived from fig 5.38-40). 
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5.5 Discussion 
5.5.1  Wnt-independent β-catenin activation via signalling 
crosstalk 
Under normal growth conditions, NHU cell cultures demonstrated confluence-
associated changes in their expression of nuclear β-catenin, whereas 
cytoplasmic expression remained constant.  Cross-reactivity with an unknown 
nuclear antigen has previously been reported with the active β-catenin antibody 
(8E7) used in this study (208).  Nuclear expression was however also evident 
with an independent β-catenin antibody (C2206; raised against amino acids 
768-781) and therefore expression was assumed to be genuine.  The fact that 
the cytoplasmic pool of β-catenin did not change implied an increase in active 
β-catenin expression rather than cytoplasmic translocation.  Western blotting 
for active β-catenin supported this theory; with the expression of active β-
catenin increasing 3-fold between the 24 and 48 hour time points.  For active β-
catenin to increase, mechanisms that regulate its degradation or 
transcription/translation would have to change.  Western blotting revealed a 
correlation between active β-catenin expression, ERK activity (phospho 42/44) 
and the serine 9 phosphorylated (inactive) form of GSK3.  Both EGFR and MAPK 
blockades reduced active β-catenin expression/nuclear translocation, ablated 
expression of phosphorylated GSK3 and impaired expression of the TCF-
transcriptional target, Axin2.  From these results it can be inferred that in the 
absence of Wnt ligand, TCF-gene targets such as Axin2 were still being 
transcribed via β-catenin-dependent crosstalk with the EGFR MAPK signalling 
cascade.  The exact mechanism of crosstalk was not fully explored in this study, 
but evidence in the literature suggests β-catenin-dependent crosstalk with the 
MAPK pathway can be driven via ERK activation of P70 S6/P90 RSK and 
subsequent phosphorylation of the destruction complex component GSK3β 
(Figure 5-42) (166, 169). Work by McManus and colleagues has shown that 
mutating GSKβ at serine 9 does not impact on β-catenin release via the classical 
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Wnt ligand pathway and implies another form of destruction complex inhibition 
is utilised during canonical signalling (176).  Further studies such as 
immunoprecipitation of GSK3 would be a useful experiment to ascertain 
whether P70 S6/P90 RSK does infact phosphorylate GSK3β.  Over-expression of 
a mutant form of GSK3 (at serine 9) could also be employed and would 
establish the definitive role of GSK3β phospho-inhibition in β-catenin release 
from the destruction complex. 
 
Figure 5-42 β-catenin and EGFR/MAPK crosstalk  
Illustration of β-catenin-dependent crosstalk with the EGFR/MAPK pathway.  ERK/P90RSK 
associates with GSK3β and primes its inactivation resulting in up regulation of active β-catenin 
and cell proliferation via TCF-mediated transcription of target genes.  Pharmacological inhibitors 
are shown in red.  Adapted from (169). 
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Previous experiments with the GSK3β inhibitor, SB415286 failed to elicit a 
significant response in NHU cells.  Pre-treatment with the EGFR tyrosine kinase 
inhibitor, PD153035 and sequential co-treatment with SB415286 and PD153035 
resulted in an increase in β-catenin nuclear translocation, viable cell biomass 
and TCF-mediated transcription, compared to cells treated with PD153035 
alone.  These results suggest that no response was seen with SB415286 alone 
because of masking via signalling crosstalk and demonstrate for the first time 
that β-catenin activation and TCF-mediated transcription of target genes can 
drive NHU cell proliferation in the absence of EGFR signalling.  No increase in 
nuclear β-catenin, proliferation rate or TCF-activity was evident when NHU cells 
were pre-treated with either U0126 or LY294002.  The fact that all signalling 
downstream from the EGFR must be blocked to observe any response with 
SB415286 implies phospho-inhibition of GSK3 via MAPK/ERK may not be the 
only point of crosstalk between the EGFR and β-catenin signalling cascade.  
NHU cells immunolabelled with active β-catenin antibody (8E7) revealed a 
residual nuclear β-catenin pool remained after treatment with U0126 and 
implied a second convergence point between EGFR and β-catenin may exist.  
One such convergent point could be at the EGFR tyrosine kinase itself. EGFR TK 
activity has previously been shown to phosphorylate β-catenin at tyr-654, 
destabilising the E-cadherin/β-catenin complex and releasing β-catenin for 
translocation to the nucleus (193, 195, 198).   
5.5.2 The role of cell:cell contact  
Seeding NHU cells at a low density resulted in prolonged nuclear expression of 
β-catenin, whereas high seeding densities resulted in weak nuclear expression.  
The most obvious explanation for this apparent confluence-related effect on  
β-catenin activity is the previously published data showing EGFR down-
regulation in confluent NHU cell cultures (33).  Data corroborates these 
published findings, as a reduction in P-ERK expression was seen as cell cultures 
became more densely populated.  Adherens junction formation has been shown 
Chapter 5 
234 
 
to modulate the availability of β-catenin for nuclear translocation by 
sequestration at the cell membrane (209) and could potentially be an important 
link in modulating the proliferative/quiescent switch seen in NHU cells.  In low 
calcium growth medium such as KSFMc, calcium-dependent cell:cell 
engagement is weak and β-catenin expression at the cell membrane is low.  
Permitting adherens junction engagement by increasing extracellular calcium 
did not reduce nuclear β-catenin or TCF activity.  These results suggest that 
once released from the destruction complex, β-catenin preferentially 
translocates to the nucleus.  How this is regulated remains unclear, but 
evidence from the literature suggests activated EGFR can phosphorylate β-
catenin at tyr-654, negating its ability to complex with E-cadherin at the 
adherens junction (195, 198).  Data in appendix XII supports this theory, as 
treatment with an EGFR tyrosine kinase inhibitor (PD153035) not only reduced 
nuclear localised β-catenin but also increased β-catenin at the membrane.   
5.5.3 The role of β-catenin in NHU proliferation 
In NHU cells, β-catenin protein expression was successfully reduced by ~58% 
using RNA interference.  Over a six day time course, MTT assays revealed a 
significantly reduced biomass in the βCATKD cell culture compared to isogenic 
control.  In sub-confluent culture, fewer βCATKD cells appeared to be actively 
dividing (as measured by MKi67 expression) and thus a decrease in 
proliferation, rather than an increase in apoptosis was deemed to be the cause.  
Western blotting on βCATKD whole cell lysates revealed a significant reduction 
in phospho-ERK expression compared to control.  Interestingly, phospho-AKT 
expression showed the opposite effect and was up-regulated in comparison to 
control.  These results implied βCATKD urothelial cells had switched from a 
mainly ERK-driven mode of proliferation, to one utilising the PI3K pathway.  
Normally, NHU cells treated with PI3K inhibitor suffer only a short-lived 
inhibition of proliferation which they rapidly overcome (207).  Growth assays 
performed in the presence of LY294002 revealed βCATKD urothelial cells to be 
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more reliant on the PI3K/AKT pathway.  Data thus implied that phospho-AKT 
activity was being used as an alternate pathway to drive proliferation when 
MAPK/ERK signalling was impaired (70).  The cause of this reduced ERK activity 
was not fully revealed during this study, but evidence from the literature would 
suggest there may be several points of convergence between β-catenin and the 
pathways downstream of EGFR.  In the mouse liver, constitutive β-catenin 
signalling was shown to lead to an increase in EGFR transcription and might 
account for the observed changes in phospho-ERK activity in βCATKD cells 
(210).  Another mechanism by which β-catenin/TCF-mediated transcription 
might influence ERK/AKT signalling was postulated by Yun and colleagues in 
2005 (211).  In their NIH-3T3 mouse fibroblast cell model, TCF-mediated 
transcription of an as yet unidentified molecule resulted in an increase in Raf-1 
and subsequent MAPK/ERK activity (211, 212).   
By collating all the published data on Wnt/ERK crosstalk, Kim and colleagues 
have postulated that a positive feedback loop between Wnt and ERK signalling 
may exist (Figure 5-43(213)).  In their computational model, EGFR and/or Wnt 
signalling, stabilises the activity of both pathways and could be a potentially 
important mechanism during urothelial tissue homeostasis.  One should note, 
however, that many of the studies claiming crosstalk with β-catenin have been 
undertaken in transformed cell lines and thus their relevance to normal cell 
systems remains to be proven. 
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Figure 5-43 A schematic diagram summarising the proposed positive 
feedback loop between Wnt and ERK signalling  
1)Activation of Ras by Wnt signalling (211) leads to the phosphorylation of ERK, 2)Phospho-ERK 
phosphorylates GSK3β inactivating the destruction complex (169, 214), 3)β-catenin is released 
from the destruction complex and translocates to the nucleus where it mediates the 
transcription of an unknown molecule (molecule X), 4)Molecule X activates Raf-1 which 
activates the MAPK/ERK pathway (211, 212).  Adapted from (213). 
 
In summary, data presented in this chapter has demonstrated the following: 
1. Crosstalk between the pathways downstream of EGFR and β-catenin.  
 
2. A role for cell:cell contact in the reduction of β-catenin/TCF-mediated 
transcription. 
 
3. A positive feedback mechanism between β-catenin and ERK which 
potential could lead to the stabilisation of both pathways.   
 
ERK GSK-3β β-catenin 
β-catenin/TCF Raf-1 MEK   X 
Erk inactivates GSK-3β 
(Ding et al., Mol. Cell 2005) 
β-catenin/TCF upregulates 
molecule X which activates Raf-1 
(Yun et al., J. Cell Sci. 2005) 
Positive feedback Loop 
Wnt signalling can activate Ras  
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Data present in this chapter provided preliminary evidence for a communication 
network between EGFR signalling, β-catenin signalling and cell:cell contact and 
is outlined in figure 5-44. 
 
 
Figure 5-44 Schematic illustrating the potential role of signalling 
crosstalk and cell:cell contact in modulating NHU cell proliferation 
 (A)At low density, the receptor tyrosine kinase (RTK) EGFR is present on the cell surface and 
binds EGF ligand.  Activation of the RTK leads to phosphorylation of ERK, translocation to the 
nucleus and cell proliferation.  P-ERK inactivates the destruction complex allowing β-catenin to 
accumulate and enter the nucleus.  (B)Crosstalk between β-catenin and AKT/ERK leads to a 
positive feedback loop and highly proliferative phenotype.  Proliferation leads to an increase in 
cell number.  (C)Confluency-induced reduction in the expression of EGFR (or up-regulation in 
ERBB2/3) leads to a decline in EGFR signalling and reduction in phospho-inhibition of GSK3. 
Activity of the destruction complex is reinstated.  Cytosolic β-catenin binds to the cytoplasmic 
tail of E-cadherin and adherens junctions form.  Once a critical number of cell:cell contacts have 
been made, excess β-catenin is targeted for degradation via the destruction complex.  P-ERK is 
low, active β-catenin is low and the cells enter G1 growth arrest. 
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6 Wnt ligand activation of the canonical Wnt 
cascade in NHU cells 
6.1 Introduction 
6.1.1 Wnt ligand  
The Wnt family of growth factors comprises a large group of highly conserved, 
secreted glycoproteins which are named after their two founding members, Int-1 
in the mouse (215) and Wingless in the Fruit fly (216).  In humans, 19 Wnt 
genes have been identified and have demonstrated important tissue-specific 
effects in a variety of areas, including development, tissue homeostasis and 
disease (Table 6-1).  Even though they have very diverse roles, every member of 
the Wnt family has several characteristics in common: all are approximately 350-
400 amino acids in length and 40KDa in weight; all contain a cysteine-rich amino 
acid sequence making them highly-charged (153).  Despite this charged state, 
Wnts are hydrophobic in nature due to the many essential lipid modifications 
that occur during the maturation process.  This lipid modification makes Wnt 
proteins highly insoluble and once secreted they are found mainly bound to 
either cell membranes or the extracellular matrix (ECM) (217).  
6.1.2 Processing of Wnt ligand 
Post-translational modification of Wnt occurs in the endoplasmic reticulum (ER) 
and begins with the addition of a hydrophobic palmitate moiety, a process 
known as palmitoylation which occurs on the first, absolutely conserved 
cysteine residue (Cys77 in Wnt 3a and Cys104 in Wnt 5a)(96, 218).  Mutations 
at this conserved cysteine result in secretion of non-biologically active protein 
and indicate that this modification is essential for activity, but not secretion (96, 
158).  Over the last five years, other lipid modifications have also been 
discovered.  Takada and colleagues have shown that Wnt 3a is acylated with a 
mono-unsaturated palmitoleic acid group at serine 209, a modification which 
was shown to be necessary for exit from the ER (219).  It thus appears from 
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the data that these two acylation sites serve different functions: Serine 209 for 
secretion and cysteine 77 for activity.  The enzyme(s) that catalyse this process 
are still debated but evidence suggests porcupine in Drosophila melanogaster 
(220)/PORCN in human (221), a multipass, transmembrane  
O-acetyltransferase, may be important, as loss of function mutants of porcupine 
fail to secrete Wnt ligand (222). 
Once palmitoylated, Wnt undergoes N-linked glycosylation at several asparagine 
residues (in Wnt 3a; Asn83 and Asn298), a process thought to be undertaken via 
the oligosaccharyl transferase complex (OST)(153, 220).  The role of these 
glycans is still not fully understood, but two reports have shown that mutation at 
these sites results in reduced ligand secretion and retention of Wnt in the ER 
(157, 158).   
6.1.3 Secretion of Wnt ligand 
Secretion (exocytosis) of Wnt is not fully understood.  Once post-translational 
modification is complete, Wnt is thought to associate with its chaperone, Bip 
before being transferred to the trans-Golgi network (TGN)(154, 223).  Once in 
the TGN, Wnt interacts with Wntless (WLS; synonym Evi and Sprinter), a 
transmembrane protein first identified in Drosophila melanogaster which 
transports Wnt from the TGN to the plasma membrane (155, 156, 224).  Loss of 
WLS results in detainment in the Golgi and Wnt never exiting the secretory 
pathway (156, 225, 226).  WLS is then recycled back to the TGN in clathryn-
coated endosomes through a retromer cargo-recognition complex composed of 
Vps26a, Vps29 and Vps35 proteins (227).  
6.1.4 Receptor binding and activation 
Wnt signalling is not intrinsically mediated by the presence of Wnt protein but by 
receptor availability (228).  Fzd receptors are seven-pass transmembrane G-
protein coupled receptors (GPCR) which were first shown to transduce Wnt 
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signalling by Bhanot and colleagues approximately 15 years ago (112).  At 
present there are 10 human Fzd genes, all of which result in a protein of 
approximately 650-700 amino acids in length.  Structurally, all Fzd receptors 
contain the following: an N-terminal extracellular region containing a conserved 
cysteine rich domain (CRD) which binds to Wnt protein; a seven-pass 
transmembrane region which binds Dsh and a Ser/Thr-X(any amino acid)-Val 
motif (SXV) at the C-terminus (Figure 6-1) (229, 230).   
Interestingly, the CRD domain of Fzd is also found in two other receptors: 
smoothened (SMOH in humans) and receptor tyrosine kinase-like orphan 
receptors (ROR). SMOH, although structurally similar to Fzd, does not bind Wnt 
ligand at the CRD (231).   ROR2, however, has been shown to interact with Wnt 
5a ligand and can act as an inhibitor of canonical signalling by blocking TCF-
mediated gene transcription (Figure 6-2) (123).  
 
 
Figure 6-1 The three domains of Fzd and the approximate binding 
sites for Wnt and Dsh 
Schematic depicting the three main domains of Frizzled (Fzd):a cysteine rich domain (CRD), a 
7-pass  transmembrane region and a Ser/Thr-X-Val motif.  Adapted from (232). 
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Figure 6-2 Activation and inhibition of the canonical Wnt pathway by 
Wnt 5a 
In the presence of Fzd4 and LRP5, Wnt5a activates the canonical Wnt signalling pathway.  
However, when ROR2 is expressed, Wnt5a inhibits canonical Wnt signalling at the level of TCF-
mediated transcription. Adapted from (123). 
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6.2 Rationale 
Wnt has been shown to play a major role not only in development but also 
during normal tissue homeostasis.  Recent evidence from the mouse suggests a 
sub-population of basal urothelial cells respond in a paracrine manner to Wnt 
ligand stimulation (42).  It is as yet unknown whether human urothelial cells 
respond in the same way.  Data from chapter 3 has indicated that proliferating 
NHU cells transcribe mRNA from several Wnt as well as Fzd genes, hinting at a 
possible autocrine Wnt signalling loop in human urothelium.  In vitro, 
production and secretion of bioactive Wnt is achieved only when fetal bovine 
serum (FBS) is present in the growth medium (96, 97).  The exact 
component(s) necessary have not yet been characterised, but the literature 
would suggest albumin–bound palmitic acid (a requirement for post-
translational modification of Wnt) could be a candidate (96, 97).  NHU cells are 
routinely cultured in serum-free KSFMc which does not contain palmitic acid 
(proprietary ingredients; personal communication from Invitrogen), one can 
therefore deduce that under normal growth conditions, NHU cells are unlikely to 
produce bioactive Wnt ligand. 
6.3 Aims 
 To assess whether exogenous Wnt ligand can activate the canonical Wnt 
signalling pathway in NHU cells and thus provide evidence for its role as a 
potential growth factor in urothelial regeneration. 
 
 To determine if supplementation of low-serum/ no serum growth medium with 
palmitic acid results in the production of bioactive Wnt ligand.  
 
  To determine whether NHU cells have the potential to process and secrete 
functional Wnt ligand and whether this can be used to drive paracrine (in other 
cell types) and/or autocrine (in same cell type) canonical Wnt signalling. 
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6.4 Experimental Plan 
6.4.1 Wnt ligand choice 
Like many signalling pathways, the canonical Wnt pathway contains a lot of 
degeneracy between ligand-and receptor (Table 6-1). Two Wnt ligands were 
tested on NHU cells for the following reasons:  
 Wnt3a was chosen as a candidate exogenous ligand because it was previously 
shown to interact with several Fzd receptors (Table 6-1) including Fzd2 and 6 
which were expressed at the mRNA level in proliferating NHU cultures. Also, 
Wnt3a was readily available in the form of a secreted protein from the L Wnt-3a 
cell line, a genetically engineered L cell line which secretes high levels of soluble 
Wnt3a into the medium (96, 97, 197).  
 
 Wnt5a was tested as AffymetrixTM mRNA analysis revealed high Wnt5a mRNA 
expression in proliferating NHU cultures and as with the Wnt3a ligand, it was 
available as an active ligand secreted by L Wnt-5a cells (96, 97).  Wnt5a has 
been shown to act as both an inhibitor and activator of the canonical Wnt 
pathway depending on receptor availability. If Fzd4 is present, Wnt5a can 
activate canonical signalling, however, if the tyrosine kinase ROR2 is present, 
Wnt5a inhibits the canonical Wnt cascade (Figure 6-2) (123).  Affymetrix 
analysis suggested ROR2 was absent but Fzd4 mRNA was present in 
proliferating NHU cell cultures and therefore in these circumstances canonical 
signalling should prevail. 
 
6.4.2 Verification of Wnt secreting L-cell lines 
Parental, Wnt-3a and Wnt-5a secreting L cells (originally developed by the 
Nusse laboratory as stable cell clones (96)) were obtained from Dr. P.Genever 
(University of York).  Cross contamination of L-cell lines was ruled out by RT-
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PCR using primers designed against Wnt3a and Wnt5a transcript (Appendix V).  
Genomic DNA was used as a positive control in all PCR experiments along with 
a reverse transcriptase negative test for each RNA sample.  Integrity of the 
cDNA was verified using primers targeted to the house-keeping gene, GAPDH.  
Conditioned medium (CM) from each cell line was harvested in DMEM 
supplemented with 4mM L-glutamine, 4.5g/L glucose and 10% (v/v) FBS (96, 
97) and  tested on the Wnt responding osteoblast cell line, SaOS-2 at the 
recommended dilution of 1:10 in complete growth medium for 24 hours (259).  
β-catenin nuclear translocation and the TOPFLASH DLA assay were used to 
assess canonical Wnt pathway activity.  20mM LiCl was used as a positive 
control for inducing β-catenin activity in both immunofluorescence and 
TOPFLASH DLA experiments.  
6.4.3 Assessing the effect of exogenous Wnt ligand on NHU 
cells 
The effect of exogenous Wnt3a and Wnt5a ligand was assessed on both 
proliferating and EGFR-blocked NHU cells (pre-treated for 24 hours and 
maintained in 1µM PD153035 throughout the experiment).  NHU cell 
morphology, β-catenin localisation and TOPFLASH DLA activity were assessed.  
10µM SB415286 was included as a positive control and NHU cell cultures in 
non-conditioned medium or in CM from the parental L cell line were used as 
negative controls. 
6.4.4 Assessing the impact of low serum concentrations on the 
production of active Wnt ligand 
Over a period of four passages, all three L-cell lines were adapted to grow in 
low serum conditions (1% (v/v) FBS) and were renamed L Wnt 3a 1%, 
 L Wnt 5a 1% and L-cells 1%, respectively.  The effect of reduced serum on 
Wnt secretion and function was then assessed using the Wnt-responsive  
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SaOS-2 cell line.  β-catenin nuclear translocation and TOPFLASH DLA were used 
to evaluate the activity of the canonical Wnt pathway after a 24 hour incubation 
in normal growth medium containing a 1:10 dilution of CM.  
6.4.5 Assessing the effect of palmitic acid on the production of 
active Wnt ligand  
20-80µM Palmitic acid (solubilised in Ab. EtOH) was added to pre-warmed 
DMEM supplemented with 4mML-glutamine, 4.5g/L glucose and 1% (v/v) FBS.  
L Wnt 3a 1%, L Wnt 5a 1% and L-cells 1% were then incubated in this medium 
for 3 days.  Whole cell lysates were probed with antibodies against Wnt 3a 
(3A6) and Wnt 5a (C-16) by western blot.  CM was tested for its ability to 
activate the canonical Wnt pathway in SaOS-2 cells as assessed using both 
immunofluorescence and the TOPFLASH TCF dual luciferase assay (DLA).  
20mM LiCl was used as a positive control in all experiments.  L-cell only CM was 
used as a negative control, as well as a solvent-only control (DMEM 
supplemented with 4mM L-glutamine, 4.5g/L glucose, 1% (v/v) FBS and 0.1% 
(v/v) EtOH).   
6.4.6 Assessing the production of Wnt ligand in NHU cells 
AffymetrixTM Genechip data from proliferating, quiescent and differentiated NHU 
cell cultures was mined for components necessary for Wnt ligand post-
translational modification and secretion.  MAS5 normalised data obtained from 
proliferating NHU cell cultures was used to generate a present, absent or 
marginal “calls” database.  Changes in expression were expressed as log2 fold 
change relative to the proliferating NHU culture.  
NHU cells express mRNA from the following Wnt genes: Wnt3, Wnt5a, Wnt6, 
and Wnt7a. Of the most interest was Wnt3, as it is a known canonical ligand 
that signals via Fzd1/7(120, 233).  To permit palmitoylation of any potential 
Wnt proteins, palmitic acid (PA) was added to the growth medium of NHU cells 
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in two forms: pure palmitic acid (40-80µM) solubilised in 0.1%(v/v) EtOH or 
albumin-bound as a component of FBS.  CM was harvested at day 3, filtered 
and diluted 1:10 into SaOS-2 normal growth medium.  SaOS-2 cells were 
utilised as a responding cell line as they had previously been shown to express, 
at the mRNA level, a number of Fzd receptors (Fzd 1, 2, 3, 4 ,5,6,7,8 and 9) as 
well as the necessary co-receptors; LRP5 and LRP6 (259-261).  Most 
importantly, the protein expression of Fzd1 receptor (required for Wnt3 
signalling) had previously been established via western blot in these cells (262).  
After a 24 hour incubation with CM, β-catenin nuclear translocation and 
TOPFLASH DLA assay were used to assess activation of the Wnt pathway.  
20mM LiCl was used as a positive control. 
6.4.7 Assessing NHU autocrine response to Wnt ligand 
NHU cells (Y1056) were pre-treated with 1µM PD153035 for 24 hours to inhibit 
crosstalk via the EGFR.  Cultures were then maintained in PD153035 for a 
further 24 hours with CM from NHU cells grown in the presence of 40-80µM PA.  
β-catenin nuclear translocation was used as a hallmark of canonical Wnt 
signalling.  10µM SB415286 was used as a positive control for β-catenin nuclear 
translocation.  
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6.5 Results 
6.5.1 Verification of Wnt secreting L-cells 
6.5.1.1  RT-PCR 
Both Wnt secreting L-cell lines (L Wnt-3a and L Wnt-5a) as well as the L-cell 
parental control cell line were as described, with no cross contamination (Figure 
6-3). 
6.5.2 Testing CM from L Wnt-3a and L Wnt 5a cells on SaOS-2 
cells 
6.5.2.1  Morphology 
Photo-micrographs from Wnt-responsive SaOS-2 cells treated with L Wnt-3a, L 
Wnt-5a or L-cell CM for 24 hours showed no obvious change in morphology 
(Figure 6-4).  A slightly higher number of rounded and detached cells were 
evident in the SaOS-2 cultures treated with CM compared to the no treatment 
control but the majority of cells still appeared phase-bright and were firmly 
attached to the tissue culture flask (Figure 6-4 A-C vs. E). 
6.5.2.2  Active β-catenin expression and localisation  
In the non-treated SaOS-2 cell cultures, β-catenin localised cytoplasmically 
(Figure 6-5 E and J), whereas cultures treated with 20mM LiCl (positive control) 
showed strong nuclear labelling for β-catenin, (Figure 6-5 D and I).  Addition of 
CM from L Wnt-3a cells led to a strong nuclear expression similar in intensity to 
cultures treated with 20mM LiCl (white arrow heads; Figure 6-5 B and G vs. D 
and I). Incubation with CM from L Wnt-5a or L-cells showed no translocation of  
β-catenin to the nucleus (Figure 6-5 C and H; L-Wnt 5a cells, A and F; L-cells). 
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6.5.2.3  TCF transcription factor activity 
Treatment with 20mM LiCl resulted in a significantly higher luciferase activity 
from TOPFLASH in comparison to FOPFLASH (8-fold increase in activity 
TOPFLASH vs. FOPFLASH; Figure 6-6, P<0.001) and verified the integrity of the 
assay.  Normalised TCF DLA data revealed a significant higher TOPFLASH 
luciferase activity compared to FOPFLASH when SaOS-2 cultures were 
incubated with L Wnt-3a CM (TOPFLASH activity was 16-fold higher than in the 
FOPFLASH control; Figure 6-6 P<0.001).  Cultures incubated with L Wnt-5a CM 
and L cell control CM did not evoke any significant TCF activity in SaOS-2 cells 
(Figure 6-5).  These data verified that Wnt 3a ligand secreted from L Wnt-3a 
was active and able to elicit a response in cells expressing the appropriate Fzd 
receptor.   
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Figure 6-3 Cross contamination analysis of Wnt secreting L-cells using 
RT-PCR 
Wnt secreting L-cells (L Wnt-3a and L Wnt-5a) as well as the parental control L-cell line were 
tested for cross-contamination via RT-PCR.  RNA was extracted using TRIzol TM reagent and 
converted to cDNA using the Superscript first-strand cDNA synthesis kit.  PCR was performed 
using primers designed to mouse Wnt3a and Wnt5a using Surestart Taq polymerase and PCR 
products were run on a 1% (w/v) agarose gel and visualised using UV trans-illumination.  PCR 
for Wnt3a and Wnt5a confirmed that none of the cell lines were cross contaminated. Genomic 
DNA was used as a template control. Water only was used as the no template control (NTC). 
GAPDH was used as a positive control to verify intact cDNA. RT negatives were included to 
certify that there was no gDNA contamination in the cDNA. N=1.   
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Figure 6-4 Effect of L Wnt-3a and L Wnt-5a CM on SaOS-2 cell 
morphology 
Phase contrast micrographs of SaOS-2 cells after a 24 hour incubation with CM from L cells, L 
Wnt-3a or L Wnt-5a diluted 1:10  with normal growth medium (McCoys 5A + 15% (v/v) FBS) 
(A) L-cell CM (parental control); (B) L Wnt-3a CM; (C) L Wnt-5a CM; (D) 20mM LiCl 
(destruction complex inhibitor;positive control), (E) Negative control (no treatment). Scale bar: 
200µm. 
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Figure 6-5 Effect of L Wnt-3a and L Wnt-5a CM on β-catenin 
expression and localisation in SaOS-2 cells 
Indirect immunofluorescent labelling of SaOS-2 cells for β-catenin after a 24-hour incubation 
with L Wnt-3a, L Wnt-5a or L-cell (parental control) CM diluted 1:10 in normal growth medium 
(McCoys 5A + 15% (v/v) FBS).  Slides were formalin-fixed and immunolabelled with active  
β-catenin antibody (8E7) and rabbit anti-mouse IgG-Alexa 594 secondary antibody or total  
β-catenin (C2206) and goat anti-rabbit IgG Alexa 488 secondary antibody.  All slides were 
stained with Hoechst 33258 to delineate the nucleus and labelling was visualised under epi-
fluorescent illumination. (A-E ) Labelling with active β-catenin antibody (8E7); (F-J) Labelling 
with total β-catenin antibody (C2206); (K-O) Hoechst 33258 staining of the nucleus; (P-T) 
Merged active, total and Hoechst 33258 stain.   20mM LiCl treatment was used as a positive 
control for β-catenin nuclear labelling.  Negative controls were L-cell (parental control) CM and 
non-treated SaOS-2 cells.  Scale bar: 50µm.  N=1.  White arrow heads denote strong nuclear 
labelling after treatment with L Wnt-3a CM. 
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Figure 6-6 TCF activity in SaOS-2 cells after treatment with L Wnt 3a 
or L Wnt-5a CM 
SaOS-2 cells were seeded into a 24-well plate at 4x 104 cells per well and were transfected 24-
hours after seeding with either 0.5µg of TOPFLASH or FOPFLASH (negative control) plasmid 
along with 0.01µg of loading control, pRL-CMV.  24 hours after transfection, SaOS-2 cells were 
incubated with a 1:10 dilution of L Wnt-3a, L Wnt-5a or L-cell CM mixed with normal growth 
medium (McCoys 5A + 15% (v/v) FBS).  After 24 hours, cells were lysed and a dual luciferase 
assay was performed on 3 biological replicates.  Positive control was 20mM LiCl.  Negative 
control was CM from L-cell parental control cell line.  Data represents the mean luciferase 
activity after normalisation to loading control (±SD).*** P<0.001, using a one-way ANOVA with 
Bonferroni multiple post-test comparison. 
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6.5.3 Effect of adding exogenous Wnt 3a and Wnt 5a ligand to 
NHU cells 
6.5.3.1  Morphology 
When NHU cells were incubated with a 1:10 dilution of CM from L Wnt-3a, L 
Wnt-5a or parental control, cultures were seen to adopt a more differentiated 
morphology similar in appearance to cultures treated with 5% (v/v) ABS/2mM 
CaCl2.  This change in morphology was attributed to the fact that serum was 
present in the CM (Figure 6-7).  
6.5.3.2  Active β-catenin expression and localisation 
A 24-hour incubation of sub-confluent NHU cells with a 1:10 dilution of CM from 
either L Wnt-3a, L Wnt-5a or parental control did not increase the amount of 
nuclear active β-catenin compared to no-treatment control (Figure 6-8).  
Addition of CM from all three L-cell lines did however lead to an increase in  
β-catenin expression at the cell membrane (Figure 6-8; white arrow heads). 
This was indicative of adherens junction engagement probably driven by the 
increase in calcium ions present in the CM (1.8mM in undiluted DMEM).  
Nuclear expression of active β-catenin was evident in all samples, including the 
no treatment control (Figure 6-8).  Expression and localisation of active  
β-catenin was very different when cultures were pre-treated and maintained in 
1µM PD153035 throughout the experiment. NHU which were not exposed to CM 
had very low levels of nuclear active-β-catenin with only diffuse cytoplasmic 
labelling visible (Figure 6-8; white arrow).  Some cells labelled for active  
β-catenin at the membrane as previously seen with PD153035 treatment.  Cells 
appeared enlarged and flattened as has previously been described after EGFR 
blockade (207).  Incubation with CM from either L Wnt-3a or L Wnt-5a resulted 
in strong nuclear as well as membrane labelling for active β-catenin which was 
as intense as the positive control (10µM SB415286) (Figure 6-8; grey arrow 
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heads).  Treatment with L-cell CM had no effect on nuclear or membrane 
labelling for active β-catenin when compared to the no treatment control 
(Figure 6-8;white arrow).  
6.5.3.3  TCF activity 
TCF DLA revealed no statistically significant increase in TCF activity when sub-
confluent NHU cells were incubated for 24 hours with a 1:10 dilution of L Wnt-
3a, L Wnt-5a or L-cell control CM in KSFMc (Figure 6-9).  TCF activity did 
however increase significantly when cells were pre-treated and maintained in 
PD153035 NHU and incubated with either L Wnt-3a, or L Wnt-5a (Figure 6-9; 
P<0.001 compared to L-cell parental control CM). 
These results implied that NHU cells responded canonically to both Wnt3a and 
Wnt5a ligand but only when crosstalk from the EGFR signalling cascade was 
blocked. 
  
Chapter 6 
256 
 
 
Figure 6-7 Effect of Wnt 3a and Wnt5a CM on NHU cell morphology 
Phase contrast micrographs of NHU cells (Y1056) after a 24-hour incubation with CM from 
Wnt3a and Wnt5 secreting L-cells diluted 1:10  with normal growth medium (KSFMc) (A) L-cell 
CM; (B) L Wnt-3a CM; (C) L Wnt-5a CM; (D) 10µM SB415286 (destruction complex inhibitor; 
positive control), (E) Negative control (no treatment).  A 24 hour incubation with CM from Wnt-
secreting L-cells caused NHU cells to adopt a differentiated appearance.  Scale bar: 200µm.
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Figure 6-8 Effect of Wnt 3a and Wnt5a CM on β-catenin expression 
and localisation in EGF responsive and EGFR blocked NHU cells 
β-catenin indirect immunofluorescent labelling of NHU cells (Y1056) after a 24-hour pre-
treatment with ± 1µM PD153035 followed by a 24-hour incubation ± 1µM PD153035 with L 
Wnt-3a, L Wnt-5a or L-cell CM diluted 1:10 in normal growth medium (KSFMc).  Slides were 
formalin-fixed and immunolabelled with active β-catenin antibody (8E7) and rabbit anti-mouse 
IgG-Alexa 594 secondary antibody.  All slides were stained with Hoechst 33258 to delineate the 
nucleus and labelling was visualised under epi-fluorescent illumination.  (A-E) Active β-catenin 
antibody (8E7) labelling in non-PD153035 pre-treated NHU cells; (F-J) Active β-catenin 
labelling merged with Hoechst 33258 staining (K-O) Active β-catenin labelling (8E7) in 1µM 
PD153035 pre-treated and maintained NHU cells; (P-T) Active β-catenin labelling merged with 
Hoechst 33258 staining.  10µM SB410286 treatment was used as a positive control for β-
catenin nuclear translocation.  Negative controls were L-cell CM and non-treated (no CM) NHU 
cells.  White arrow heads denote membrane labelling due to the increase in exogenous calcium 
concentrations and adherens junction formation. Scale bar: 50µm.  N=1.  Grey arrow heads 
denote strong nuclear labelling after incubation with L Wnt-3a or L Wnt-5a CM.  White arrows 
denote weak nuclear labelling in PD153035 pre-treated cultures and after incubation with 
PD153035 and L-cell CM.   
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Figure 6-9 TCF activity in EGF responsive and EGFR blocked NHU cells 
after treatment with L Wnt 3a and L Wnt-5a CM 
NHU cells (Y1056) were seeded into a 24-well Primaria® plate at 4x 104 cells per well and were 
transfected 24-hours after seeding with either 0.5µg of TOPFLASH or FOPFLASH (negative 
control) plasmid along with 0.01µg of loading control, pRL-CMV.  6 hours after transfection, 
cells were medium changed to KSFMc ± 1µM PD153035 for 24 hours (pre-treatment) and then 
incubated with a 1:10 dilution of either L Wnt-3a, L Wnt-5a or L-cell CM mixed with normal 
growth medium (KSFMc) ± 1µM PD153035.  After 24 hours, cells were lysed and a dual 
luciferase assay was performed on 3 biological replicates.  Positive control was 10µM SB415286.  
Data represents the mean luciferase activity after normalisation to loading control (±SD).  (*** 
P<0.001, using a one-way ANOVA with Bonferroni multiple post-test comparison). Results 
revealed a significant increase in TCF activity when NHU cells were treated with L Wnt-3a and L 
Wnt-5a but only when EGFR signalling was blocked with PD153035. 
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6.5.4 The effect of reduced serum on the production and 
secretion of Wnt ligand 
6.5.4.1 Expression and localisation of β-catenin in Wnt responding 
SaOS-2 cells 
When harvested in 10% FBS, L Wnt-3a CM clearly resulted in nuclear 
translocation of β-catenin in SaOS-2 cells. (Figure 6-5).  This however was not 
the case when L Wnt-3a cells were adapted to grow in low serum 1% (v/v) FBS  
(L Wnt-3a 1%).  A 24 hour treatment of SaOS-2 cells with a 1:10 dilution of CM 
from L Wnt-3a 1% resulted in only cytoplasmic expression of β-catenin and no 
visible nuclear translocation suggesting bioactive Wnt 3a was not being 
secreted (Figure 6-10; white arrow heads). 
6.5.4.2 Effect on TCF activity in SaOS-2 cells 
A 24 hour incubation with a 1:10 dilution of CM from L Wnt-3a 1% did not elicit 
any TCF activity in SaOS-2 cells (Figure 6-11).  TOPFLASH luciferase activity 
was less than that observed from the FOPFLASH mutant TCF luciferase plasmid, 
FOPFLASH (Figure 6-11).  Data thus implied that either Wnt 3a ligand was not 
being processed or secreted properly by the low serum-adapted L Wnt-3a 1% 
cell line. 
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Figure 6-10 Effect of culturing Wnt secreting L-cells in low serum 
β-catenin indirect immunofluorescent labelling of SaOS-2 cells after a 24-hour incubation with  
L Wnt-3a 1%, L Wnt-5a 1% or L-cell 1% CM diluted 1:10 in normal SaOS-2 growth medium 
(McCoys 5A + 15% (v/v) FBS).  Slides were formalin-fixed and immunolabelled with active  
β-catenin antibody (8E7) and rabbit anti-mouse IgG-Alexa 594 secondary antibody or total  
β-catenin (C2206) and goat anti-rabbit IgG Alexa 488 secondary antibody.  All slides were 
stained with Hoechst 33258 to delineate the nucleus and labelling was visualised under epi-
fluorescent illumination.  (A-E) Labelling with active β-catenin antibody (8E7); (F-J) Labelling 
with total β-catenin antibody (C2206); (K-O) Hoechst 33258 staining of the nucleus; (P-T) 
Merged active, total and Hoechst 33258 stain.  20mM LiCl treatment was used as a positive 
control for β-catenin nuclear labelling.  Negative controls were L-cell 1% CM and non-treated 
SaOS-2 cells.  Scale bar: 50µm. N=1.  White arrow heads denote lack of nuclear labelling after 
treatment with L Wnt-3a 1% CM. 
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Figure 6-11 TCF assay from SaOS-2 cells after treatment with CM from 
L-cells grown in low serum 
SaOS-2 cells were seeded into a 24-well Primaria® plate at 4x 104 cells per well and were 
transfected 24-hours after seeding with either 0.5µg of TOPFLASH or FOPFLASH (negative 
control) plasmid along with 0.01µg of loading control, pRL-CMV.  24 hours after transfection, 
SaOS-2 cells were incubated with a 1:10 dilution of CM from Wnt secreting L-cells cultured in 
high serum (10%(v/v) FBS) or low serum (1%(v/v) FBS).  After 24 hours, cells were lysed and 
a dual luciferase assay was performed on 3 biological replicates.  Positive control was 20mM 
LiCl.  Data represents the mean luciferase activity after normalisation to loading control 
(±SD).(*** P<0.001, using a one-way ANOVA with Bonferroni multiple post-test comparison).  
Adaptation of Wnt secreting L-cells to low serum resulted in no functional Wnt ligand being 
secreted. 
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6.5.5 The role of palmitic acid in the production and secretion of 
Wnt Ligand 
6.5.5.1 Expression of Wnt protein in L Wnt-3a and L Wnt-5a cell lines  
Whole cell lysates were generated and analysed for Wnt protein by western 
blot.  L Wnt-3a 1% cell line supplemented with 40µM PA, 80µM PA or 10% 
(v/v) FBS labelled weakly with the anti-Wnt3a antibody (3A6) at the expected 
molecular weight of 39KDa (Figure 6-12).  This band was not evident in the 
parental L-cell line or the L Wnt-5a cell line suggesting that it was specific for 
Wnt3a.  Multiple bands were visualised with the anti-Wnt5a antibody (C16) and 
was therefore deemed non-specific (Figure 6-12).  Normalised densitometry 
results for Wnt 3a revealed a >3.4-fold increase in band intensity when L Wnt-
3a cells were incubated in 80µM palmitic acid compared to solvent balanced 
control (Figure 6-13) and was only slightly less than that observed with 10% 
(v/v) FBS (3.7-fold; Figure 6-13).  
 
 
Chapter 6 
263 
 
 
Figure 6-12 Assessing the effect of palmitic acid on Wnt ligand 
production 
Whole cell lysates were taken from L Wnt-3a 1%, L Wnt-5a 1% and L-cell 1% lines after a  
3-day treatment with 20-80µM palmitic acid in DMEM, 4mM L-glutamine, 4.5g/L glucose + 1% 
(v/v) FBS.  Positive and negative controls were 10% (v/v) FBS and 0.1%(v/v) EtOH (solvent 
only), respectively.  20µg of each protein lysate was subjected to SDS-PAGE within a 4-12% 
(w/v) Bis-Tris gel under denaturing conditions and immunoblotted onto PVDF membrane.  
Western blots were probed with anti-Wnt 3a (3A6), anti-Wnt 5a (C16) and β-actin (AC-15; to 
control for equal lysate loading).  Membranes were then incubated for 1 hour with either; goat 
anti-mouse IgG Alexa 680 for Wnt 3a and β-actin or donkey anti-goat IgG Alexa 680 for Wnt-
5a.  Antibody binding was visualised by epi-fluorescence illumination at 700nm.  N=1. 
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Figure 6-13 Normalised densitometry from western blots assessing 
the effect of palmitic acid on Wnt ligand production 
Normalised Densitometry results from Figure 6-12 represented graphically as bar charts. 
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6.5.5.2  Active β-catenin expression and localisation in SaOS-2 cells 
Indirect-immunofluorescence with active and total β-catenin antibodies was 
undertaken on SaOS-2 cells after a 24 hour incubation with a 1:10 dilution of 
CM from L Wnt-3a 1% or L-cell 1% cell lines which were cultured in the 
presence of 20-80µM palmitic acid.  As expected, CM from L-cells did not evoke 
a response in SaOS-2 cells regardless of the harvesting conditions (Figure 6-
14).  Both active and total β-catenin antibodies labelled the nuclear 
compartment of SaOS-2 cells when incubated with L Wnt-3a CM harvested in 
the presence of 40 or 80µM palmitic acid (Figure 6-15).  No nuclear labelling 
was visible in the solvent balanced control (Figure 6-15).  
6.5.5.3  TCF activity in SaOS-2 after treatment with CM from L Wnt-3a 
1% cells cultured in medium supplemented with palmitic acid 
Addition of 40µM or 80µM PA to the growth medium of L Wnt-3a 1% resulted in 
a significant higher TOPFLASH luciferase activity in SaOS-2 cells than that 
observed in the solvent balanced control culture (L Wnt-3a 1% + 0.1% (v/v) 
EtOH, P>0.001; Figure 6-16).  Normalised TOPFLASH luciferase activity from 
CM containing 40-80µM PA was ~1.8-2.0- fold higher than that obtained from  
L-Wnt-3a 1% cultures grown without additional PA (Figure 6-16).  Activity was 
however not as strong as that observed from L Wnt-3a cultures incubated with 
10 (v/v) FBS (normalised activity was 0.030, 0.027 from CM harvested in 40 
and 80µM PA, respectively and 0.042 from CM harvested in 10%(v/v) FBS; 
Figure 6-16).  This data along with the immunofluorescence results 
substantiated the role of palmitic acid in the proper processing and secretion of 
Wnt ligand in vitro and suggested that high serum concentrations (10% 
(v/v)FBS) could in part be substituted for by palmitic acid alone.
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Figure 6-14 Assessing activation of the canonical Wnt pathway in 
SaOS-2 cells after treatment with CM from L Wnt 3a 1% cells cultured 
in the presence of palmitic acid 
β-catenin indirect immunofluorescent labelling of SaOS-2 cells after a 24-hour incubation with a 
1:10 dilution of CM from L Wnt-3a 1% or L-cell 1% cell lines cultured with 20-80µM Palmitic 
acid.  Slides were formalin-fixed and immunolabelled with active β-catenin antibody (8E7) and 
rabbit anti-mouse IgG-Alexa 594 secondary antibody or total β-catenin (C2206) and goat anti-
rabbit IgG Alexa 488 secondary antibody.  All slides were stained with Hoechst 33258 to 
delineate the nucleus and labelling was visualised under epi-fluorescent illumination.  20mM LiCl 
treatment was used as a positive control (fig 6-15).  Negative control was non-treated SaOS-2 
cells (fig 6-15).  Scale bar: 50µm. N=1.  
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Figure 6-15 Assessing activation of the canonical Wnt pathway in 
SaOS-2 cells after treatment with CM from L Wnt 3a 1% cells cultured 
in the presence of palmitic acid 
β-catenin indirect immunofluorescent labelling of SaOS-2 cells after a 24-hour incubation with a 
1:10 dilution of CM from L Wnt-3a 1% or L-cell 1% cell lines cultured with 20-80µM Palmitic 
acid.  Slides were formalin-fixed and immunolabelled with active β-catenin antibody (8E7) and 
rabbit anti-mouse IgG-Alexa 594 secondary antibody or total β-catenin (C2206) and goat anti-
rabbit IgG Alexa 488 secondary antibody.  All slides were stained with Hoechst 33258 to 
delineate the nucleus and labelling was visualised under epi-fluorescent illumination.  20mM LiCl 
treatment was used as a positive control.  Negative control was non-treated SaOS-2 cells.  
Scale bar: 50µm.  N=1. White arrows denote strong nuclear labelling when cells were treated 
with CM from L Wnt-3a 1% + 40µM PA and from L Wnt-3a 1% + 80µM PA. 
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Figure 6-16 Assessing TCF activity in SaOS-2 cells after treatment 
with CM from L Wnt 3a 1% cells cultured in the presence of palmitic 
acid 
SaOS-2 cells were incubated with a 1:10 dilution of CM from Wnt secreting L-cells cultured in: 
high serum (10% FBS): low serum (1% FBS) or low serum + 40-80µM PA.  After 24 hours, cells 
were lysed and a dual luciferase assay was performed on 3 biological replicates.  Positive 
control was 20mM LiCl.  Negative controls were solvent balanced CM containing 0.1% (v/v) 
EtOH and no treatment control.  Data represents the mean luciferase activity after 
normalisation to loading control (±SD).(*** P<0.001, NS non-significant using a one-way 
ANOVA with Bonferroni multiple comparison post-test).  Low serum in the growth medium of L-
Wnt-3a cell cultures resulted in poor Wnt ligand secretion into the medium but this could be 
improved by the addition of PA.  
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6.5.6 Assessing the production of Wnt ligand in NHU cells 
6.5.6.1  Gene Microarray analysis 
Previously validated and ranked AffymetrixTM data (chapter 3) was mined for 
components of the Wnt post-translation and secretory pathway.  In the 
proliferative NHU culture, PORCN was classified as present by the MAS5 
generated calls database, as well as WLS and all three components of the 
retromer cargo-recognition complex (Vps26a, Vps29 and Vps35; Table 6-2).  
The data set was then mined for changes in the Wnt ligand processing and 
secretory pathway after differentiation or quiescence.  No striking differences 
were observed in expression.  Only WLS mRNA expression significant changed 
(>2-fold) in the TZ/PD culture and was not mirrored in the ABS/Ca model 
(Table 6-2). 
 
Table 6-2 Genes necessary for production of functional Wnt ligand 
MAS5 normalised AffymetrixTM mRNA microarray analysis of components of the Wnt ligand post-
translational processing and secretory pathway in cultures of proliferating, quiescent and 
differentiated (TZ/PD and ABS/Ca) NHU cells (Y676).  Genes with at least a 2-fold change in 
expression compared to the proliferative culture are highlighted with either a red (up-regulated) 
or green arrow (down-regulated).  Actual changes in mRNA expression are detailed within the 
table and are expressed as signal log ratios (log base 2). 
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6.5.6.2  Morphology of NHU cells after PA treatment 
NHU cells cultured for 3 days with palmitic acid appeared morphologically 
similar to the solvent-balanced control and to the no-treatment control (Figure 
6-17).  A slightly higher proportion of rounded and detached cells were evident 
in the culture treated with 80µM PA.  All cultures appeared to be at a similar 
density (Figure 6-17).  
6.5.6.3  Active β-catenin expression and localisation in SaOS-2 cells 
after treatment with CM from NHU cells 
SaOS-2 cells were incubated for 24 hours with a 1:10 dilution of CM from NHU 
cultured in KSFMc ± 40-80µM palmitic acid; 10% (v/v) FBS or solvent only 
control (0.1% (v/v) EtOH).  When labelled with the active β-catenin antibody 
(8E7) it was evident that CM from NHU cells incubated in the presence of 10% 
(v/v) FBS or 80µM PA did evoke clear nuclear translocation of β-catenin (White 
arrows; Figure 6-18 B and G). Labelling was however not as intense as that 
seen with 20mM LiCl treatment (Figure 6-18).  CM from NHU cells which had 
been harvested in the presence of 40µM PA showed some nuclear labelling but 
the majority of cells labelled only cytoplasmically (white arrow heads; Figure 6-
18C).  CM from solvent balanced NHU cell cultures did not evoke any nuclear 
translocation of β-catenin in SaOS-2 cells (Figure 6-18 panel A).  
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Figure 6-18 Assessing the production of Wnt ligand in NHU cells 
SaOS-2 cells after a 24-hour incubation with CM from NHU cells (Y1056) cultured in KSFMc + 
10% (v/v) FBS or 40-80µM PA.  Slides were formalin-fixed and immunolabelled with active  
β-catenin antibody (8E7) and rabbit anti-mouse IgG-Alexa 594 secondary antibody.  All slides 
were stained with Hoechst 33258 to delineate the nucleus and labelling was visualised under 
epi-fluorescent illumination.  20mM LiCl treatment was used as a positive control.  Negative 
controls were CM from NHU cells harvested in KSFMc + 0.1% (v/v) EtOH (solvent balanced 
control) as well as non-treated SaOS-2 cells.  Scale bar: 50µm.  N=1.  White arrows denote 
strong nuclear labelling when cells were treated with CM from NHU cells cultured in the 
presence of 10%(v/v)FBS or 80µM PA. White arrow head denotes cytoplasmic labelling in SaOS-
2 cells treated with CM from NHU cells cultured in 40µM PA.  
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6.5.6.4  TCF activity in SaOS-2 cells after incubation with NHU CM 
Treatment with 20mM LiCl resulted in a strong TCF-driven luciferase activity 
from TOPFLASH and no significant luciferase activity from the FOPFLASH 
negative control, thus verifying the integrity of the experiment (Figure 6-19).   
Incubation with a 1:10 dilution of NHU CM did not elicit any significant increase 
in TOPFLASH TCF-driven luciferase activity, regardless of harvesting conditions 
(Figure 6-19). 
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Figure 6-19 Assessing Wnt ligand production in NHU cells 
SaOS-2 cells were incubated for 24 hours with a 1:10 dilution of CM from NHU cells (Y1056) 
cultured in KSFMc + 10% (v/v) FBS or 40-80µM PA.  Cells were then lysed and a DLA was 
performed on 3 biological replicates.  Positive control was 20mM LiCl.  Negative controls were 
solvent balanced CM (0.1% (v/v) EtOH) and a no treatment control.  Data represents the mean 
luciferase activity after normalisation to loading control (±SD).(*** P<0.001, NS non-significant 
using a one-way ANOVA with Bonferroni multiple comparison post-test).  CM from NHU cells did 
not elicit any significant increase in TOPFLASH TCF-driven luciferase activity in SaOS-2 cells.  
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6.5.7 Autocrine Wnt signalling 
6.5.7.1  Active β-catenin expression in EGFR-blocked NHU cells after 
treatment with NHU CM containing palmitic acid  
Upon first inspection, EGFR-blocked NHU cells incubated with CM from PA 
treated NHU cells appeared not to have any nuclear active β-catenin (Figure 6-
20). However, on closer inspection, approximately 5% of cells did show some 
nuclear labelling.  In the culture treated with CM + 40µM PA and CM + 80µM 
PA, approx 5% of cells labelled strongly for nuclear β-catenin (White 
arrowheads; Figure 6-20B).  NHU cells treated with the positive control (10µM 
SB415286) had strong nuclear labelling verifying the integrity of the experiment 
(Figure 6-20). 
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6.6 Discussion 
6.6.1 Response to exogenous Wnt ligand 
Incubation of NHU cells with exogenous Wnt3a ligand induced nuclear 
translocation of β-catenin and TCF activation, two hallmarks of canonical Wnt 
signalling.  Activity of the Wnt pathway was however masked by EGFR 
signalling and was only visible when EGFR signalling was blocked.  By mining 
data generated from the AffymetrixTM mRNA analysis (chapter 3) it could be 
inferred that NHU cells were probably signalling via Fzd2 or Fzd6, as both these 
receptors are known to dock with Wnt3a and were expressed as transcripts in 
proliferating NHU cells.  NHU cells also appeared to signal canonically via 
Wnt5a, a dual acting Wnt known to activate but also block canonical Wnt 
signalling, depending on receptor availability (123).  When ROR2 receptor is 
expressed on the cell surface, Wnt5a inhibits the canonical Wnt pathway, 
whereas when Fzd4 is expressed, a canonical Wnt signal is transduced. 
Interestingly, both RT-PCR and Q-PCR analysis of ABS/Ca2+ treated NHU cells 
vs. proliferating NHU cell cultures showed a significant down-regulation in Fzd4 
expression upon differentiation suggesting that a canonical response to Wnt5a 
may be reduced upon differentiation. 
6.6.2 The role of serum in the processing and secretion of Wnt 
ligand 
NHU cells are routinely cultured under serum-free conditions, where they adopt 
a “wound-healing” response and lose markers of terminal differentiation such as 
the uroplakins and tight junctional markers. Addition of serum and physiological 
calcium to the growth medium of NHU cells results in mitotic quiescence and 
expression of markers of terminal differentiation. To date, research into the 
production of bioactive Wnt ligand has always recommended the inclusion of 
10% (v/v) FBS when harvesting CM, as serum contains albumin-bound palmitic 
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acid, the fatty acid required for Wnt post-translational palmitoylation (232).  
This posed a real difficulty to assessing whether NHU cells secreted their own 
Wnt ligand, as addition of serum would inevitably result in phenotypic changes 
and the induction of differentiation.  
CM from serum-reduced Wnt secreting L cell lines did not produce significant 
amounts of bioactive Wnt ligand and thus supported previous publications (96, 
97).  To try and overcome this, palmitic acid was added to the growth medium 
of L Wnt-3a cells instead of 10% (v/v) FBS.  The concentration of palmitic acid 
found in bovine serum has previously been quantified as ~1.1mM (or 110µM in 
DMEM+10%(v/v)FBS; as assessed by gas-liquid chromatography) (263).  
Because of issues with the solubility and precipitation of PA in aqueous medium 
it was not possible to obtain a concentration of 110µM.  A maximum 
concentration of 80µM PA was obtained.  Addition of PA at a concentration of 
40 or 80µM was seen to restore Wnt ligand secretion and activity to ~50% of 
that seen with 10% (v/v) FBS, thus confirming that palmitic acid was required 
for the production of bioactive Wnt ligand.  This provides the first conclusive 
evidence that serum can be reduced when harvesting bioactive Wnt ligand, but 
only if the growth medium is supplemented with palmitic acid. 
6.6.3 Secretion of Wnt ligand from urothelial cells   
Analysis of Affymetrix® mRNA expression data revealed all components 
necessary for post-translational modification and secretion of Wnt ligand were 
present at the mRNA level in proliferating NHU cultures. CM from NHU cells 
cultured in PA resulted in an increase in nuclear β-catenin in SaOS-2 cells but 
did not elicit a significant TCF response via the TOPFLASH DLA. The most likely 
cause for this may be assay sensitivity or may possible be the result of some 
form of nuclear inhibition, such as CBY or NLK activation in SaOS-2 cells after 
treatment with NHU CM.  One could potentially test this by adding L Wnt-3a in 
conjunction with CM from NHU cells.  
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6.6.4 Autocrine Wnt signalling in NHU cells 
EGFR-blocked NHU cells which had been incubated with CM from isogenic PA-
treated NHU cell cultures showed limited evidence of Wnt pathway activation. 
Nuclear β-catenin expression was however evident in a small proportion of cells 
(<5%) treated with NHU CM harvested in the presence of 40µM PA.  At present 
the basis for this heterogeneity and its implications are unclear, however data 
would imply that there may be a subset of cells capable of driving self-renewal 
in response to their own Wnt ligand.  
6.6.5  Further work  
Ideally one would perform an ELISA on CM to test for secreted proteins but 
unfortunately no suitable antibodies against Wnt3, 5a, 6 or 7a were available at 
the time of this study. Production of reliable antibodies to vertebrate Wnt 
proteins has been difficult to manufacture and those that have been made can 
usually only detect over-expressed Wnt protein and not endogenous levels 
(232).  In the last six months, several new Wnt antibodies have come to market 
and would be worth testing on CM from NHU cells. 
Chapter 7 
 
280 
 
7 Thesis overview and conclusions 
This thesis has investigated Wnt signalling in normal human urothelial cells and 
has made the following novel observations: 
1. All components necessary for a functional Wnt cascade are present at 
the mRNA level in proliferating NHU cell cultures. 
2. Several components of the canonical Wnt pathway are differentially 
expressed between quiescent, differentiated and proliferative NHU cell 
cultures. 
3. Proliferating NHU cells display a high level of endogenous active  
β-catenin that is driven via EGFR-mediated phosphorylation of GSK3β. 
4. Pharmacological activation of the Wnt pathway can drive NHU 
proliferation in the absence of EGFR signalling. 
5. Culture density affects β-catenin activity but not via sequestration at the 
adherens junction. 
6. β-catenin regulates the activity of ERK and AKT and forms a bi-
directional feedback loop with EGFR signalling. 
7. All NHU cells can respond to exogenous Wnt3a and Wnt5a but only a 
subset can respond to an autocrine Wnt signal. 
 
These points are discussed in more detail and in the context of other 
knowledge below: 
All components necessary for a functional Wnt cascade are present at 
the mRNA level in proliferating NHU cell cultures. 
The interrogation of previously generated arrays provided a powerful screening 
tool to assess the presence of an intact Wnt signalling pathway and to identify 
key regulators as a starting point for further analysis.  MicroarrayTM chip files 
generated from non-differentiated cultures over time were ranked according to 
their expression of a core set of proliferation-associated markers called the 
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“proliferation signature” (115). Analysis of the most proliferative culture implied 
all components for a functional Wnt cascade were present at the mRNA level. 
Seven Fzd receptors were expressed suggesting proliferating NHU cells may 
respond to several Wnt ligands.  In fact, proliferating NHU cells also expressed 
mRNA transcribed from 4 Wnt genes (Wnt3, Wnt5a, Wnt6 and Wnt7a) 
indicating that they may possess an autocrine Wnt signalling mechanism.  
Interestingly, RT-PCR on freshly isolated (quiescent) urothelium expressed no 
Wnt3 or Wnt7a mRNA implying that their expression was either culture-induced 
or activated in response to perceived “injury”.  No mRNA transcript was found 
for either Wif1 or sFrp1; two secreted Wnt antagonists whose expression is 
down-regulated by promoter hypermethylation in UC (79-81).  Negative 
regulation of the Wnt pathway by secreted antagonists has been postulated as 
an important mechanism to curtail Wnt-driven proliferation in the urothelium 
and therefore the lack of Wif1 expression in proliferating NHU cell cultures was 
promising evidence for pathway activity (79-81).    
The expression of Axin2, a hallmark of canonical Wnt signalling (131, 264)was 
evident in proliferative NHU cell culture along with several other downstream 
gene targets, indicating that the pathway was active. 
Several components of the canonical Wnt pathway are differentially 
expressed between quiescent, differentiated and proliferative NHU 
cell cultures  
The microarray interrogation approach adopted to identify components of Wnt 
signalling also revealed several Wnt signalling components as well as 
downstream targets were differentially expressed when compared to the 
proliferating NHU cell culture.  Noteworthy changes included: the down 
regulation of two Fzd receptors (Fzd2 and Fzd4) and up-regulation of Fzd1 
using both differentiation protocols, the induction of Wif1 expression in 
quiescent NHU cells and the down-regulation of four Wnt signalling 
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transcriptional targets, including Axin2, in both differentiated cultures as well as 
quiescence.  The regulation of Fzd receptor has been described as one of the 
major mechanisms used to modulate Wnt signalling activity and may represent 
an important mode of Wnt pathway control in human urothelium (123).  This is 
supported by the findings indicating a reduction in transcript for four Wnt gene 
targets.   
No expression of Wif1 was evident in freshly isolated urothelium and therefore 
contradicts the hypothesis present by Urakami and colleagues, implying Wif1 
suppression via promoter hypermethylation is an important factor in the onset 
of UC (79).  
The aims of this analysis were to determine if fundamental components of the 
canonical Wnt signalling pathway were present at the mRNA level in NHU cells 
and to investigate the hypothesis that Wnt signalling was involved in the 
development and maintenance of the proliferative phenotype.  Based on the 
presented evidence, one can conclude that at the transcript level, all 
components for a functional canonical Wnt cascade were present in NHU cells 
and evidence was found for potential repression of the pathway when cells 
were displaying a non-proliferative phenotype.   
Proliferating NHU cells display a high level of endogenous active  
β-catenin that is driven via EGFR-mediated phosphorylation of GSK3  
Proliferating NHU cells were shown to contain a significant nuclear-localised 
pool of β-catenin (indicative of an active cascade).  A review of published 
literature implied Wnt ligand would not be active in serum–free tissue culture 
system and therefore pathway activity was assumed to be via another 
mechanism other than ligand-receptor engagement (96, 97).  Intersection 
between signalling pathways had previously been shown to regulate β-catenin 
activity in other cell types and was therefore investigated as a potential means 
Chapter 7 
 
283 
 
of pathway activation in our normal urothelial cell system (159, 167-175).   
Endogenous β-catenin activity was demonstrated to be the result of pathway 
crosstalk via EGFR-mediated phosphorylation of GSK3 and inhibition of the β-
catenin destruction complex.  Both EGFR and MEK1/2 blockades impaired active  
β-catenin nuclear labelling, ablated the phospho-inhibition of GSK3 and reduced 
Axin2 transcription, thereby advocating MAPK/ERK signalling as the point of 
convergence.  The exact mechanism of crosstalk was not fully explored in this 
study, but the literature suggests GSK-dependent crosstalk with the MAPK 
pathway can be driven via ERK activation of P70 S6/P90 RSK (166, 169). 
Pharmacological activation of the Wnt pathway can drive NHU 
proliferation in the absence of EGFR signalling 
Results demonstrated for the first time that β-catenin activation and TCF-
mediated transcription of target genes could promote NHU cell proliferation in 
vitro and highlighted β-catenin as a potentially important player in the 
regulation of urothelial tissue homeostasis. 
Culture density affects β-catenin activity but not via sequestration at 
the adherens junction 
When cultured in low calcium containing medium, culture density was shown to 
affect the expression of β-catenin within the nucleus of NHU cells.  In high 
density cultures, β-catenin was mainly cytoplasmic, where as cells seeded at a 
low initial plating density displayed strong nuclear labelling with the anti-active 
β-catenin antibody.  In the literature, cell:cell contact had previously been 
highlighted as a means of modulating the activity of the canonical Wnt pathway 
by sequestration of β-catenin into the adherens junction complex (reviewed by 
(209)).  To test this potentially important link between cell:cell contact and β-
catenin/TCF-mediated gene expression, the extracellular calcium concentration 
was altered to permit or prohibit the formation of adherens junctions.  In low 
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calcium containing growth medium, such as KSFMc (0.09mM CaCl2), calcium-
dependent adherens junction formation was weak. This resulted in low β-
catenin expression at the membrane and strong nuclear localisation.  Increasing 
the extracellular calcium concentration to near physiological levels (2mM CaCl2) 
led to strong β-catenin expression at the membrane and strong nuclear 
expression.  EGFR tyrosine kinase activity has previously been shown to 
phosphorylate β-catenin at tyr-654, inhibiting its ability to complex with E-
cadherin at the membrane (195, 198).  This would potentially lead to a 
reduction in cell:cell contact in the presence of EGF growth factor stimulation 
and is likely to be an important means of uncoupling cell:cell adhesion in 
preparation for proliferation.  Data in appendix XII supports this theory, as 
treatment with an EGFR tyrosine kinase inhibitor (PD153035) not only reduced 
nuclear-localised β-catenin but also increased membrane labelling, thus 
confirming a role for EGFR tyrosine kinase activity in the regulation of  
β-catenin. 
β-catenin regulates the activity of ERK and AKT and forms a bi-
directional feedback loop with EGFR signalling 
β-catenin protein expression was modulated to investigate its potential role in 
urothelial self-renewal. By utilising shRNA, β-catenin expression was 
successfully reduced by ~58%.  NHU cells with reduced β-catenin expression 
appeared morphologically normal but MTT assays revealed a reduced 
proliferation rate which was attributed to both a reduction in β-catenin and a 
lower than normal level of MAPK/ERK activity.  Proliferation in the β-catenin 
knock-down cells was shown to be more reliant on the PI3K/AKT pathway than 
isogenic control.  The mechanism(s) controlling this switch from MAPK/ERK to 
PI3K/AKT driven proliferation was not fully elucidated in this study but previous 
published data has implied β-catenin can indirectly (ie via transcription) affect 
the activity of the MAPK/ERK and PI3K/AKT signalling cascades.  For example, 
in the mouse liver, EGFR has been demonstrated to be a transcriptional target 
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of the β-catenin and could alter MAPK/ERK activity by modulating EGFR 
availability at the membrane (210).  This mechanism would however not 
support the observed increase in phospho-AKT as all signalling downstream 
from the EGFR would potentially be impaired.  A better explanation for the 
modulation in MAPK/ERK signalling may be the observed crosstalk between Raf-
1 and an as yet, unidentified product of β-catenin/TCF-mediated transcription 
(211). 
Knock-down of β-catenin also led to a significant increase in the expression of 
the adherens junction protein, E-cadherin, which was presumed to be via a 
reduction in the β-catenin/TCF-mediated transcriptional target, Twist, a known 
transcriptional repressor of E-cadherin (135). 
All NHU cells can respond to exogenous Wnt3a and Wnt5a but only a 
subset can respond to an autocrine Wnt signal 
The aim of this work was to determine whether cultured NHU cells had the 
potential to autocrine Wnt signal.  Initial experiments from NHU cells treated 
with pre-validated conditioned medium containing either Wnt3a or Wnt5a 
demonstrated that all NHU cells within a culture were able to mount a full, 
paracrine-induced canonical Wnt cascade.  Evidence in the literature implied 
that under normal growth conditions (without palmitic acid), NHU cells would 
not produce functional Wnt ligand (96, 97).  To remedy this, palmitic acid was 
added to the growth medium of NHU cells.  Interestingly, a small proportion of 
NHU cells displayed a high level of nuclear-localised β-catenin after incubation 
in NHU conditioned medium harvested in the presence of palmitic acid. This 
data, although not conclusive, may highlight a sub-population of cells with the 
ability to initiate their own programme of self-renewal, such as a stem cell.   
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7.1 Concluding Remarks  
The purpose of this thesis was to investigate how the dynamics between 
growth factor-mediated gene transcription and cell:cell contacts regulate 
urothelial self-renewal.  In this thesis, the canonical Wnt signalling cascade was 
examined as a potential key pathway due to the pivotal role of β-catenin in 
both Wnt-mediated gene transcription and intercellular adherens junctions.  
Before this work was undertaken, little was known about the role of Wnt 
signalling in the bladder urothelium.  Research into UC had hinted at the 
possible involvement of β-catenin in urothelial transformation, but no conclusive 
evidence for a role in either normal or transformed cell growth had been 
demonstrated (73-81).  Work by Thievessen and colleagues concluded that 
there was no active β-catenin signalling in normal human urothelium using the 
TOPFLASH/FOPFLASH TCF-reporter assay (72), but work presented here 
indicates that FOPFLASH is unsuitable for use in urothelial cells because of the 
high level of background it generates.  In fact, evidence presented in this thesis 
establishes β-catenin as an important component of a bi-directional feedback 
loop, linking EGFR and β-catenin- mediated proliferation with cell:cell contact.  
As proposed in figure 7-1,  β-catenin plays a central role in the regulation of 
this network and therefore catapults it into the limelight as a prominent figure 
in the maintenance of urothelial tissue homeostasis, as well as a potential 
target for deregulation in the transition from normal to malignant cell growth.  
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Figure 7-1 The role of β-catenin in NHU proliferation 
Schematic illustrating the available data on the role of β-catenin in NHU proliferation. Sections 
in bold and with solid lines have either been demonstrated in this thesis or previously shown in 
human urothelium.  Sections in grey with dotted lines are possible links seen in other cell types 
(references shown in brackets).  Red lines indicate a positive effect on proliferation.  Blue lines 
indicate a negative effect on cell proliferation. 
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Appendix I  
List of Suppliers 
Supplier Webpage/Address 
Adobe Systems Inc  www.adobe.com 
Affymetrix UK Ltd www.affymetrix.com 
Agilent Technologies UK Ltd www.agilent.co.uk 
Ambion Europe Ltd Supplied by Invitrogen 
American Type Culture Collection 
(ATCC) 
Supplied by LGC 
Amersham Biosciences UK Ltd www.gelifesciences.com 
Applied Biosystems (ABI) www.abi.org.uk 
Autogen Bioclear UK Ltd Holly Ditch Farm, Mile Elm, Calne,Wiltshire SN11 
0PY Axygen Inc Supplied by Fisher Scientific 
Beckman Coulter Inc www.beckmancoulter.com 
BD Biosciences www.bdbiosciences.com/eu 
BDH Supplied by VWR 
Bioline Reagents Ltd www.bioline.com/h_uk.asp 
Bio-Rad Laboratories Ltd www.bio-rad.com 
BOC UK www.boconline.co.uk 
C A Hendley Essex Ltd Oakwood House,12 Oakwood Hill Industrial 
Estate, Oakwood Hill, Loughton, Essex IG10 3TZ Calbiochem Supplied by Merck 
Clontech (Takara Bio Inc) www.clontech.com 
Cogenics  (Beckman Coulter 
Genomics) 
www.cogenics.com 
ELGA (Veolia Water Solutions UK Ltd) www.elgalabwater.com 
Ensembl Genome Browser www.ensembl.org 
Envair Ltd www.envair.co.uk 
Eppendorf UK Ltd www.eppendorf.co.uk 
Eurofins MWG Operon www.eurofinsdna.com 
European Bioinformatics Institute www.ebi.ac.uk 
Falcon  Supplied by VWR 
Fisher Scientific UK Ltd www.fisher.co.uk 
Genomatix Software GmbH   www.genomatix.de 
Gentaur Ltd www.gentaur.com 
Graphpad Software Inc www.graphpad.com 
Greiner Bio-one Ltd www.greinerbioone.com/en/england/start/ 
Harlan Sera-Lab Ltd www.harlanseralab.co.uk 
Hettich Centrifuges(DJB Labcare Ltd) www.hettichcentrifuge.co.uk 
Hybaid Ltd Supplied by Thermo Scientific 
Ingenuity Systems Inc  www.ingenuity.com 
Insight Biotechnology Ltd www.insightbio.com 
Invitogen Ltd www.invitrogen .com 
Jencons-PLS Supplied by VWR International 
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Supplier Webpage/Address 
Leica Microsystems (UK) Ltd www.leica-microsystems.com 
LGC standards www.lgcstandards.com 
Li-Cor Biosciences UK Ltd www.licor.com 
Media Cybernetics Inc www.mediacy.com 
Merck KgaA www.merck.co.uk 
Microsoft Corporation www.microsoft.com 
Molecular Probes Supplied by Invitrogen 
Nalgene Europe Ltd Supplied by Fisher Scientific 
National Centre for Biotechnology 
Information 
www.ncbi.nlm.nih.gov 
National Diagnostics www.nationaldiagnostics.com 
New England Biolabs (UK) Ltd www.neb.uk.com 
Novacastra Laboratories Ltd www.novocastra.co.uk/ 
Olympus Optical Company Ltd www.microscopy.olympus.eu/microscopes/ 
Pall Life Sciences Supplied by VWR 
Parke Davis (Pfizer Ltd) www.pfizer.co.uk 
PerkinElmer Inc www.perkinelmer.com 
Pierce Supplied by Thermo Scientific 
Promega UK Ltd  www.promega.com 
Qiagen Ltd www.qiagen.com 
R A Lamb Ltd www.ralamb.co.uk 
Roche Diagnostics Ltd www.roche.co.uk/portal/uk/diagnostics 
Santa Cruz Biotechnology Supplied by Insight Biotechnology Ltd 
Sartorius Ltd www.sartorius.co.uk 
Scientific Laboratory Supplies (SLS) 
Ltd 
www.flowgen.net 
Sigma-Aldrich  Company Ltd www.sigmaaldrich.com 
Solent Scientific Ltd www.solentsci.com 
Sorvall Centrifuges (DJB Labcare) www.sorvallcentrifuge.co.uk 
Starlab (UK) Ltd www.starlab.co.uk 
Starstedt Ltd www.sarstedt.com 
Sterilin Ltd Supplied by SLS 
Statebourne Cryogenics Ltd www.statebourne.com 
Syngene (Synoptics Ltd) www.syngene.com 
Takara Bio Inc www.takara-bio.com 
ThermoFisher Scientific Inc www.fisher.co.uk 
Vector Laboratories Ltd www.vectorlabs.com 
VWR international www.vwr.com 
Whitehead Institute for Biomedical 
Research 
www.wi.mit.edu 
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Appendix II 
Stock solutions 
General Solutions: 
Phosphate Buffered Saline (PBS) 
137mM NaCl, 2.7mM KCl, 3.2mM Na2HPO4 and 147mM KH2PO4, pH7.2 in dH2O. 
Prepared from tablets (Sigma; P4417) and autoclaved. 
Tris Buffered Saline (TBS) 
50mM Tris-HCl (pH7.4) and 150mM NaCl in dH2O 
PBSc 
0.5mM MgCl2 and 0.9mM CaCl2 in PBS. 
 
Cell culture solutions: 
Collagenase IV (Sigma; C5138) 
Diluted in 20,0000U in 100ml of Hank’s Balanced Salt’s Solution (HBSS)(without 
Ca 2+ and Mg 2+) and containing 10mM HEPES (Invitrogen). 
Stripper Medium 
500ml of HBSS (without Ca 2+ and Mg 2+), 10mM HEPES, 500,000 Kallikrein 
inactivating units (KIU) Trasylol (Bayer) and 0.1% (w/v) EDTA. 
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Transport Medium  
500ml of HBSS (without Ca 2+ and Mg 2+), 10mM HEPES, 500,000 Kallikrein 
inactivating units (KIU) Trasylol. 
 
Molecular Biology Solutions: 
Luria Broth (LB) 
10g Tryptone, 10g NaCl, 5g of Yeast extract to 1l of dH2O, pH7.0 and 
autoclaved immediately. 
LB-Agar 
LB containing 2% (w/v) agar and utoclaved immediately. 
10x TBE Buffer 
0.9M Tris, 0.9M Boric acid, 25mM EDTA in dH2O. Diluted 1:10 in dH2O prior to 
use. 
 
Western Blotting Solutions: 
2x SDS lysis buffer 
125mM Tris-HCl (pH6.8), 20% (w/v) glycerol, 2% (w/v) SDS, 200mM Sodium 
fluoride, 2mM Sodium Orthovanadate, 40mM Tetra-sodium pyrophosphate and 
made to 50ml in dH2O. 
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“Towbin” Transfer Buffer 
12mM Tris, 38mM Glycine, 20% (v/v) Methanol made to 1l in dH2O. 
 
Immunofluorescence Solutions: 
DABCO/Glycerol Antifade Mountant 
0.01M NaHCO3 and 2.5% (w/v) 1,3 diazobicyclo (2,2,2)-octane in glycerol, pH 
8.0. 
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Appendix III 
Y-Number Tissue Information  
 
Y-number Operation Tissue Sex Age 
Y372 Nephrectomy Ureter - - 
Y387 Nephrectomy Ureter F 44 
Y579 Nephrectomy Ureter F 33 
Y676 TURP Bladder M 78 
Y878 Pyeloplasty Renal Pelvis - - 
Y919 Nephrectomy Ureter M 67 
Y924 Nephrectomy Ureter M 63 
Y970 Re-implant ureter Ureter - - 
Y1056 Renal transplant Ureter F 62 
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Appendix IV 
Genotyping 
 
 Electropherograms for EJ cell line  
DNA (STR) profile for EJ cell line was as published by ATCC (Amelogenin: XCSF1PO: 10,12 
D13S317: 12 D16S539: 9 D5S818: 10,12 D7S820: 10,11 THO1: 6 TPOX: 8,11 vWA: 17).  
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Electropherograms for RT112 cell line 
DNA (STR) profile for RT112 cell line was as published by Sigma-Aldritch (Amelogenin: 
XCSF1PO: 10,11 D13S317: 13,14 D16S539: 11,13 D5S818: 10,13 D7S820: 11,12 THO1: 7 
TPOX: 8,11 vWA: 14,17). 
Appendix 
296 
 
 
Electropherograms for RT4 cell line 
DNA (STR) profile for RT112 cell line was as published by Sigma-Aldritch (Amelogenin: X,Y 
CSF1PO: 10,12 D13S317: 8 D16S539: 9 D5S818: 11,12  D7S820: 9,12 THO1: 9,9.3 TPOX: 8,1 
vWA: 14,17).  
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Allelic ladder
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Appendix V 
Primers 
Gene 
target 
FWD 5’  3’ REV 5’  3’ 
APC GGAGCCAAGCCATCTGTGAA TGCTTTACTTGACCCACCTATTTG 
Axin2 CAAGGGCCAGGTCACCAA CCCCCAACCCATCTTCGT 
c-MYC GAGGAGACATGGTGAACCAGAGT TCCTGGATGATGATGTTTTTGATG 
CyclinD1 CGTGGCCTCTAAGATGAAGGA TGTCGGTGTAGATGCACAGCTT 
DKK3 GGGTCTTTGTCGCGATGGTA GTTCTTGATAGCGTTGGAATTGAG 
CDH1 AATCTGAAAGCGGCTGATACTGA CGGAACCGCTTCCTTCATAG 
Fzd2 CCAGTTCTATCCGCTGGTGAA GCGTACATGGAGCACAGGAA  
Fzd4 GTCTCAGTCTGGGGTTGCTC GGATGAGCGGTGTGAAAGTT 
Fzd6 CGGAACCAAGAAAAACTAAAGAAATT ATAGACGTAACATCCGAGAAGTGT
CA GAPDH CAAGGTCATCCATGACAACTTTG GGGCCATCCACAGTCTTCTG 
Lef1 GGACGAGATGATCCCCTTCA CTTCCTCTTCGGGATGACTGAT 
MKI67 CAAGAGCATCAGAACGTTTAAGGA TTCTTGGCCACTTCTTCATTCC 
ROR2 CCGGTTTGGGAAAGTCTACA CGTGCGAACAGTAGCTGAAG 
UPK2 CAGTGCCTCACCTTCCAACA TGGTAAAATGGGAGGAAAGTCAA 
UPK3a CGGAGGCATGATCGTCAT CAGCAAAACCCACAAGTAGAAAGA 
Wif1 GGCACCTTTTACACATGATTTCAG TGGAATGGATATTGACAGGAATAG
C Wnt3 AAGGGACCGGACTTGCAAT GGCCACAGCAGAGCAGATC 
Wnt3a  
(mouse) 
CTGGCAGCTGTGAAGTGAAG TGGGTGAGGCCTCGTAGTAG 
Wnt5a 
(mouse) 
CTGGCTCCTGTAGCCTCAAG AATCTCCGTGCACTTCTTGC 
Wnt5a AACTCGCCCACCACACAAG TCATTGCGCACGCAGTAGTC 
Wnt7a GGCCCACCTTCCTGAAGATC  GTACACCAGGTCCGTGTCCAT 
Wnt11 GGGAGGATGTGCGGACAA GAAAACTTGGCCCCCATGA 
Wnt14 GGAGGCCGTGAGCATGAGT TGCAGTTCCAGCGCTCAA 
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Appendix VI 
Dissociation curves 
APC 
 
c-MYC 
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Appendix VII 
FACS analysis 
 
Optimising NHU cell transfection using lipid based reagents  
NHU Y924 (P3) cells were transfected with between 0.1-1µg of pBabe-EGFP using 5 different 
lipid base transfection reagents as outlines in the table. 48 hours post-transfection cells were 
analysed via FACs for percentage viability and GFP expression. 
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 Comparison of lipid-based transfection reagents in NHU cells  
NHU Y924 (P3) cells seeded into a 24-well Primaria® plate at 4x 104 cells per well were 
transfected 24-hours after seeding with between 0.1-1µg of pBabe-EGFP using 5 different lipid 
based transfection reagents. Cells were assayed 48-hours post-transfection using FACS. 
Percentage of viable to non-viable cells was calculated using forward and side scatter dot blots 
versus a non-transfected control.  Percentage of transfected cells was calculated using EGFP 
expression. 10,000 events were collected per sample. 
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Scatter plots and histograms for Fugene 
 
 Scatter plots and histograms for Lipofectamine  
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Scatter plots and histograms for Metafectene 
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Scatter plots and histograms for Metafectene 
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 Scatter plots and histograms for Effectene and GeneJuice 
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Appendix VIII 
TOPFLASH/FOPFLASH promoter sequence 
TOPFLASH TCF-specific promoter:  
AAGATCAAAGGGGGTAAGATCAAAGGGGGTAAAATCAAAGGGGGCCCCCTTTGATCT
TACCCCCTTTGATCTTACCCCCTTTGATCTTA 
FOPFLASH mutant TCF promoter:  
GCCAAAGGGGGTAAGGCCAAAGGGGGTAAGGCCAAAGGGGGCCCCCTTTGGCCTTA
CCCCCTTTGGCCTTACCCCCTTTGGCCTT 
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Appendix IX 
Western blots 
 
Western blots for: Active β-catenin (8E7), Total β-catenin(C2206),  
E-Cadherin (HECD1), PAN-ERK (16), P-AKT (D9E), β-actin, P-GSK3β (AB30619), 
P-ERK (D13.14.4E)   
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Appendix X 
β-catenin shRNA sequence  
Adapted from (206). 
FWD 
5’gatccAAGTCCTGTATGAGTGGGAACTTCAAGAGAGTTCCCACTCATACAGGACTTT
TTTTTACGCGTg 3’ 
REV 
5’aattcACGCGTAAAAAAAAGTCCTGTATGAGTGGGAACTCTCTTGAAGTTCCCACTCA
TACAGGACTTg 3’ 
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Appendix XI 
Verification of the β-Catenin shRNA pSIREN RetroQ 
retroviral vector 
 
 
Verification of the β-Catenin shRNA pSIREN RetroQ retroviral vector  
An shRNA hairpin was designed, annealed and ligated into the retroviral vector pSIREN RetroQ 
using the EcoRI and BamHI restriction sites present in the multiple cloning site (MCS). To verify 
the presence of the shRNA sequence, plasmid DNA was digested with the restriction enzyme 
MluI and the resulting DNA fragments were separated on an ethidium bromide stained 1% 
(w/v) agarose gel using gel electrophoresis. Undigested plasmid was run alongside for 
comparison as well as empty pSIREN RetroQ plasmid (clone 8). Clones carrying the β-catenin 
shRNA sequence cut with the restriction enzyme MluI to give a linear product at 6.4kb. 
Undigested plasmid and plasmid not containing the shRNA sequence ran as supercoiled DNA 
above the 10kb marker. DNA marker: Hyperladder I. 
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Appendix XII 
β-catenin expression in NHU cultured in physiological 
calcium and PD153035 
 
Expression and localisation of β-catenin in NHU cells cultured in 
KSFMc supplemented with physiological calcium concentrations and 
1µM PD153035 
NHU cells (Y919) at P4 were cultured for 24 hours, 48 hours and 72 hours in KSFMc+2mM 
CaCl2. Slides were fixed and immunolabelled with; active β-catenin antibody (8E7) and rabbit 
anti-mouse IgG-Alexa 594 secondary antibody, total β-catenin (C2206) and goat anti-rabbit IgG 
Alexa 488 secondary antibody or E-cadherin antibody (HECD1) and anti-mouse IgG-Alexa 594. 
All slides were stained with Hoechst 33258 to delineate the nucleus and labelling was visualised 
under epi-fluorescent illumination. Photo-micrographs are of NHU cells labelled with anti-active 
β-catenin (A-C) with the corresponding Hoechst stain underneath (D-F), total β-catenin labelling 
(G-I) and E-cadherin (J-L) with the matched Hoechst staining below (M-O). Scale bar:100µM. 
Arrows denote unusual nuclear labelling with both active and total β-catenin antibodies at 48 
hours post seeding.   
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Quantification of nuclear and cytoplasmic active β-catenin in NHU 
cells over time when cultured in KSFMc supplemented with 
physiological calcium concentrations and PD153035 
Line graph represents nuclear and cytoplasmic active β-catenin pixel intensities and standard 
deviations as quantified from each micrograph using Adobe Photoshop® software.     
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Glossary 
Abbreviation  
µg micro gram 
µl micro litre 
µM micro molar 
ABS Adult bovine serum 
AJ Adherens junction 
AKT Murine thymoma viral oncogene (protein kinase B) 
AML Acute Myelogenous Leokaemia 
AMP Ampicillin 
APC Adenomatous Polyposis Coli 
Asn Asparagine 
ATP Adenosine triphosphate 
AUM Asymmetric unit membrane 
Bad BCL2-associated agonist of cell death  
BLAST Basic Local Alignment and Search Tool 
bp Base pair 
BPE Bovine pitutary extract 
BrdU 5-bromo-2'-deoxyuridine 
BUB1 Budding uninhibited by benzimidazoles 1 homolog  
CD Cluster of Differentiation 
CDH1 Epithelial cadherin 
CDK Cyclin-dependant kinase 
cDNA complementary Deoxyribonucleic Acid 
CIS Carcinoma in situ 
CK Cytokeratin 
CKI Casein Kinase Iα 
CLDN Claudin 
cm centimetre 
CRD Cysteine rich domain 
CSDA Cold shock domain protein A 
CT Cholera toxin 
Cxs Connexins 
Cys Cysteine  
DEPC Diethyl Pyrocarbonate 
DKK Dickkopf 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic Acid 
dNTP Deoxynucleotide triphosphate 
Dsh Dishevelled 
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E.coli Escherichia coli 
ECM Extracellular Matrix 
EDTA Ethylene Diaminetetraacetic Acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ER Endoplasmic Reticulum 
ERK Extracellular regulated kinase 1/2 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FGF Fibroblast growth factor 
FGFR3 Fibroblast growth factor receptor 3 
Fzd Frizzled 
g gram 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GDP guanosine diphosphate  
GEF guanine nucleotide exchange factors  
GPCR G-protein coupled receptors 
GSK3β glycogen synthase kinase 3β  
GTP guanosine triphosphate  
h hour 
HB-EGF heparin-binding Epidermal growth factor 
HBSS Hank's balance salt solution 
HEPES  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium 
salt HGF Hepatocyte growth factor 
Hh Hedgehog 
HPACC Health Protection Agency Culture Collection 
hTERT Human telomerase 
IC Interstitial Cystitis 
IC50 Half maximal inhibitory concentration 
ICAT beta-catenin-interacting protein 1 
IGF Insuli-like growth factor 
ILK Integrin-linked kinase 
IRS Insulin receptor substrate 
ISUP International Society for Urological Pathology 
JAK Janus kinase 
JAM Junctional adhesion molecule 
JNK c-Jun N-terminal kinase 
Kb Kilo base pair 
KDa Kilo Dalton 
KIU Kallikrein inactivating units  
KSFM keratinocyte serum-free medium  
KSFMc keratinocyte serum-free medium (complete) 
LB Luria Broth 
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LBA Luria Broth Agar 
LEF lymphoid enhancer-binding factor  
LRP Low density lipoprotein receptor 
M Molar 
mAb Monoclonal antibody 
MAGUK Membrane-associated guanylate kinases  
MAPK Mitogen-activated protein kinases 
Me:Ac Methanol:Acetone 
Min Minute 
MKI67 Antigen Ki-67 
mL Millilitre 
mM Millimolar 
mRNA messenger Ribonucleic Acid 
mTOR mechanistic target of rapamycin  
MTT Methylthiazolyldiphenyl-tetrazolium bromide 
NFAT Nuclear factor of activated T-cells 
NHU Normal Human Urothelial cells 
NLK Nemo-like kinase 
nM nanomolar 
P Passage number 
pAKT phospho-activated Murine thymoma viral oncogene 
(protein kinase B) PBS Phosphate buffered saline 
PBSc Phosphate buffered saline with calcium 
PCNA Proliferating cell nuclear antigen  
PCR Polymerase chain reaction 
PD PD153035 
PDK phosphoinositide dependent kinase-1  
pERK phospho-activated Extracellular regulated kinase 1/2 
PGK Phosphoglycerate kinase  
pGSK3 phospho-inhibited glycogen synthase kinase 3β 
PI3K Phosphatidyl inositol-3 kinase 
PIP2 phosphatidylinositol (4,5) triphosphate 
PIP3 phosphatidylinositol (3,4,5) triphosphate  
PLC Public limited company 
PORCN porcupine homolog 
PPARγ peroxisome proliferator activated receptor-γ 
PPRE peroxisome proliferator response elements  
pTEN phosphatase and tensin homolog  
Puro Puromycin 
Raf Murine leukemia viral oncogene homolog  
RAS Rat sarcoma viral oncogene homolog  
Rb Retinoblastoma 
rhEGF Recombinant human epidermal growth factor 
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RNA Ribonucleic Acid 
RNase Ribonuclease 
ROR receptor tyrosine kinase-like orphan receptors  
rpm revolutions per minute 
RT Reverse transcriptase  
RTq-PCR Reverse transcriptase quantitative polymerase chain reaction 
RXR retinoid X receptor a  
SC squamous carcinoma  
Ser Serine 
sFrp Secreted frizzled related protein 
SH Src homologue  
Shh Sonic hedgehog 
SMOH Smoothened 
SNAI1 Snail homolog 1 
SOS Son of Sevenless  
STAT signal transducers and activators of transcription  
SXV Ser/Thr-X(any amino acid)-Val motif  
TCF T-cell factor 
TGF Transformig growth factor 
TGN trans-Golgi network  
Thr Threonine 
TJ Tight junction 
TNM Tumor-Nodes-Metastasis 
Tyr Tyrosine 
TZ Troglitozone 
UC urothelial carcinoma  
UPK Uroplakin 
UV Ultra violet 
WHO World Health Organisation 
Wif Wnt inhibitory factor 
WLS Wntless 
ZO Zonular occludin 
β-TrCP β-transducin repeat-containing protein  
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